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Abstract 
 
 
Thapsigargin is a sesquiterpene lactone of the guaianolide class whose structure was first 
assigned in 1984. It is a highly cytotoxic agent, inhibiting the sarco/endoplasmic Ca
2+
- 
ATPase (SERCA) at sub-nanomolar concentrations (KD = 0.4 nM), and its prodrug 
formulations have been of intense interests for many oncological applications. 
 
In collaboration with the group of J.-P. Férézou, a strategy towards the construction of the 
carbon skeleton of thapsigargin and related natural and unnatural analogues was developed 
based on a ring-closing ene-yne metathesis (RCEYM) step. In this work the scope of that 
strategy was expanded to fulfil the enantioselectivity requirement of the synthesis via the 
use of asymmetric transfer hydrogenation under dynamic kinetic resolution conditions on a 
cyclopentenone γ-ester. These enantioenriched cyclopentenone derivatives have then been 
used to construct [5,7]-bicyclic structures with varying substitutions. 
 
These resulting bicyclic derivates were sensitive to many subsequent reaction conditions, 
however a robust synthetic strategy was found to chemoselectively oxidise the C-7/8 
double bond and from there further derivation was possible, resulting in an advanced 
[5,7,5]-tricyclic derivative.  
 
Finally, the flexibility of the RCEYM strategy was demonstrated through the concise 
synthesis of an unnatural [5,8]-bicyclic thapsigargin core analogue from a common ketone 
precursor. 
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Chapter 1: Introduction 
 
1.1 Terpenoids 
 
Terpenoids are the largest class of natural products found in living organisms.
1
 The 
functional role of many of the approx. 25,000 discovered terpenoids
2
 have yet to be 
investigated. Of particular interest are the relatively small (< 1 kDa), biologically active 
terpenoid natural products, as they allow for simpler derivatisation, structural elucidation 
and total synthesis as well as providing a general improvement in druglikeness.
3
 
 
Sesquiterpene lactones are a large class of over 5000 known compounds
4
 with most of 
these found in quite prolific plant species. These terpenoids are constructed 
biosynthetically from three isoprene units and contain a γ-lactone ring, with varying 
oxidation levels around the core structure. Although a large number of sesquiterpene 
lactones are considered toxic at levels found in plants,
5
 dose regulation reveals the 
therapeutic potential of many compounds, and one area of particular interest is anti-cancer 
activity.
6
 Among those under investigation are the more well known thapsigargin 1 (Tg), 
helenalin 2 and artemisinin 3 (Figure 1).  
 
 
 
Figure 1. Three sesquiterpene lactone anti-cancer candidates. 
 
Although they are structurally related, the mechanisms of their anti-cancer activity differ 
significantly. Thapsigargin 1 is a potent inhibitor of sarco/endoplasmic reticulum Ca
2+
 
                                           
1
 Gershenzon, J.; Dudareva N. Nat. Chem. Bio. 2007, 3, 408. 
2
 Buckingham, J. “Dictionary of Natural Products” 1994, Chapman and Hall. 
3
 Feher, M.; Schmidt, J. M. J. Chem. Inf. Comput. Sci. 2003, 43, 218. 
4
 Wedge, D. E.; Galindo, J. C. G.; Macías, F. A. Phytochemistry 2000, 53, 747. 
5
 Amorim, M. H.; Gil da Costa, R. M.; Lopes, C.; Bastos, M. M. Crit. Rev. Toxicol. 2013, 43, 559. 
6
 Zhang, H.; Won, Y.-K.; Ong, C.-N.; Shen, H.-M. Curr. Med. Chem. – Anti-cancer Agents 2005, 5, 239. 
14 
 
ATPase (SERCA), which regulates the flow of Ca
2+
 ions from the cytosol of the cell back 
to storage, leading to a Ca
2+
 flow disruption and eventual apoptosis.
7
 Helenalin 2 on the 
other hand impairs DNA and protein synthesis, significantly affecting the growth of 
tumours.
8 , 9
 While thapsigargin and helenalin are also very cytotoxic against healthy 
cells,
10 , 11
 artemisinin 3 is well tolerated in humans at clinically relevant doses as its 
mechanism of action utilises its unusual peroxide bridge to induce oxidative stress in 
typically iron-rich cancer cells.
12
 
 
1.2 Terpenoid biosynthesis 
 
1.2.1 Terpenoid precursors 
 
All terpenoids are constructed from one or more isoprene units. 3-Isopentenyl 
pyrophosphate 4 (IPP) and dimethylallyl pyrophosphate 5 (DMAPP) are the two building 
blocks used to make larger and more complicated terpenoids. IPP 4 and DMAPP 5 are 
isomeric, and are made via the same pathways. Most eukaryotes, archaea and some 
bacteria utilise a pathway named the mevalonate-dependant (MAD) or HMG-CoA 
reductase pathway (Scheme 1).
13
  
                                           
7
 Drew, D. P.; Krichau, N.; Reichwald, K.; Simonson, H. T. Phytochemistry Rev. 2009, 8, 581. 
8
 Berges, C.; Fuchs, D.; Opelz, G.; Daniel, V.; Naujokat, C. Mol. Immunol. 2009, 46, 2892. 
9
 Lim, C. B.; Fu, P. Y.; Ky, N.; Zhu, H. S.; Feng, X., Li, J.; Srinivasan, K. G.; Hamza, M. S.; Zhao, Y. BMC 
Complement. Altern. Med. 2012, 12, 93. 
10
 Ganley, I. G.; Wong, P.-M.; Gammoh,  N.; Jiang, X. Mol. Cell. 2011, 42, 731. 
11
 Chapman, D. E.; Roberts, G. B.; Reynolds, D. J.; Grippo, A. A.; Holbrook, D. J.; Hall, I. H.; Chaney, S. 
G.; Chang, J.; Lee K. H. Tox. Sci. 1988, 10, 302. 
12
 Cabello, C. M.; Lamore, S. D.; Bair, III W. B.; Qiao, S.; Azimian, S.; Lesson, J. L.; Wondrak, G. T. 
Investigational New Drugs 2012, 30, 1289. 
13
 a) Beytía, E. D.; Porter, J. W. Annu. Rev. Biochem. 1976, 45, 113. b) Goldstein, J. L.; Brown, M. S. Nature 
1990, 343, 425. 
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Scheme 1. Biosynthetic pathway leading to IPP and DMAPP 
 
First, the formation of mevalonic acid 6 is accomplished through the Claisen condensation 
of acetyl-CoA 7 catalysed by thiolase and subsequent aldol reaction with 8, followed by 
reduction of 9 using two equivalents of nicotinamide adenine dinucleotide phosphate 
(NADPH). It is then phosphorylated twice to form 10. A final phosphorylation using 
adenosine triphosphate (ATP) then dehydrates and decarboxylates 10 to produce IPP 4, 
which can undergo isomerisation to DMAPP 5. An alternative biosynthetic pathway to IPP 
and DMAPP also exists in most bacteria, certain protozoa and in the plastids of higher 
plants.
14
 
 
1.2.2 Guaianolides and psuedoguaianolides 
 
Thapsigargin and helenalin belong to the sesquiterpene lactone subclasses of guaianolides 
and pseudoguaianolides respectively. Like all sesquiterpenoids, the guaianolide and 
pseudoguaianolide biosynthetic pathways originate from farnesyl pyrophosphate 11 
(FPP),
15
 which in turn is made from 3-isopentenyl pyrophosphate 4 (IPP) and dimethylallyl 
pyrophosphate 5 (DMAPP) (Scheme 2). 
 
                                           
14
 Lichtenthaler, H. K.; Schwender, J.; Disch, A.; Rohmer, M. FEBS Lett. 1997, 400, 271. 
15
 Bohlmann, J.; Meyer-Gauen, G.; Croteau, R. Proc. Natl. Acad. Sci. 1998 95, 4126. 
16 
 
 
Scheme 2. Sesquiterpene lactone precursor FPP biosynthesis from IPP and DMAPP. 
 
The biosyntheses of guaianolides and pseudoguaianolides share much of the same route, 
and only diverge in later stages.
16
 As a general route, first FPP 11 undergoes direct 
cyclisation to macrocycle 12, which is then oxidised, hydroxylated and lactonised
17,18 
to 13 
(Scheme 3). 
 
Scheme 3. Guaianolide biosynthesis. 
 
The second part of the biosynthesis in Apiaceae is thought to utilise an epoxidation of 13, 
followed by an intramolecular nucleophilic attack (Scheme 4).
17,19,20
 Depending on the 
enzymes involved, both 4,5 and 1,10-epoxidation are possible.
21
 At this point, the route to 
guaianolides and pseudoguaianolides diverge; α-proton elimination in 14 and 15 will lead 
to double bond formation and the guaianolide core structures of 16 and 17. However, a 
                                           
16
 Albrecht, Ł.; Albrecht, A.; Janecki, T. “Natural Lactones and Lactams: Synthesis, Occurrence and 
Biological Activity” 2013, Wiley, 147. 
17
 De Kraker, J. W.; Franssen, M. C. R.; Joerink, M.; de Groot, A.; Bouwmeester, H. J. Plant Physiol. 2002, 
129, 257. 
18
 Ikezawa, N.; Göpfert, J. C.; Nguyen, D. T.; Kim, S.-U.; O’Maille, P. E.; Spring, O.; Ro, D.-K. J. Biol. 
Chem. 2011, 286, 21601. 
19
 Bouwmeester, H. J.; Kodde, J.; Verstappen, F. W. A.; Altug, I. G.; De Kraker, J. W.; Wallaart, T. E. Plant 
Physiol. 2002, 129, 134. 
20
 Dewick, P. M. Nat. Prod. Rep. 1995, 12, 507. 
21
 Song, Q.; Gomez-Barrios, M. L.; Hopper, E. L.; Hjortso, M. A.; Fischer, N. H Phytochemistry 1995, 40, 
1659. 
17 
 
formal 1,3-hydride shift followed by a 1,2-methyl migration to the 5-position on 15 will 
result in the closely related pseudoguaianolide structure 18. Many rearrangement reactions 
are of course possible, and lead to a wide variety of other sesquiterpene lactones. 
 
 
Scheme 4. Biosynthetic route to both guaianolides and pseudoguaianolides. 
 
1.2.2 Thapsigargin 
 
Thapsigargin 1 is a highly oxygenated guaianolide whose structure was first elucidated in 
1984 by Christensen.
22
 It is found in the Mediterranean plant Thapsia garganica, part of 
the Apiaceae family, and has been used in local herbal medicine for centuries to combat 
rheumatic pain. Structurally it contains a γ-lactone, four ester groups, two free hydroxyl 
groups and a total of eight stereogenic centres, three of which are fully substituted, all 
attached to the core [5,7,5] tricycle (Figure 2). 
 
                                           
22
 a) Christensen, S. B.; Norup, E.; Rasmussen, U.;  Madsen, J. Ø. Phytochemistry 1984, 23, 1659. b) 
Christensen, S. B.; Norup, E. Tetrahedron Lett. 1985, 26, 107. 
18 
 
 
Figure 2. Thapsigargin. 
 
Sixteen other thapsigargin-like molecules have also been isolated alongside thapsigargin 
from species in the Apiaceae family, and are included in Table 1. They differ only in the 
substituents attached to the C-2 and C-8 positions. Throughout this report, the thapsigargin 
numbering system will be used to indicate the corresponding skeletal carbons in 
thapsigargin. 
 
Table 1. The thapsigargin family. 
 
 Entry Name R
1
 R
2
 
1 thapsigargin O-Oct But 
2 trilobolide H (S)-2-MeBut 
3 nortrilobolide (19) H But 
4 thapsivillosin F H Sen 
5 thapsivillosin C O-Oct 2-MeBut 
6  thapsigargicin O-Hex But 
7 thapsitranstagin O-iVal 2-MeBut 
8 thapsivillosin A O-Ang Sen 
9 thapsivillosin B O-Ang 2-MeBut 
10  thapsivillosin D  O-6-MeOct Sen 
11 thapsivillosin E O-6-MeOct 2-MeBut 
12  thapsivillosin O-6-MeHept 2-MeBut 
13  thapsivillosin H O-Ang or -Sen Ang or Sen 
14  thapsivillosin I O-Ang But 
15  thapsivillosin J O-iVal But 
16  thapsivillosin L O-But But 
17 thapsivillosin K O-Sen 2-MeBut 
But = Butanoyl, Sen = Senecioyl, Ang = Angeloyl, Hex = Hexanoyl, 
Hep = Heptanoyl, Oct = Octanoyl, iVal = Isovaleroyl. 
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Although the full biosynthetic pathway of thapsigargin and related compounds has not yet 
been established, several aspects of the early stages of biosynthesis have been elucidated. It 
has been shown that the rather unusual C-6 configuration is likely introduced at an early 
stage by the action of the sesquiterpene synthase TgTPS2 found in the roots of                     
T. garganica,
23
 which converts FPP 11 into epikunzeaol 20 via the proposed mechanism in 
Scheme 5. A 1,3-hydride shift to allyl cation 21 allows for the installation of the C-6 
hydroxyl without the need for a discreet oxidation step. This was evidenced by the 
detection of secondary metabolites 22 and 23, which arise from carbocation 21 in the 
absence of a water quench. 
 
 
Scheme 5. Early thapsigargin biosynthesis stages establishing C-6 configuration. 
 
Later investigation also identified a sesquiterpene specific cytochrome P450, 
TgCYP76AE2, present in T. garganica, which completely converts epikunzeaol 20 into a 
possible downstream metabolite epidihydrocostunolide 24 (Scheme 6).
24
  
 
 
Scheme 6. TgCYP76AE2 mediated oxidation of epikunzaeol. 
 
 
 
 
                                           
23
 Pickel, B.; Drew, D. P.; Manczak, T.; Weitzel, C.; Simonsen, H. T.; Ro, D.-K. Biochem. J. 2012, 448, 261. 
24
 Anderson, T. B.; Martinez-Swatson, K. A.; Rasmussen, S. A.; Boughton, B. A.; Jørgenson, K.; Andersen-
Ranberg, J.; Nyberg, N.; Christensen, S. B.; Simonsen, H. T. Plant Physiol. 2017, 174, 56. 
20 
 
1.3 Thapsigargin biological activity 
 
1.3.1 SERCA inhibition and mode of action 
 
The sarco/endoplasmic reticulum Ca
2+
 ATPase is part of a family known as P-type 
ATPases. P-ATPases are known throughout nature as cross-membrane ion and lipid 
pumps,
25
 utilising ATP as an energy source. SERCA is encoded for by three major specific 
gene sequences in the human genome, each resulting in a SERCA paralog. These are 
expressed at different levels within different cell types, such as cardiac and skeletal 
muscles, and also non-muscle tissues such as lymphocytes, salivary gland and platelets, 
amongst others.
26, 27, 28 
 
Figure 3. Calcium transport between the cytosol and SR. 
 
SERCA is found in the membrane of the sarcoplasmic reticulum (SR), or the smooth 
endoplasmic reticulum, which acts as a storage for Ca
2+
, to be released during cell 
stimulation. Ca
2+
 is released quickly by ryanodine receptors (RYR) into the cytoplasm, 
after which it diffuses and activates receptors according to the function of the cell.
29
 
SERCA then gradually pumps the Ca
2+
 back into the lumen of the sarcoplasmic reticulum, 
                                           
25
 Møller, J. V.; Juul, B.; Le Maire, M. Biochim. Biophys. Acta 1996, 1286, 1. 
26
 Guglielmi, V.; Vattemi, G.; Gualandi, F.; Voermans, N. C.; Marini, M.; Scotton, C.; Pegoraro, E.; 
Oosterhof, A.; Kósa, M.; Zádor, E.; Valente, E. M.; De Grandis, D.; Neri, M.; Codemo, V.; Novelli, A.; 
van Kuppevelt, T. H.; Dallapiccola, B.; van Engelen, B. G.; Ferlini, A.; Tomelleri, G. Mol. Genet. Metab. 
2013, 110, 162. 
27
 Dode, L.; Wuytack, F.; Kools, P. F.; Baba-Aissa, F.; Raeymaekers, L.; Briké, F.; van de Ven, W. J.; 
Casteels, R.; Brik F. Biochem. J. 1996, 318, 689. 
28
 Liu, L. H.; Paul, R. J.; Sutliff, R. L.; Miller, M. L.; Lorenz, J. N.; Pun, R. Y. K.; Duffy, J. J.; Doetschman, 
T.; Kimura, Y.; MacLennan, D. H.; Hoying, J. B.; Shull, G.E. J. Biol. Chem. 1997, 272, 30538. 
29
 Schiemann, A. H.; Paul, N.; Parker, R.; Pollock, N.; Bulger, T. F.; Stowell, K. M. Anesth. Analg. 2014, 
118, 375. 
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returning the levels of Ca
2+
 in the rest of the cell back to normal levels (Figure 3). In 
addition, free Ca
2+
 can be bound to a protein called calsequestrin in the SR, which serves to 
lower the Ca
2+
 concentration gradient that SERCA has to work against.
30
 
 
Thapsigargin is a potent non-competitive, irreversible inhibitor of SERCA proteins, active 
at sub-nanomolar concentrations (KD = 0.4 nM), and has been a target of interest for its 
cytotoxic and calcium concentration modulation effects.
31, 32
 Crystal structures obtained in 
2000 by Toyoshima et al. showed, in detail, some of the mechanisms in calcium transport 
and inhibition by thapsigargin.
33 , 34
 The two crystal structures shown in Figure 4 are 
calcium-bound SERCA E1(Ca
2+
) and thapsigargin-bound SERCA E2(TG).  
Figure 4. SERCA crystal structures showing binding to both Ca
2+
 and thapsigargin. The 
three cytoplasmic domains N, P and A movement between E1(Ca
2+
) and E2(Tg) is shown 
by arrows. 
33,35,36
 
 
E1(Ca
2+
) illustrates the beginning of the calcium transport cycle, before phosphorylation. 
The two calcium ions highlighted are bound in an oxygen rich environment after being 
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guided into the pocket by a series of residues via hydrogen bonding. As the Ca
2+
 reaches 
the binding site, they induce a significant conformation change in E1 not only in the 
transmembrane helices but also to the cytoplasmic domains. This change to E1(Ca
2+
) 
exposes Arg 351 in the P domain and allows a phosphorylation to take place on that 
residue. Phosphorylation causes a large-scale conformational change whereby domains N, 
P and A block off the ion channel on the cytoplasm side by forming a compact structure 
E1(P). This is accompanied by a rearrangement of the transmembrane helices which 
encompass the Ca
2+
 ions. This exposes the Ca
2+
 to less favourable hydrophobic residues 
after which binding affinity is reduced by a factor of 3 and subsequently they are released 
into the SR lumen.
37
 This calcium-released structure E2 is analogous to E2(Tg),
38
 a crucial 
insight as it allows direct comparison of E1(Ca
2+
) and E2(Tg). Irreversible SERCA 
inhibition also stems from the conformational similarity of E2 and E2(Tg), as E2 retains 
the closed cytoplasmic head of E1(P) and requires a conformational change to E1 before 
another pair of Ca
2+
 ions can be bound. 
 
It is therefore interesting to note that when thapsigargin irreversibly binds to SERCA in 
E2(Tg), it does so in a hydrophobic pocket that is only favourably configured in the E2 
state, but has been shown in the crystal structures to be too small for thapsigargin to enter 
in E1(Ca
2+
). Tg binding thus restricts the helical movements, which accounts for the 
stability of E2(Tg)  compared to solubilised SERCA, which denatures in the absence of 
phospholipid support as well as high concentrations of Ca
2+
.
39
 This restricted movement 
keeps the N, P and A domains locked in place and prevents any further Ca
2+
 transport. 
Many hydrophobic residues on three separate helices (M3, M5 and M7) are implicated in 
the binding affinity of thapsigargin to SERCA (Figure 5), however only one weak 
hydrogen bond between Ile 829 and the O-8 ester could be established.
34,40 
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Figure 5. (A) Location of hydrophobic residues in the E2(Tg) binding pocket. (B) 
Calculated hydrophobic potential colour-mapped onto the SERCA(E2) Connolly 
surface.
34,41,42,43
 
 
1.3.2 Thapsigargin analogues 
 
Before the crystal structure elucidation in 2000 by Toyoshima et al., structure-activity 
relationship (SAR) studies yielded many semi-synthetic analogues produced from the 
selective modification of natural thapsigargin (Figure 6). Some of the most important 
insights from the SAR investigations concern the various oxygenated positions 
surrounding the thapsigargin core. 
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Figure 6. Semi-synthetic thapsigargin analogues. Relative activity (RIC) is obtained by 
dividing the corresponding IC50 value by the IC50 value of thapsigargin 1. 
 
Unlike many guaianolides,
44
 the biological activity of thapsigargin does not seem to 
critically depend on the γ-lactone as is demonstrated by the high relative activity of acetal 
25 and tetrahydrofuran 26. The inversion of the C-8 and C-3 stereocenters in 27 and 28 
respectively is accompanied by a large drop in activity not accounted for by the 
replacement of the C-3 angeloyl by octanoyl alone as shown by natural epimer 29. 
Similarly the lack of the C-10 acetate in analogue 30 demonstrates the moiety's 
involvement in the inhibitory potential of thapsigargin.
4546
 
 
These results can be rationalised when compared with Tg-bound SERCA crystal structures.  
The binding site mapped out in figure 5 (B) clearly shows two hydrophobic pockets that fit 
the natural orientation of the C-8 and C-3 esters, while the lack of significant hydrogen 
bonding around the lactone region allows substantial modification without impacting 
activity. When combined, these results can be used for the rational design of potent 
SERCA inhibitors; although the C-10 acetate of 1 contributes a significant hydrophobic 
interaction, the carbonyl moiety is also responsible for an unfavourable electrostatic 
interaction with Phe834 (Figure 7). This configuration is adopted as a consequence of 
                                           
44
 Merfort, I. Curr. Drug Targets 2011, 12, 1560. 
45
a) Christensen, S. B.; Hergenhahn, M.; Roeser, H.; Hecker, E. J. Cancer Res. Clin. Oncol. 1992, 118, 344. 
b)Christensen, S. B.; Andersen, A.; Poulsen, J. C. J.; Treiman, M. Febs Lett. 1993, 335, 345. c) Andersen, 
A.; Cornett, C.; Lauridsen, A.; Olsen, C.  E.; Christensen, S.  B. Acta Chem. Scand. 1994, 48, 340            
d) Nielsen, S. F.; Thastrup, O.;  Pedersen, R.; Olsen, C.  E.; Christensen, S.  B. J. Med.Chem. 1995, 38, 
272 e) Christensen, S. B.; Andersen, A.; Smitt, U. W. Prog. Chem. Org. Nat. Prod. 1997, 71, 129. 
46
 Christensen, S. B.; Skytte, D. M.; Denmeade, S. R.; Dionne, C.; Møller, J. V.; Nissen, P.; Isaacs, J. T. 
Anticancer Agents Med. Chem. 2009, 9, 276. 
25 
 
carbonyl dipole-dipole minimisations (with O-2, O-3 and O-10) and the conformational 
rigidity introduced by the C-4/5 olefin. Since nortrilobolide 19 possesses nearly the same 
inhibitory activity as thapsigargin,
47
 C-2 deoxygenation would be expected to have a 
marginal impact on activity. Fully saturated analogue 31 then not only removes the 
unfavourable electrostatic interaction, but introduces a new favourable electrostatic 
attraction between the partial positive charge of the acetate carbonyl carbon and the 
electron-rich Phe834 π-system. Indeed, this rational design of 31 leads to a 10-fold 
increase in inhibitory potential compared to thapsigargin.
48
  
 
 
Figure 7. Orientation of the Tg and x29 C-10 acetate relative to Phe834 alongside a partial 
hydrophobic potential surface map. 
 
It is important to note that although many peripheral modifications of Tg exist, to date 
there have been no reports of [5,7] core modified analogues, leaving unexplored chemical 
space that is yet to be investigated.  
 
 
 
                                           
47
 Søhoel, H.; Jensen, A. M. L.; Møller, J. V.; Nissen, P.; Denmeade, S. R.; Isaacs, J. T.; Olsen, C. E.; 
Christensen, S. B. Bioorganic Med. Chem. 2006, 14, 2810. 
48
 Sohoel, H.; Liljefors, T.; Ley, S. V.; Olivier, S. F.; Antonello, A.; Smith, M. D.; Olsen, C. E.; Isaacs, J. T.; 
Christensen, S. B. J. Med. Chem. 2005, 48, 7005. 
26 
 
1.3.3 Prostate cancer 
 
Prostate cancer is the fifth leading cause of cancer-related deaths in men world-wide.
49
 
Prostate cancer occurs almost exclusively in men over the age of 50 and is usually slow 
growing, with the prognosis being a long or complete life when detected locally and early, 
but it also poses a problem for the effective treatment of metastatic prostate cancer. The 
basis of chemotherapy is centred on the use of drugs to systemically target cell mitosis, 
disproportionately affecting the fast division of malignant tumour cells, and it is thus 
ineffective against the slow proliferation of prostate cancer. Standard frontline treatment of 
metastatic prostate cancer includes the use of hormone therapy as a subpopulation of 
prostate cancer tumours are androgen-dependent and will undergo apoptosis in response to 
reduced levels of testosterone. However, the remaining tumour cells are androgen-
independent (castration-resistant) and growth relapse occurs once the tumour becomes 
unresponsive to hormone suppression.
50
 Many second-line chemotherapeutic options exist, 
the vast majority acting by the classical approach of inhibiting the mitotic phase of the 
cancer cells, thereby increasing life-expectancy significantly. However, due to the 
relatively low activity of antimitotic drugs in this setting, once a castration-resistant 
metastatic stage is reached it is considered eventually fatal.
51
 
 
Thapsigargin’s mode of action is different from standard chemical treatment options and  
is effective against both normal and castration-resistant metastatic prostate cancer cells. 
The indiscriminate high cytotoxicity exhibited by Tg is also the drawback to this approach, 
as systemic use analogous to standard antimitotic therapies would result in benign cells 
being attacked with equal potency.
52
  
 
Two peptidases have recently become the focus of targeted therapeutics in relation to 
prostate cancer. Prostate specific antigen (PSA) is produced by prostate cells where it 
serves multiple functions, from liquefying semen to dissolving the cervical mucus after 
ejaculation, allowing free movement for the sperm cells.
53
 Because PSA is produced by 
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prostate epithelial cells and found almost exclusively in benign as well as malignant 
prostate tissue, it has great potential as a tool to target drugs directly at metastatic prostate 
cancer tumours.
54
 Prostate specific membrane antigen (PSMA) is normally produced in 
healthy epithelial prostate cells, as well as parts of the liver, kidneys, the small intestine 
and in the central nervous system.
55
 PSMA expression is upregulated in prostate cancer 
cells, and subsequently they contain over 1000 times the concentration of PSMA compared 
to PMSA-containing non-prostate tissue.
56
 Importantly, however, PSMA is found at 
significant levels in the endothelium of the neovasculature supporting all solid tumour 
types; no PSMA expression is found in comparable benign vasculature.
57
 
 
Prodrug 32 (G115) was developed to be cleaved exclusively by PSA (Figure 8).
 46,52,58
 
Analogue L12ADT has a slightly lower inhibitory potential (IC50) compared with 
thapsigargin, but a nearly identical cytotoxic potential (LC50) towards prostate cancer cell 
lines. A long linker (more than 8 methylene units)  was necessary as the attachment of a 
short linker causes the amino group necessary for peptide coupling to occupy the 
hydrophobic pocket reserved for the O-8 acyl group (Figure 4), causing unfavourable 
interactions. Additionally, a leucine had to be incorporated into the active analogue 
structure, as PSA studies indicated the need for amino acids to be present on both sides of 
the cleavage site.
59
 The attached Mu-His-Ser-Ser-Lys-Leu-Gln peptide sequence is 
recognised exclusively by PSA and cleaved at the indicated Leu-Gln site, ensuring 
L12ADT is delivered exclusively to localised areas. This is exemplified by in vivo stability 
in mice, with less than 0.5% of 32 hydrolysed after 24h.
52
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Figure 8. PSA specific activation of prodrug G115. 
 
Another prodrug candidate 33, (G202, mipsagargin), uses PSMA to effect cleavage of its 
peptide side chain (Figure 9).
60, 61
 Although PSMA is also expressed in some benign cells, 
expression typically occurs beyond the epithelial layers where G202 does not penetrate. In 
addition, the blood-brain barrier is thought to prevent significant amounts of the highly 
polar prodrug accumulating in the central nervous system.
62
 
 
Figure 9. G202/Mipsagargin. 
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Prodrug 33 proved to be stable in human plasma and to a range of purified human 
peptidases other than PSMA. This was again demonstrated in mice where molar equivalent 
dosing of 33 >150× the LD100 of Tg produced no significant systemic toxicity.  A further 
advantage to targeting vascular epithelial cells is that 12ADTβAsp is released 
extracellularly, additionally affecting those cells which do not express PSMA in the 
tumour environment. Mipsagargin has undergone a phase II clinical trial in patients with 
Nexavar-refractory hepatocellular carcinoma and has been granted Orphan Drug 
designation by the U.S. Food and Drug Administration. Provided clinical trials prove 
successful, annual demand for Tg 1 is expected to be in the order of 1 ton per annum.
63
 
Since Tg is currently only available in large quantities from wild T. Garganica, a succesful 
synthetic route is preferred.  
 
1.4 Previous synthetic efforts towards thapsigargin 
 
1.4.1 Ley's synthesis of thapsigargin 
 
Three total syntheses of thapsigargin have been published to date. The Ley total synthesis, 
completed in 2007, starts from (S)-carvone 34 in a linear sequence of 42 steps with an 
overall yield of 0.62%.
64
 The synthesis starts with a Favorskii ring contraction of α-
chloroketone 35 to give methyl ester 36 as a single diastereomer on >100 g scale (Scheme 
7). 
  
 
 
Scheme 7. Favorskii ring contraction. 
 
Felkin-Anh chelation-assisted addition of allylmagnesium bromide onto C-10 ketone 37 
yields a consistent diastereomeric ratio of 8:1 in favour of the desired diastereomer 38 
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(Scheme 8). The undesired diastereomer 39 can be removed via column chromatography 
after derivation to 40. 
  
 
Scheme 8. Felkin-Anh controlled allylation. 
 
Addition of lithiated ethyl vinyl ether under Felkin-Anh control to aldehyde 41 afforded 42 
as an exclusive diastereomer, followed by ring-closing methathesis of protected alcohol 42 
to give key bicycle 43 in good yield. A further three steps were required to complete the 
carbon skeleton (Scheme 9): hydroxylation of the key C-8 position diastereoselectively 
under Sharpless conditions and generation of lactone 44 via a tethered Horner-Wadsworth-
Emmons reaction. 
 
 
 
 
Scheme 9. Felkin-Anh addition and ring-closing metathesis. 
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Dihydroxylation of 45 oxygenates the crucial C-7/C-11 positions with the correct 
configuration for the final lactone 46. Late-stage substrate-controlled reduction of enone 47 
affords the desired S configuration at C-3. Peripheral modification of 48 completes the 
total synthesis of thapsigargin in 6 steps (Scheme 10). 
 
 
Scheme 10. Dihydroxylation, late stage reduction and endgame. 
 
The strength of this synthesis lies in the ability to branch off at different stages of the 
synthesis to produce both natural and unnatural analogues. Not only was the total synthesis 
of thapsigargin completed, but thapsivillosin C and F, trilobolide and nortrilobolide were 
also synthesised, and later routes were devised to unnatural analogues from a single 
precursor present in the total synthesis, 49 (Scheme 11).
65
 However, the number of steps 
involved make it prohibitive for large scale industrial applications. Additionally, there has 
been no exploration of modifications involving the [5,7] guaianolide core, but this is not an 
inherent problem with the synthesis as the Felkin-Ahn allylation of 37 can be modified to 
provide other skeletal analogues. 
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Scheme 11. Unnatural analogue synthesis from a common precursor. 
 
1.4.2 Baran's synthesis of thapsigargin 
 
The Baran synthesis of thapsigargin was completed in 2017, in only 11 steps in length and 
has an overall yield of 0.33%.
66
 Starting with a Robinson annulation between (+)-
dihydrocarvone and ethyl vinyl ketone, all 15 skeletal carbons were installed immediately 
(Scheme 12). Bubbling molecular oxygen through the reaction mixture after the annulation 
event oxidised the C-6 position in one pot to deliver decalin 50 with complete 
stereoselectivity. Next, a one-pot, four-step procedure first generates the α-bromoketone 
from a pre-formed silyl enol ether, which is subjected to elimination conditions followed 
by silyl deprotection to generate an intermediate dienone. This dienone is then immediately 
converted via dehydration to the extended dienone using Burgess’ reagent. Finally, 
dihydroxylation on the most electron-rich alkene provides diol 51 with moderate 
diastereoselectivity. 
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Scheme 12. Baran's concise total synthesis 
 
Key intermediate 52 for the planned photochemical rearrangement was obtained through a 
Riley oxidation after primary alcohol protection, followed by a Mitsunobu inversion of the 
obtained unnatural C-8 alcohol epimer to install the requisite butanoate moiety. Baran et 
al. then built on Massanet's photosynthetic approach to the [5,7] skeleton (Scheme 13),
67,68
 
allowing dienone 52 to undergo a photochemical rearrangement to guaianolide skeleton 53, 
with further oxidation and peripheral modifications completing the total synthesis. The 
dienone rearrangement is thought  to involve the skeletal rearrangement of a diradical 
excited state 54, subsequent electron demotion to the ground state zwitterion 55 and finally 
nucleophilic attack by acetic acid. 
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Scheme 13. Massanet's approach to the guaianolide core. 
 
The strength of Baran's synthesis lies in its brevity and scalability. Reliance on well-known 
classical reactions (Sharpless dihydroxylation being the newest method in the synthesis) 
and avoidance of extreme temperature ranges makes it an attractive process in an industrial 
setting despite the rather low overall yield. Unfortunately the central photochemical 
rearrangement leaves little scope for skeletal modifications. 
 
1.4.3 Evans' synthesis of thapsigargin 
 
The group of P.A. Evans completed the second total synthesis of 2017; a short convergent 
synthesis consisting of 12 steps as the longest linear sequence and an overall yield of 5.8% 
from (R)-carvone 56.
69
 Starting with a selective allylic chlorination of 56, followed by 
reduction and protection to construct allylation partner 57, a diastereoselective Tsuji-Trost 
allylic alkylation with the enolate of fragment 58 as the nucleophile then installs all the 
required core carbons (Scheme 14). Ozonolysis of diene 59 affords the cleavage of the 
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electron-rich trisubstituted olefin as the major product. In situ aldol condensation of 60 
neatly affords the challenging tetrasubstituted olefin as well the exocyclic aldehyde 61. 
 
 
Scheme 14. Evans' synthesis of fragment 61 from (R)-carvone. 
 
Although not mentioned in the paper, starting material 62 is not readily commercially 
available and can be constructed in a classic 4-step sequence  from ethylene glycol 63 
(Scheme 15).
70
 
 
Scheme 15. Synthesis of starting material 62. 
 
The next stage involved the pinacol coupling of dicarbonyl 61 mediated by the in situ 
generation of the reagent [V2Cl3(THF)6]2[Zn2Cl6] (Scheme 16). Single electron reduction 
of both carbonyl groups generates the intermediate diradical dianion 64 which undergoes 
intramolecular coupling and lactonisation to the guainolide skeleton 65. Coordination of 
both anions to the reducing agent ensures the near complete diastereoselective outcome of 
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this reaction. Slow addition over the course of several hours was needed to ensure the 
minimisation of side reactions as a consequence of homocoupling. 
 
 
Scheme 16. Pinacol coupling and lactonisation. 
 
The conformation of the [5,7,5] ring system in 65 then provides access for selective 
hydration across the C-10/C-14 olefin under Mukaiyama conditions to the correct face of 
the molecule as in 66 to give 67 (Scheme 17).  
 
Scheme 17. Mukaiyama hydration. 
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Finally, the correct configuration of C-8 is set by substrate-controlled diastereoselective 
reduction in a sequential hydrogenation-oxidation-reduction procedure from benzyl ether 
68 to triol 69. Peripheral modifications similar to previous syntheses completes the total 
synthesis of thapsigargin (Scheme 18). 
 
 
Scheme 18.  Evans' thapsigargin endgame. 
 
A similar drawback of this synthesis like many other total syntheses is the use of 
temperature extremes and thus a lack of large scalability. It is however a robust synthesis, 
relying on many established procedures for an efficient constuction of the guaianolide 
core. It is also high-yielding and can easily provide many peripheral analogues on a 
research scale; however, the positioning of the C-9 chloride on 57 for the Tsuji-Trost 
allylic alkylation and the ketone on fragment 58 for the pinacol coupling exclude obvious 
modifications to the synthesis for the construction of skeletal analogues.  
 
1.5 Project aims 
 
As has been noted previously, total synthesis approaches to date have been varied but none 
have demonstrated sufficient flexibility to allow access to unnatural core-modified 
analogues of thapsigargin 1. The only obvious candidate for this modification would be the 
Ley synthesis, but the length of this synthesis is prohibitive. Therefore a flexible and rapid 
approach to the guaianolide skeleton is required. To address this issue, a joint project was 
devised between the Prunet and Férézou groups. First it was envisioned that the 
retrosynthetic analysis of thapsigargin 1 leads to a formal synthesis via Ley's intermediate 
70 in the synthesis of trilobolides, as the thapsigargin semi-synthesis by Christensen from 
38 
 
nortrilobolide 19 makes this a formal synthesis of thapsigargin (Scheme 19).
71
 
Disconnection of the natural lactone carbon-oxygen bond to access lactone 71 was 
envisioned to provide the correct face of exocyclic methylene 72 for a hydration event to 
construct the challenging C-11 tetrasubstituted centre. Oxidation of the C-7/C-8 olefin 
could potentially be directed by the correctly configured C-6 hydroxyl group and would 
provide a means to the other contiguous tertiary alcohol on C-7, as well as providing a 
means to control the biologically crucial stereochemistry of C-8. The key step would then 
build on expertise within the Prunet group of utilising metathesis in natural product 
synthesis, using a ring-closing ene-yne metathesis (RCEYM) to construct the C-13 
methylene unit 73. 
 
 
Scheme 19. A retrosynthetic approach to thapsigargin. 
 
The first project aim would be the development of a successful, robust and enantioselective 
route to allylation precursors such as 74. The second phase of the synthesis would include 
the construction of RCEYM precursors 75. The final stage would then focus on the 
synthesis of the [5,7] bicycles and further elaboration to thapsigargin and analogues.  The 
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second aim was to establish the proof of concept and deliver core-modified analogues of 
thapsigargin by our key RCEYM step. This analogue synthesis would then build on the 
work of Ley, chain length can be varied on demand. For instance, the addition of a 
homoallylic nucleophile can eventually lead to a [5,8,5]-core homologue of thapsigargin 
(Scheme 20). 
 
Scheme 20. Strategy towards the synthesis of core-modified analogues. 
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Chapter 2: Cyclopentenone derivatives 
 
2.1 Previous work by Férézou et al. 
 
Earlier work for this project conducted in the Férézou group by M. Jouanneau followed the 
broad retrosynthetic approach towards a fragment 75.
72
 The first approach involved the use 
of a one-pot Michael-intramolecular Wittig reaction to synthesise cyclopentenone core 76 
(Scheme 21).
73
 
 
Scheme 21. Sequential Michael-Wittig approach to cyclopentenones. 
 
Subsequent derivatisation to the crucial C-10 ketone proved to be too low yielding  to 
continue this synthetic strategy, therefore a new route was needed. Starting from 
commercial diketone 77, deprotonation and methylation led to methyl enol ether 78. 
According to a similar procedure from Ciufolini,
74
 the generation of the thermodynamic 
enolate using LiHMDS (pKaH ~26) could be achieved at low temperature due to the 
weaker base favouring the thermodynamic enolate. Further assistance of the methyl enol 
ether  by coordinating the lithium counterion promotes γ-deprotonation, much like α-
deprotonation reactions are assisted by the adjacent carbonyl in the classic enolate 
formation (Scheme 22). The use of Mander's reagent
75
 (methyl cyanoformate) then 
resulted in exclusive C-methoxycarbonylation to give ester 79. The use of LDA (pKaH 
~36) as a base however forms the kinetic enolate as evidenced by the generation of diester 
80 as the major product.   
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Scheme 22. Kinetic vs. thermodynamic enolate methoxycarbonylation. 
 
1,4-Cyanation of enone 79 could then be performed using Nagata's reagent
76
 
(diethylaluminium cyanide). The Lewis acidity of the reagent simultaneously activates the 
C-2 carbonyl as well as being a source of the cyanide anion. The presence of  a leaving 
group (OMe) allows the resultant enolate to regenerate the enone functionality in nitrile 81 
(Scheme 23). 
 
 
Scheme 23. Lewis acid mediated 1,4-cyanation. 
 
Diastereoselective reduction to alcohol 82 is performed using sodium borohydride at low 
temperature in order to avoid further reduction of the ester functionality. The relative steric 
hindrance of the C-5 position favours the 1,2 reduction, while the steric bulk of the ester 
below the face of the cyclopentenone directs the incoming hydride source to the opposite 
face, accounting for the diastereoselectivity in favour of the major 1,3-cis product (Scheme 
24).  
 
 
Scheme 24. Diastereoselective 1,2 reduction of enone 81. 
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Once alcohol 82 was converted to the corresponding Weinreb amide 83, the diastereomers 
could be separated with conventional column chromatography, and a final addition of 
methylmagnesium bromide furnished the allylation precursor ketone 84 (Scheme 25). 
 
 
Scheme 25. Synthesis of ketone 84 avoiding overaddition. 
 
2.2 Synthesis of allylation precursors 
 
2.2.1 Regioselective alkoxycarbonylation 
 
To start the synthesis, methyl enol ether 78 was generated from diketone 77 in quantitative 
yield. Although the crude material had acceptable purity as measured by 
1
H NMR 
spectroscopy, it was possible to recrystallise the product from cyclohexane (Scheme 26). 
 
 
Scheme 26. Enolate methylation. 
 
Deprotonation and methoxycarbonylation using Mander's reagent proved to be more 
difficult than previously indicated, however, with variable and non-reproducible yields. On 
larger scale especially, the yield dropped far below 50% (Scheme 27), with side products 
80 and 85 and other unidentified minor products becoming more significant and often 
inseparable even through multiple chromatographic purifications. The generation of double 
addition products implies the formation of LiCN in the reaction mixture, but attempts to 
take advantage of this in order to install the required C-5 nitrile under the reaction 
conditions using Lewis acids proved fruitless. Mander's reagent has been documented to 
produce unwanted side-reactions in certain ketone substrates during attempts at C-
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acylation, being sensitive to very specific reaction conditions.
77,78
 This limitation to scaling 
up and moving the synthesis forward led to a re-evaluation of this reaction.  
 
 
Scheme 27. Regioselective methoxycarbonylation using Mander's reagent. 
 
Different carbonyl electrophiles were investigated: dimethyl carbonate 86,
79
 Weinreb 
amides 87
80
 and 88,
81
 dimethyl oxalate 89,
82
 ethyl chloroformate 90
83
 and methyl 
chloroformate 91.
84
 Weinreb amides 87 and 88 first had to be synthesised from N,O-
dimethylhydroxylamine (Scheme 28).
85
 Table 2 summarises the results from the enolate 
addition to the various reagents.  
 
 
Scheme 28. Various carbon electrophiles.  
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Table 2. Acylation attempts. 
 
 
Entry Electrophile Temp (°C) Time (h) Yield (%) (A:B:C) 
1 86 -78 to rt 24 nr 
2 87 -78 to rt 24 nr 
3 88 -78 to rt 24 nr 
4 89 -78 to rt 24 nr 
5 90 -78 to 0 2 67 (3:0:1) 
6 91 -78 to 0 2 77 (3.5:1:0) 
7
a
 91 -78 to 0 2 86 (>20:1:0) 
a) Reverse addition. 
 
Reactions with electrophiles 86-89 (Entries 1-4) did not produce any desired product even 
with extended reaction times, and would possibly require even more forcing conditions to 
proceed. However, the use of chloroformates 90 and 91 (Entries 5-7) gave exclusive C-
alkoxycarbonylation. Although chloroformates commonly lead to O-acylation with 
ambident enolates, a number of factors contribute to the C-acylation exhibited. The small 
lithium cation is less electropositive compared to Na
+
 or K
+
, leading to a more covalent 
character of the Li-O bond, and consequently a reduced nucleophilicity of the oxygen 
atom. Empirical evidence suggests that tightly bound ion pairs and higher aggregates lead 
to increased C attack.
86
 The use of lower polarity solvents such as THF favours the Li-O 
ion pairing leading to the formation of higher aggregates. Although the low temperature is 
not likely to lead to higher aggregates,
87
 it, along with reverse addition, does control the 
deprotonation of the resulting product by unreacted enolate which would lead to over-
addition of methyl chloroformate, although a slow raising of the temperature to 0°C is still 
required to drive the reaction to completion. Finally, the presence of a methoxy substituent 
at the β-position of 78 is expected to enhance the γ-acylation of dienolates due to added 
                                           
86
 Mayr, H.; Breugst, M.; Ofial, A. R. Angew. Chem. Int. Ed. 2011, 50, 6470. 
87
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electron density as the γ-reaction site,88 where normally the greater electron density lies at 
the α-position of dienolates of α,β-unsatured ketones, leading to α-alkylation/acylation.89 
 
2.2.2 Selective enone reduction 
 
1,4-Cyanation of enone 79 using Nagata's reagent was practically difficult; a commercial 
supply was not available and synthesis of the reagent is highly hazardous.
90
 Fortunately the 
use of TMSCN in combination with a Lewis acid
91
 to mimic the dual role of Nagata's 
reagent was amenable to reproducible large scale synthesis (Scheme 29). 
 
 
Scheme 29. Alternative cyanation procedure. 
 
2.2.2.1 Diastereoselective enone reduction 
 
Previous results indicated good diastereoselectivity when reducing nitrile 81 at low 
temperature with NaBH4 to alcohol 82. However, it was not possible to reproduce this 
result and the reaction consistently produced a lower diastereomeric ratio of 4:1, even at 
higher temperatures (Table 3, entries 1-3). Luche reduction conditions (Entry 4) produced 
an equal mixture of diastereomers, while milder or bulkier hydrides failed to react or 
caused extensive degradation (Entries 5 and 6), presumably from over-reduction and 
competing 1,4-conjugate reduction although the side products could not be identified. 
Finally, it was decided to move forward with the inseparable diastereomeric mixture (4:1) 
obtained at lower temperatures (Entry 7) to improve reproducibility and overall yield by 
minimizing over-reduction of the ester functionality.  
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Table 3. Reduction of 81. 
 
 
Entry Reducing agent Solvent 
Temp 
(°C) Time 
Yield 
(%) 
d.r. 
(cis:trans) 
1 NaBH4 MeOH -55 1h 46 3.5:1 
2 NaBH4 MeOH -42 1h 70 4:1 
 
    quant
a
 5:1
b
 
3 NaBH4 MeOH -10  quant
a
 3:1 
4 NaBH4, CeCl3 MeOH -78 30 min quant
a
 1:1 
5 Na(CH3COO)3BH
 
AcOH/CH2Cl2 
(1:1) 
rt 2h n.r. n.r. 
6 L-selectride THF -78 2h 0 n/a 
7 NaBH4 MeOH -78 1h 93 4:1 
a) crude yield. b) only on 0.558 mmol scale. 
 
2.2.2.2 Enantioselective enone reduction 
 
A preliminary investigation into the asymmetric reduction of nitrile 81 by Férézou et al. 
revealed that the Corey-Bakshi-Shibata (CBS) reagent could be used to reduce the enone 
carbonyl with good to excellent enantioselectivity, but unfortunately with little control over 
the diastereoselectivity (Scheme 30).
72,92
 
 
 
Scheme 30. CBS reduction of nitrile 81. 
 
To date only one previous report has been published concerning the catalytic asymmetric 
reduction of 5-membered γ-keto esters 92 (Scheme 31). The ruthenium(II)-catalysed 
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 Corey, E. J.; Helal, C. J. Angew. Chem. Int. Ed. 1998, 37, 1986. 
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asymmetric transfer hydrogenation (ATH) of rac-3-methoxycarbonyl-1-indanone 93 by 
Mohar et. al. proceeded with excellent diastereoselectivity and enantioselectivity when 
performed under dynamic kinetic resolution (DKR) conditions using γ-sultam-core ligand 
94
93
, which is  based on the conventional Noyori 1
st
 generation TsDPEN ligand 95.
94
 
 
 
 
Scheme 31. Substrates and ligands for Ru(II)-catalysed ATH-DKR. 
 
By observing that δ-keto ester 96 produced equal mixtures of diastereomers and therefore 
did not undergo racemisation under the reaction conditions they postulated that 1-indanone 
93 underwent DKR by epimerisation of C-3 via the benzylic/allylic position of enol-
tautomer 97 (Scheme 32).  
 
                                           
93
 Rast, S.; Modec, B.; Stephan, M.; Mohar, B. Org. Biomol. Chem. 2016, 14, 2112. 
94
 Fujii, A.; Hashiguchi, S.; Uematsu, N.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1996, 118, 2521. 
48 
 
 
Scheme 32. ATH-DKR of keto esters 96 and 93. 
 
The transition state based on previous calculations for Ru(II)-ATH (Scheme 32)
95
 shows 
that the diastereoselectivity arises from si-face attack onto (S)-93. The (S)-enantiomer is 
preferentially reduced because the steric bulk of the ester is pointing outward away from 
the bulky diamine ligand. This is further helped by a favourable electrostatic interaction 
between the partial positive charge of the p-cymene C-H hydrogens and the substrate’s 
electron-rich aromatic π-system. Applying this rationale to nitrile 81 however would 
necessitate a change in ligand. A reasonable assumption can be made that the phenyl ring 
in keto ester 93 is planar in nature and does not clash with the diamine phenyl rings. 
However, when using nitrile 81, although the nitrile can be assumed to be planar and 
similarly sterically undemanding, the C-15 methyl hydrogens would be expected to 
interfere with the 94 diamine phenyl (Figure 10). Using Noyori's original (R,R)-TsDPEN 
ligand, this interaction on the si-face of the (S)-enantiomer can be minimised and therefore 
this ligand would be expected to produce the desired product (3S,1R)-82 selectively.
96,97
 
This is not the case with both faces of the (R)-enantiomer, where the C-15 methyl and the 
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C-1 ester produce unfavourable interactions in the re and si-face respectively, the result 
being a slow hydrogen transfer reaction. 
 
 
Figure 10. Ligand-substrate steric interactions for 81 and 93. Ru(II) and p-cymene omitted 
for clarity. 
 
Indeed this is the case; when the reaction was carried out with the commercially available 
RuCl[(p-cymene)(R,R)-TsDPEN] complex in the presence of a transfer hydrogenation 
source the reduction of 81 went to completion in 18 hours with good enantiomeric excess  
(Scheme 33), as determined by HPLC of the crude product.  
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Scheme 33. Trial reaction using ATH-DKR. 
 
This proof of concept was encouraging, but after purification a reduced diastereomeric 
ratio was always encountered. Assuming that the reaction conditions were sufficient to 
epimerise the C-3 position in situ and that almost if not all formic acid was removed during 
aqueous workup, then residual triethylamine could be reasonably expected to cause 
epimerisation of the product in combination with silica gel. Rigorous removal of 
triethylamine during workup increases the diastereomeric ratio not only in the crude 
product after removal of volatiles but also in the final product after purification (Scheme 
34).  
 
 
Scheme 34. Optimisation of ATH-DKR. 
 
By forming the catalyst in situ from the [RuCl(p-cymene)]2 dimer and (R,R)-TsDPEN 95 
and rigorously removing adventitious water from the solvent system beforehand, the 
reaction could be optimised to give good yields and excellent enantiomeric excesses; there 
was no reactivity difference even when performed on decagram scale. Presumably the 
remaining trans diastereomer arises from the weakly disfavoured steric interaction of the 
ligand with the si-face of (R)-81 (Figure 10); although the C-3 ester is now facing inwards 
towards the catalytic site, it does not directly clash with one of the diamine phenyl 
substituents. Similarly, the lower enantiomeric excess exhibited by the trans diastereomer 
can be explained by the disfavoured re-face of (R)-81, where the steric penalties can be 
expected to be slightly lower than that of the re-facial hydrogenation of (S)-81 as the ester 
is now pointing outwards. 
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A few attempts to explore the generality of ATH on α,β-unsaturated γ-keto esters with the 
TsDPEN ligand 95 met with failure (Scheme 35). No reaction was observed with ketoester 
79 under the reaction conditions; presumably, the electron-donating β-OMe substituent 
either raises the reduction potential above that of the catalytic system, as electron-rich 
ketones are known to generally be poor substrates under Noyori ATH conditions
98
 or 
enone 79 introduces steric incompatibility into the transition state, according to Figure 10, 
in a way that nitrile 81 does not. Attempts to generate the Weinreb amide analogue of 81 
for testing were unsuccesful (Scheme 35 and Table 2, Entry 2) as direct conversion of the 
ester resulted in slow decomposition. 
 
 
Scheme 35. ATH of methyl enol ether 79 and attempted amidation of ester 81. 
 
2.2.3 Weinreb amide synthesis 
 
Although the conversion of ester 82 to its Weinreb amide according to previous conditions 
was not problematic (Scheme 36),
99
 a consistent outcome was noticed whereby the 
diastereomeric ratio of the starting material (dr 4:1 cis) changed during the course of the 
reaction and generated a product with an increased diastereomeric ratio (dr 9:1 cis) without 
recovery of either starting materials or identifiable byproducts. The diastereomers of ester 
82 are not separable by standard chromatographic means, and although Weinreb amide 83 
can be separated from the accompanying trans diastereomer, it is a difficult separation that 
often requires several chromatographic separations before a sufficiently pure product is 
obtained, thus the reason for this diastereomeric enrichment is of clear interest.  
 
                                           
98
 Noyori, R.; Hashiguchi, S. Acc. Chem. Res. 1997, 30, 97. 
99
 Basha, A.; Lipton, M.; Weinreb, S. M. Tetrahedron Lett. 1977, 18, 4171. 
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Scheme 36. Weinreb amide formation driven to completion. 
 
Under normal conditions, the reaction takes around 18-24 hours to completely consume the 
starting material. Reducing the equivalents of hydroxylamine salt and activating agent 
trimethylaluminium and analysing reaction aliquots at a halfway time interval via NMR 
allows for useful insights into the reaction mechanism (Figure 11). The diagnostic peak for 
the diastereomeric ratio of 82 is that of the proton at C-3 (cis = δ 4.56 ppm, trans = δ 4.91 
ppm), as it is distinct in each diastereomer as well being separated from other protons. The 
conversion of cis-82 is fast compared to the that of trans-82 as evidenced by the decreasing 
diastereomeric ratio over time of the starting material and initial exclusive formation of 
cis-83. After 4 hours the conversion stalled according to TLC analysis and essentially pure 
cis-83 was present according to NMR analysis of the crude material and could be isolated 
without laborious chromatographic diastereomer separation. 
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Figure 11.
 
NMR analysis of the sub-stoichiometric conversion of ester 82 to amide 83. 
 
Because these reactions were performed on the racemic ester 82, attempts were made to 
check that an in situ epimerisation was not occurring under the reaction conditions 
(Scheme 37). Subjecting the starting material of varying diastereomeric ratios to various 
conditions did not however result in any change.  
 
 
Scheme 37. Epimerisation conditions. 
 
An explanation for this behaviour would likely be due to the assistance of the C-3 hydroxyl 
group; the cis configuration allows for a relatively close proximity to the C-1 ester when 
compared to trans-82. Many such examples of hydroxyl-assisted ester reactivity exist, 
especially for saponification reactions, for instance the selective saponification of the cis-
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ester in diester 98 during the total synthesis of macrolide antibiotic (±)-brefeldin A by 
Yamaguchi (Scheme 38).
100
 
 
 
Scheme 38. Selective saponification during the total synthesis of (±)-brefeldin A. 
 
Looking at a possible minimised structure (MM2, Chemdraw) of 82 and comparing it to a 
simplified Na
+
-bound alkoxide 99 (Figure 12), it can be seen that the ester carbonyl lone 
pairs can assist in the ion-pairing of sodium, which can be extended to the synthesis of 
amide 83 by the assumption that Lewis acid coordination is fast compared to amine 
substitution.  
 
 
Figure 12. Minimisations of ester 82 and alkoxide 99. 
 
In the aluminium cis-complex 100 this means that the Lewis acid can now intramolecularly 
activate the C-1 ester for the conversion to Weinreb amide 83, something which is not 
possible with aluminium complex trans-101 (Scheme 39).  
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Scheme 39. Hydroxyl-assisted amide synthesis. 
 
Based on this rationale, a set of optimised conditions can then be selected to take 
advantage of the faster reaction of cis-82 (Scheme 40). After 18 hours, full conversion of 
cis-82 is observed and trans-82 can be recovered alongside the nearly diastereomerically 
pure product 83. An adjustment to the reagent quantities has to be made according to the 
starting material diastereomeric ratio. 
 
 
Scheme 40. Optimised conditions for Weinreb amide synthesis. 
 
Although some attempts were made to recycle the isolated trans-82 to the corresponding 
enone this was not successful, and because the remaining quantities of the trans alcohol 
after ATH-DKR were so low, this was not pursued further (Scheme 41). 
 
 
Scheme 41. Allylic alcohol oxidation attempt. 
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2.2.4 Allylation ketone precursor 
 
With the diastereomerically pure Weinreb amide 83 in hand, synthesis of the 
corresponding methyl ketone was straightforward. Addition of excess methylmagnesium 
bromide cleanly converted the amide to ketone 84 (Scheme 42).  
 
 
Scheme 42. Synthesis of ketone 84. 
 
The ketone was not stable to standard, deactivated or pH neutral silica for chromatographic 
purification, and it epimerised easily at the C-1 position. Fortunately, it was found to be 
sufficiently pure to continue the synthesis using the crude product. Although the racemic 
crude ketone can be isolated as a yellow oil, addition of diethyl ether to crude (3S,1R)-84 
resulted in crystallisation. A sufficiently large single crystal could be grown via slow 
vapour diffusion and analysed by X-ray crystallography (Figure 13) in order to finally 
establish the absolute configuration produced by the earlier ATH-DKR experiments. 
 
Figure 13. Single-crystal structure of 84. Single unit and H-bonding interactions shown. 
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2.3 Conclusions 
 
Ketone 84, the precursor required for allylation, has been synthesised according to 
modified methodology from a previously established path. These modifications allowed 
reliable production of the highly enantioenriched synthetic intermediate 84 in decagram 
quantities in good to excellent yields, an outcome that compares favourably with previous 
results (Scheme 43).  
 
 
Scheme 43. Route comparison with previous attempts. 
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Chapter 3: Synthesis of the [5,7]-bicyclic core 
 
3.1 Previous work by Férézou et al. 
 
Analogous to Ley's allylation approach of ketone 37 (Scheme 8), chelation-controlled 
Grignard addition to ketoester 102 proceeded with good yield and exclusive 
diastereoselectivity. Ketonitrile 84 exhibited a best-case diastereomeric ratio of 4:1 in 
favour of the desired diastereomer 103 when an excess of allylmagnesium bromide and 
zinc chloride was used (Scheme 44). This outcome was attributed to competing chelation 
effects of the C-3 alcohol and C-5 nitrile with the zinc-activated C-10 ketone which change 
with temperature. The inseparable mixture of diastereomers was carried through the rest of 
the synthesis. 
 
 
Scheme 44. Stereoselective allylation reactions. 
 
One-pot sequential double hydroxyl protection of 103 followed by reduction of nitrile 104 
with DIBAL-H furnished aldehyde 105 in good yield over two steps (Scheme 45). Later 
work also showed that mono-protection of the C-3 alcohol could allow the separation of 
the previously inseparable diastereomers. 
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Scheme 45. One-pot double-protection, and DIBAL-H reduction. 
 
Alkynyl addition was accomplished by deprotonation of the corresponding terminal alkyne 
and addition of the resulting anion to aldehyde 105 at low temperature, followed by 
quenching of the resulting alkoxide with water or an electrophilic trapping agent (Scheme 
46). Initial assignment of the resulting exclusive diastereomers by M. Jouanneau was done 
on the basis of nucleophilic attack on the minimal-energy conformer 106, because 
corroborating evidence from NOE studies was difficult to obtain. Later work performed by 
R. Bonnepally involving NOE studies on more rigid cyclised derivatives suggested that the 
opposite diastereomer 107 had formed. This could be rationalised more appropriately by 
consideration of the more reactive conformer and this will be explored later in this chapter.  
 
 
Scheme 46. Stereoselective alkynylation. 
 
After a screening of some common metathesis conditions, the key ring-closing ene-yne 
metathesis step was accomplished on various substrates in toluene using 10 mol% of     
2
nd
-generation Grubbs initiator 108 under elevated temperatures and an ethylene 
atmosphere (Scheme 47). These conditions were successful for all the substrates, although 
reaction of the substrate bearing free allylic alcohol was shown to be less efficient 
compared to those of protected analogues and required the use of 20 mol% of catalyst to 
deliver reproducible yields. In many cases an hydroxyl group proximal to the metathesis 
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site can increase reactivity in different types of metathesis reactions,
101
 but a full 
accounting for this particular case was not explored. 
 
 
Scheme 47. Ring-closing ene-yne metathesis. 
 
3.2 RCYEM precursors 
 
3.2.1 Ketone allylation 
 
Subjection of ketone 84 to the previous allylation conditions (Scheme 44) led to variable 
outcomes in many cases, mostly characterised by low yields and poor diastereoselectivities 
(Scheme 48). Due to the highly hygroscopic nature of the pre-dried ZnCl2, it is hard to rule 
out interference of moisture from the atmosphere, although the large excess of Grignard 
reagent which is mixed with the ZnCl2 before the addition of the ketone substrate should 
minimize this.  
 
 
Scheme 48. Trial zinc-mediated allylations. 
 
This barrier to efficient stereoselective access of the C-10 tertiary alcohol prompted a 
closer look at the reaction conditions. First, the rationale for transmetallation of the 
Grignard reagent with ZnCl2 is that the high reactivity of allylmagnesium halides often 
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leads to diasteoselectivity problems because the rates of reaction approach the limit of 
diffusion,
102
 whereas corresponding organozinc halides can show improved selectivity, 
although the reduced Lewis acidity of Zn(II) does not activate carbonyl compounds 
well.
103
 The first assumption that can be made is that deprotonation of the free alcohol is 
much faster than nucleophilic attack (Scheme 49) and that this leaves an alkoxide-metal 
ion pair which can coordinate to the C-10 carbonyl. The large electron density surrounding 
the oxygen would then also be expected to largely eliminate any coordination competition 
with the C-5 nitrile. In addition, if chelation competition with a C-5 substituent was taking 
place, a similar chelation competition would be expected in ketoester 102 leading to 
complex 109, which does not correspond to the observed outcome of near complete 
diasteroselectivity. 
 
 
Scheme 49. Initial deprotonation and unlikely chelation competition in ketoester 102. 
 
The identity of M can be ambiguous, as the stoichiometric mixing of alkylmagnesium 
halides and zinc chloride is known to result in mixed magnesium-zinc alkyl halide 
species.
104
 However, both Zn
2+
 and Mg
2+
 can form multicoordinate complexes, which is 
important to differentiate between ketonitrile 84 and ketoester 102. Figure 14 shows a 
possible minimized interaction 110 (MM2, Chemdraw) of Mg
2+
, Zn
2+
, a bridging Cl
-
 (as 
Br
-
 is not expected to participate as a bridging anion) and the ketoester substrate. The 
alkoxide and both carbonyl groups are able to participate in coordination to the more 
oxophilic
105
 Mg
2+
 and this leaves only the si-face accessible for nucleophilic attack, as 
evidenced by the high stereocontrol of this reaction at varying temperatures (Scheme 44). 
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Figure 14. Possible configuration of chelate complex between mixed magnesium-zinc 
alkyl halides and ketoester 102. 
 
This type of dinuclear chelate complex 111 is widely invoked for the asymmetric 
alkylations of carbonyl compounds by alkyl magnesium/zinc reagents using chiral diols or 
amino alcohols to induce enantioselectivity (Figure 15). In this case, one metal centre is 
usually coordinated to the carbonyl while the other effects alkyl transfer to one face 
preferentially.
106
 
 
 
Figure 15. Asymmetric alkylation chelate complex involving two metal centres. 
 
The tridentate nature of ketoester 102 is not present in ketonitrile 84, and the smaller steric 
encumbrance of the "needle-like" C-5 nitrile both indicate that the re-face is now more 
accessible (Figure 16). Chelate complex 112 can also be expected to be more susceptible to 
variation in temperature compared to complex 110, as the now internally coordinatively-
unsaturated metal centre is not as rigidly positioned.  
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Figure 16. Possible configuration of chelate complex between mixed magnesium-zinc 
alkyl halides and ketonitrile 84. 
 
A similar temperature dependence was noticed by Sibi et al. during radical allylation 
reactions of α-bromooxazolidinone imides (Scheme 50). 107  The Lewis acid-mediated 
allylation of 113 at low temperature proceeded with a small selectivity in favour of the 
unexpected diastereomer 114. An increase in the temperature led to the formation of the 
opposite diastereomer 115 as the major product.  
 
 
Scheme 50. Temperature dependence of radical allylations. 
 
Taking into account all their observations, they proposed the pathway laid out in Scheme 
51. Without a Lewis acid, dipole-dipole minimized structure 116 is thought to exist 
predominantly, and only the portion of molecules that exist as rotamer 117 can adopt a 
Lewis acid chelate before radical generation. Mono-complexed rotamer 118 can still 
generate radical 190 which can proceed to product 114 with weak stereoinduction in 
favour of the (S) configuration. At higher temperatures, bond rotation in radical 119 is 
more likely to form bidentate radical 120, which leads to the desired (R) configuration 115. 
The use of slower radical trapping agents to allow time for bond rotation and favour the 
(R)-configured product supported this explanation. It should also be noted that changing 
the nature of the chelating metal centre also had an effect on diastereoselectivity, attributed 
to changing steric interactions favouring chelation of MgBr2 over that of Yb(OTf)3.  
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Scheme 51. Temperature dependant allylation proposed pathway. 
 
This predetermined conformation before Lewis acid involvement could be key to the 
selectivity of the allylation reaction of ketonitrile 84. If, like before, the assumption is 
made that deprotonation of ketonitrile 84 is much quicker than allylation, then 
uncomplexed alkoxide 121 can play a large role in the selectivity, especially at low 
temperatures (Figure 17). In particular, a charge-dipole interaction can be considered part 
of the initial conformation after deprotonation. Analogous to the temperature dependence 
of Sibi's radical allylations, if the thermodynamic chelation control is not fully established 
at low temperatures, the re face might be expected to react with an allylating agent as a 
kinetic effect, leading to the observed reversed selectivity. The tridentate nature of 
ketoester 102 would be expected to enforce the chelated complex quicker due to the 
increased favourable electrostatic interactions. 
 
 
Figure 17. Possible conformation of the corresponding alkoxide of ketonitrile 84. 
 
On this basis modifications can be made to the allylation reaction conditions in order to 
suit nitrile 84 better. Stoichiometric and catalytic amounts of zincates [R2Zn-R]
-
 have been 
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shown to add efficiently to a wide range of ketone substrates to yield the corresponding 
tertiary alcohols (Scheme 52).
108
 In addition, the cyclic transition-state 122, involving 
carbonyl activation by a [MgCl]
+
 species, fits closely with proposed chelate model 112.  
 
 
Scheme 52. Zn(II)-ate mediated ketone alkylations. 
 
The addition of LiCl to standard Grignard reagents in THF to form so-called "turbo-
Grignard" reagents by Knochel has led to greatly enhanced reactivity and functional group 
tolerance in many cases (Scheme 53).
109
 This has been proposed to occur through the 
breaking of polymeric aggregates 123 to give monomeric species due to the high polarity 
of Li
+
. This inclusion of Li
+
 could be used in chelated complex 112 to effect faster 
chelation and avoid the involvement of complex 121.  
 
 
Scheme 53. Use of "Turbo Grignards" in sensitive substrates. 
 
It is also possible to use zinc(II)-ate complexes to increase the steric bulk of the 
nucleophile. By first generating the catalytic Zn complex 124, which includes two bulky 
non-transferable alkyl groups, from the corresponding starting Grignard reagent 
TMSCH2MgCl, and subsequently using that complex to transfer alkyl nucleophiles to 
substrates, Hatano was able to efficiently alkylate difficult substrates that were prone to 
                                           
108
 Hatano, M.; Suzuki, S.; Ishihara, K. J. Am. Chem. Soc. 2006, 128, 9998. 
109
 Krasovskiy, A.; Knochel, P. Angew. Chem. Int. Ed. 2004, 43, 3333. 
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hydride transfer and other side-reactions even with the previous inclusion of catalytic 
ZnCl2 (Scheme 54). 
110
 Additionally, these reactions could be performed with bromide and 
iodide Grignard reagents, which are easier to obtain because of the high propensity of Mg 
to insert into these C-X bonds, but are also less reactive alkylating reagents compared to 
RMgCl.  
 
 
Scheme 54. Alkylation catalysed by Zn(II)-ate complexes bearing non-transferable 
ligands. 
 
Finally, reagents generated by stoichiometric transmetallation of Grignard reagents with 
the highly oxophilic CeCl3 have previously shown remarkable nucleophilicity and reduced 
basicity, resulting in highly selective addition of hindered nucleophiles and 
hindered/enolisable ketones (Scheme 55).
111
 CeCl3 exhibits a tendency to form chelated 
complexes with ketones, and could improve the low temperature chelation of ketonitrile 
84. 
 
 
                                           
110
 Hatano, M.; Ito, O.; Suzuki, S.; Ishihara, K. Chem. Commun. 2010, 46, 2674. 
111
 Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. J. Am. Chem. Soc. 1989, 111, 4392. 
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Scheme 55. Imamoto's CeCl3 mediated alkylations. 
 
Re-examination of temperature dependence in the original allylation conditions (Entries 1-
3, Table 4) revealed no further improvement over ambient temperature. In fact, the 
reduction in yield of 103 in Entry 3 indicates that side-reactions occur more readily at 
higher temperatures with no improvement in diastereoselectivity. The chloride Grignard 
reagent (Entry 4) showed a decreased yield as well, possibly due addition reactions to the 
C-5 nitrile because of its higher reactivity.
112
 The lithium chloride salt effect (Entries 5) 
also caused additional reactivity problems, creating a mixture of multi-allylated products. 
Stoichiometric and catalytic use of zinc(II)-ates (Entries 6 and 7) gave similarly 
disappointing reactivity issues. Hatano's alkylsilylzinc(II)-ate catalytic conditions did 
improve the yield when used in combination with allylmagnesium chloride (Entry 9) but 
the added steric bulk did not lead to better diastereoselectivity. The inherent high reactivity 
of these complexes meant that the reactions had to be run at -78°C in order to avoid 
competing side-reactions. Fortunately, the use of oxophilic alkylcerium reagents (Entries 
10 and 11) provided consistent yields with superior stereocontrol. Avoiding the 
deactivation of CeCl3 through hydrolysis during the drying of the cerium chloride hydrate 
proved key to successful reproducibility. The use of allylMgBr in this reaction leads to 
comparable yields and diastereomeric ratios. 
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 Allen, B. B.; Henze, H. R. J. Am. Chem. Soc. 1939, 61, 1790. 
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Table 4. Allylation of ketonitrile 84. 
 
 
Entry RMgX Additives Temp (°C) Yield (%) S:R 
1 AllylMgBr (4 equiv) ZnCl2 (5 equiv) rt 50 2.8:1 
2 AllylMgBr (4 equiv) ZnCl2 (5 equiv) 0 52 1.6:1 
3 AllylMgBr (4 equiv) ZnCl2 (5 equiv) 40 23 2.6:1 
4 AllylMgCl (4 equiv) ZnCl2 (5 equiv) rt 40 3:1 
5 AllylMgBr (4 equiv) ZnCl2 (5 equiv)  
LiCl (2 equiv) 
rt 33 2:1 
6 AllylMgCl (3 equiv) ZnCl2 (1 equiv)  
LiCl (2 equiv) 
rt 5 3:1 
7 AllylMgBr  (3 equiv) ZnCl2 (0.1 equiv) rt 9 3:1 
8 AllylMgBr (4 equiv) ZnCl2 (0.1 equiv) 
TMSCH2Cl (0.2 equiv) 
 LiCl (2 equiv) 
-78 44 2.2:1 
9 AllylMgCl (4 equiv) ZnCl2 (0.1 equiv) 
TMSCH2Cl (0.2 equiv)  
LiCl (2 equiv) 
-78 73 3:1 
10
a 
AllylMgCl (2.2 equiv) CeCl3 (2 equiv) -78 88 4:1 
11
b 
AllylMgCl (2.2 equiv) CeCl3 (2 equiv) -78 93 6:1 
a) CeCl3.7H2O dried at 140 °C for 8h b) Careful drying of CeCl3.7H2O
113
 
 
Therefore highly active cerium chlorides seemingly led to efficient chelation even at low 
temperature, helping to improve facial selectivity of incoming nucleophiles. The 
inseparable mixture of diastereomers was carried over into the next stage of the synthesis. 
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3.2.2 Stereoselective alkynylation 
 
3.2.2.1 Alkynylation precursor 
 
Selective TBS-protection of the C-3 alcohol led to mono-silylated alcohol 125, which 
allowed separation of the allylation product diastereomers (Scheme 56). Protection of the 
tertiary C-10 alcohol as the triethylsilyl ether 104 proceeded in excellent yield and this silyl 
ether proved to be a very stable synthetic intermediate, as large quantities could be stored 
at ambient conditions for >6 months without obvious degradation.  
 
 
Scheme 56. Sequential double silylation. 
 
The selective reduction of nitrile 104 using excess DIBAL-H did proceed with high 
conversion to the presumed imine intermediate, but standard workup conditions for 
DIBAL reductions (Fieser method
114
/Rochelle's salt) generally gave somewhat 
disappointing crude yields, exacerbated by large yield reductions during subsequent 
chromatographic purification (Scheme 57). 
 
 
Scheme 57. Initial attempts at nitrile reduction. 
 
Mild imine hydrolysis has previously been used to good effect on sensitive substrates 
within the Prunet group during the synthesis of the tricyclic core 126 of taxol.
115
 Reduction 
                                           
114
 Ho, T.-L.; Fieser, M.; Fieser, L.; Danheiser, R.; Roush, W.; Smith, J. In Fieser and Fieser’s Reagents for 
Organic Synthesis; John Wiley & Sons, Inc., 2013, 253. 
115
 a) Letort, A.; Aouzal, R.; Ma, C.; Long, D. L.; Prunet, J. Org. Lett. 2014, 16, 3300. 
 b) Letort, A.; Long, D. L.; Prunet, J. J. Org. Chem. 2016, 81, 12318. 
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of TMS-protected cyanohydrin 127 was carried out using DIBAL-H in hexane, after which 
the addition of silica gel facilitated the mild hydrolysis (Scheme 58).  
 
 
Scheme 58. Nitrile reduction during synthetic efforts towards taxol. 
 
Applying this strategy to nitrile 104 conveniently furnished the desired crude aldehyde 105 
after DIBAL-H reduction by stirring with an amount of silica gel for up to 4 hours 
followed by simple filtration (Scheme 59). The crude aldehyde is recovered quantitatively 
and essentially pure by NMR and was therefore carried on into the next reaction without 
further purification. 
 
 
Scheme 59. Improved nitrile reduction through mild imine hydrolysis. 
 
3.2.2.2 Aldehyde alkynylation  
 
As NOE studies had previously suggested the formation of the (S)-configured C-6 
secondary alcohol during alkynylation of aldehyde 105, it is likely that cis-105 is the 
reactive conformer. An energy difference of approximately 2.3 kcal/mol (MM2, 
ChemBio3D) between the cis and trans conformers allows for an equilibrium with some 
cis character during the reaction. A rough estimate of the rotational energy barrier (ΔE° ≈ 
5.0 kcal/mol, MM2, ChemBio3, calculated at 1° intervals, Figure 18) then also allows for 
the rapid interconversion between both conformations. 
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Figure 18. Rotational energy diagram of aldehyde 105. 
 
Because the product distribution does not mirror the expected equilibrium between the two 
conformations, the reaction can be assumed to be operating under the Curtin-Hammett 
principle, whereby the transition state leading to cis-105 lies lower in lower in energy to 
the transtition state towards trans-105, leaving the reaction under kinetic control. A 
previous investigation of the reactivity differences between the conformation of acrolein 
has been performed by Houk et al. using ab initio MO calculations for the cyanide anion 
addition to the acrolein carbonyl, whereby the transition state of cis configured acrolein-
addition is energetically favoured compared to the trans configuration (Figure 19), 
however there is no accounting for either the solvent system or the counter ion in this 
particular system.
116
 A small but important steric interaction with the C-15 methyl also 
seems likely, therefore further investigation of the relevant transition states is needed for a 
complete accounting of the stereocontrol exhibited. 
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Figure 19. Energy diagram representation of ab initio MO calculations performed by 
Houk et al. on the addition of CN
-
 to acrolein. 
 
Nevertheless, a range of alkynylation reactions were carried out with the previously 
observed near-complete stereocontrol (Table 5). The use of excess propiolate generally led 
to full consumption of the aldehyde starting material, and in general no reactivity 
difference was observed between 1.5 and 3.0 equivalents. A reduced reaction time to 1 
hour also made little difference, as the alkynyl addition reaction generally seemed to be 
complete within 20 minutes according to monitoring via TLC. Various trapping reagents 
were used to generate the corresponding silyl ethers and acetyl esters. The assignment of 
the C-6 stereocentre was made based on previous results obtained by R. Bonepally with 
benzyl ester derivatives.
117
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Table 5. Alkynylation of aldehyde 105. 
 
 
Entry R
1 
R
2
 Additive
 
Trapping agent Product Yield (%) 
1 CO
2
Me H CeCl3 H2O 128 90
 
2 CO2Me TMS None TMSCl 129 100 
3 CO2Me TMS CeCl3 TMSCl 129 75 
4 CO2Me Ac None AcCl 130 45 
5 CO2Me Ac None Ac2O 130 74 
6 CO2
t
Bu H CeCl3 H2O 131 78 
7 CO2
t
Bu TMS None TMSCl 132 32 
8 CO2
t
Bu Ac None Ac2O 133 80 
9 CO2Bn H CeCl3 H2O 134 94 
 
Dry cerium chloride
113
 additive was used to synthesise the corresponding α-alkynyl 
alcohols because the direct hydrolysis of the lithium alkynyl alkoxides failed to give 
reproducible yields. Reactivity towards hydrolysis of alkoxycerium products can be 
expected to be lower compared to the lithium equivalents as cerium is less 
electropositive.
118
 This strategy was employed by Myers et al. during the total synthesis of 
neocarzinostatin (Scheme 60).
119
 An incomplete and less clean reaction was observed in 
the absence of CeCl3. 
 
 
Scheme 60. Cerium(III) chloride mediated intramolecular alkynylation. 
 
However, the use of cerium(III) chloride with a trapping agent other than H2O led to a 
lower yield (Entry 3), presumably because the cerium alkoxide is less reactive. Acetylation 
was more efficient using acetic anhydride compared to acetyl chloride (Entries 4 and 5), 
                                           
118
 Athar, T.; Reddy, K. R. Chinese J. Chem. 2008, 26, 751. 
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although sometimes small quantities of the original alcohol 128 can also be recovered. 
These could be converted to the C-6 acytelated product 130 by stirring in acetic 
anhydride/pyridine (Scheme 61).  
 
 
Scheme 61. Propargylic alcohol acetylation. 
 
The tert-butyl and benzyl ester equivalents could also be obtained (Entries 6-9) by the 
addition of the corresponding propiolate. tert-Butyl propiolate 135 was synthesised by 
several methods, most efficiently from propiolic acid and isobutene with sulfuric acid 
catalysis (Scheme 62), avoiding the commonly encountered base-catalysed byproduct 136. 
Isobutene was generated in situ from tert-butyl alcohol.
120
 Benzyl propiolate 137 was also 
prepared from propiolic acid by esterification with benzyl bromide.
121
 
 
 
Scheme 62. Propiolic acid esterification. 
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 Wright, S. W.; Hageman, D. L.; Wright, A. S.; McClure, L. D. Tetrahedron Lett. 1997, 38, 7345. 
121
 Chalumeau, C.; Deffieux, D.; Chaignepain, S.; Quideau, S. ChemBioChem 2011, 12, 1193. 
75 
 
3.3 Ring-closing ene-yne metathesis 
 
3.3.1 RCEYM using Grubbs 2nd generation catalyst 
 
Using previously reported conditions, the fully protected RCEYM substrates were 
converted into their respective bicyclic adducts without difficulty (Table 6). 
 
Table 6. Ring-closing ene-yne metathesis. 
 
 
Entry SM R
1 
R
2
 Temperature
 
108 (x mol%) Product Yield (%) 
1 128 CO
2
Me H 80°C 20 mol% 138 63 
2 129 CO2Me TMS 80°C 10 mol% 139 quant 
3 130 CO2Me Ac 80°C 10 mol% 140 quant 
4 131 CO2
t
Bu H 100°C 30 mol% 141 23 
5 132 CO2
t
Bu TMS 80°C 10 mol% 142 76 
6 133 CO2
t
Bu Ac 80°C 10 mol% 143 93 
7 134 CO2Bn H 80°C 12.5 mol% 144 47 
 
Reactions of the free alkynyl alcohols 128, 131 and 134 proceeded with difficulty, 
generally needing more catalyst to consume the starting material completely. tert-Butyl 
ester 131 required more forcing conditions, as the substrate only slowly degraded over time 
at 80°C (Entry 6). The proposed reaction pathways for the RCEYM reaction are shown in 
Scheme 63. The two pathways are based on DFT calculations performed on the entire ene-
yne metathesis pathway by Straub et al.
122
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Scheme 63. Proposed RCEYM reaction pathway. 
 
The important features to note are 1) the initial scission of the terminal alkene by the 
ruthenium alkylidene catalyst in accordance with the  "ene-first" mechanistic pathway,
123
 
2) no cyclobutene intermediate is thought to be present, 3) alkyne insertion into the 
ruthenium alkylidine is irreversible, 4) cycloreversion to product diene complexes 145 and 
146 is the rate-limiting step in an ethylene atmosphere.  
 
From here the apparent lower reactivity of free α-alkynyl alcohols can be partly 
rationalised. First, no [5,8] bicyclic products have been isolated or observed in these 
reactions, therefore the assumption can be made that the irreversible alkyne insertion step 
in the endo-pathway does not occur at significant rates and can therefore be excluded from 
the explanation. Extensive catalyst degradation during the reaction implies a 
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proportionately larger amount of unproductive metathetical reactions,
124
 therefore either 
the energy barrier to alkyne insertion is increasing or the equilibrium lies more in the 
direction of intermediate 147. Since the rate-limiting step is thought to be the 
cycloreversion of ruthenium carbene 148 it is likely that the latter is contributing to the rate 
reduction. Increased steric bulk (Me<Bn<
t
Bu) of the various propiolic esters is correlated 
to decreasing reactivity, likely because steric interactions between the bulky spectating 
ligands and the ester moieties disfavour approach of the ruthenium alkylidene in 
conformation 149. This has been noticed before during the ene-yne CM of alkynes with 
significant steric difference between the two alkyne sites.
125
 Finally, propargylic alcohols 
can not only coordinate to ruthenium and favour the endo-conformation 147, but also 
interfere with the rate-determining cycloreversion process by stabilising ruthenium carbene 
in complex 150, which stabilises the proposed catalytic resting state 151 after alkyne 
insertion (Figure 20), thereby retarding the regeneration of active catalyst. Protection of the 
hydroxyl group not only prevents this coordination but also can be expected to enhance the 
RCEYM through the Thorpe-Ingold effect in combination with bulky trimethylsilyl 
ethers.
126
 
 
 
Figure 20. Propargyl alcohol coordinative stabilisation of a ruthenium carbene and the 
proposed catalyst resting state. 
 
Similar inhibition of enyne metathesis by nearby electron-donation capable hetereatoms 
has been noticed before. During the total synthesis of several epoxyquinoids, propargyl 
alcohol 152 did not proceed to the desired REYCM-metallotropically shifted product 153 
(Scheme 64).
127
 Although reaction failure was attributed to steric congestion around the 
vinyl group, heteroatom coordination of the methoxymethyl group (154) or indeed the free 
hydroxyl (155) is possible, thereby preventing the reaction from proceeding. By changing 
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the protection strategy in propargyl silyl ether 156 and introducing a relay-metathesis 
strategy, the desired transformation to adduct 157 was possible. 
 
 
Scheme 64. Heteroatom hindrance of a RCEYM strategy towards epoxyquinoids. 
 
Mori also noticed a near-complete reduction in activity during cross ene-yne metathesis 
(CEYM) of various substrates bearing heteroatoms catalysed by 158; mostly starting 
materials were recovered from these reactions (Scheme 65).
128
 
 
 
Scheme 65. Heteroatom interference in CYEM. 
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3.3.2 Further exploration of RCEYM conditions 
 
Varying the ligand substitution around ruthenium metathesis catalysts can have many 
dramatic effects on their reactivity patterns. Because the bicyclic alcohol adducts 138, 141 
and 144 seemed to offer a promising way forward with the synthesis, other RCEYM 
conditions were explored in an attempt to overcome the previously lacklustre reactions. 
Hoveyda-Grubbs 2nd-generation catalyst 159 and derivatives offer enhanced thermal 
stability compared with phosphine-containing analogues;
129
 M71-SIMes 160 bears an 
additional trifluoromethylamide substituent on the isopropoxystyrenyl carbene, the 
electron-withdrawing effect of which allows it to initiate the reaction faster compared to its 
parent catalyst 159.
130
 As well as tuning electronic properties, steric interactions on the N-
heterocyclic carbene (NHC) ligands can be varied to good effect; M20-SIPr 161 bears 
bulky isopropyl groups,
131
 whereas the Stewart-Grubbs catalyst 162 has a decreased steric 
interaction compared to its parent Grubbs-II catalyst 108 owing to the mono-substituted 
ortho-methyl tolyl NHC.
132
 These complexes have all been documented to catalyse various 
RCEYM and CEYM reactions (Scheme 66).
133,134 
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Scheme 66. Catalyst variety in RCEYM and CEYM reactions. 
 
Table 7 summarises the new RCEYM conditions attempted on various propargylic 
alcohols. Catalysts 160 and 161 were provided by Umicore N.V. and gratefully received. 
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Table 7. New conditions for RCEYM. 
 
 
Entry SM R
1 
Catalyst Temperature
 
Time Yield (%) 
1
a 
128 CO2Me 159 (10 mol%) 80°C 18h n.r. 
2
b 
134 CO2Bn 160 (2 mol%) 40°C 18h n.r. 
3
c 
134 CO2Bn 160 (2 mol%) 80°C 24h n.r. 
4
a 
134 CO2Bn 161 (2 mol%) 80°C 24h n.r. 
5
b 
134 CO2Bn 162 (2 mol%) 40°C 18h n.r. 
6
a 
134 CO2Bn 162 (2 mol%) 80°C 18h n.r. 
7
a 
134 CO2Bn 162 (10 mol%) 80°C 24h 
d 
a) Reaction performed in toluene [0.02 M]. b) Reaction performed in CH2Cl2 [0.02 M]. c) 
Reaction performed in DCE [0.02 M]. d) extensive degradation of starting material. 
 
Disappointingly none of the conditions produced even traces of product; they mostly led to 
recovery of a reduced amount of starting material after column chromatography. The 
failure of the Grubbs-II type 162 to catalyse any RCEYM reactions was particularly 
puzzling.  
 
The use of Lewis acids to complex with polar heteroatom groups that interfere in 
metathesis has been used to great effect by Percy et al. in the synthesis of allylic alcohol-
containing eight-membered rings.
135
 However, when this approach was applied to our 
substrate no improvement was noticed, in fact the reaction proceeded more sluggishly than 
before, and only 32% of desired bicyclic adduct 144 was obtained (Scheme 67). 
 
 
Scheme 67. Attempted RCEYM enhancement through the use of a Lewis acid. 
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Finally, it was noticed that many bicyclic adducts contained the characteristic 
yellow/brown colour from [Ru] contamination, especially at the higher catalysts loadings 
required for propargylic alcohol substrates, even after several chromatographic 
purifications. All adducts were prone to degradation under ambient conditions over the 
course of several days to a week, therefore it might be desirable to remove as much [Ru] as 
possible, metathetically active or not, after the reaction has been stopped.  
 
 
Scheme 68. Example isocyanide-quenched RCEYM reaction. 
 
Grela has shown that isocyanide ruthenium scavenger 163 has a remarkable ability to 
remove residual [Ru] from reactions with 164 after filtration through a short silica plug 
(Scheme 68).
136
 The easily handled crystalline solid was prepared in two steps from bis-
piperazine derivative 165 (Scheme 69), but unfortunately its inclusion in previous 
metathesis reactions did not lead to an overall improvement in either isolated yield or 
product stability. 
 
 
Scheme 69. Synthesis of isocyanide scavenger. 
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3.4 Conclusions 
 
A wide range of [5,7]-bicyclic structures 138-144 have been synthesised though the use of 
improved allylation and alkynylation procedures, followed by the application of the key 
ring-closing ene-yne metathesis step (Scheme 70).  
 
 
Scheme 70. Summary of route towards [5,7]-bicycles from ketone 84. 
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Chapter 4: Derivatisation of [5,7]-bicyclic structures 
 
4.1 Previous derivatisation attempts by Férézou et al. 
 
Several attempts were made to derivatise some of the bicycles previously obtained by 
Férézou et al. Degradation is a common outcome under more forcing conditions because 
these substrates have proven to be rather sensitive However, an SN2' reaction under 
Mitsunobu conditions was observed for allylic alcohol 138, and the rearrangement of 
allylic acetates 140 and 143 using Au(I)-catalysis
137
 proceeded to give the C-8 acetate 
adducts 166 and 167 (Scheme 71) using complex 168. 
 
 
Scheme 71. Previously successful derivatisation of [5,7]-bicycles. 
 
Further preliminary investigations conducted by R. Bonepally showed that selective 
directed epoxidation onto the C-7/8 double bond could be achieved (Scheme 72). 
 
 
Scheme 72. Directed epoxidation. 
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4.2 Selective deprotection of persilylated compounds 
 
Because RCEYM reactions of propargylic alcohols were not always efficient compared to 
those of their protected analogues, the use of selective deprotection of the latter was one 
way to attempt to obtain reliable quantities of allylic alcohols 138, 142 and 144. 
Additionally, there was a marked increase in stability of fully silylated substrate 138 
compared to other adducts derived from starting nitrile 104; it showed no sign of 
decomposition in ambient conditions over the course of several weeks.  
 
Table 8 lists a range of deprotection conditions that were explored. In addition, use of 
TBAF was previously shown to affect global deprotection. Only acid-mediated 
deprotections provided any selectivity (Entries 2, 8, and 11) but in general these reactions 
were not reproducible. 
 
Table 8. Selective deprotection of persilylated 139. 
 
 
Entry Conditions Time Temp (°C) Yield (%) 
1 HF-Pyridine, THF/Pyridine (10:1) 4h rt n.r. 
2 PPTS (6 mol%) MeOH/CH2Cl2 (1:1) 1h rt 34 
3 AcOH, H2O, THF (4:1:1) 1h rt degradation 
4 KF, TEG 24h rt n.r. 
  24h 50 degradation 
5 Sc(OTf)3 (0.5 mol%), H2O (5 equiv), THF 10 min -20 degradation 
6 FeCl3 (1 mol%), CH3CN 10 min -20 degradation 
7 I2 (5 mol%), MeOH 10 min rt degradation 
8 I2 (5 mol%), MeOH 3.5h -78 73
a 
9 K2CO3, MeOH 72h rt n.r. 
10 MeOH, sonication 3 min rt 
b 
11 citric acid (10 mol%), MeOH 4h rt 22
a 
12 0.1N  HCl, THF 24h rt n.r. 
a) Not reproducible. b) Mixture of deprotected products. 
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Similarly, deprotection of silylated tert-butyl ester 142 also does not exhibit a high degree 
of selectivity (Table 9). A small range of deprotection conditions was tested on this 
substrate but none of the reactions showed any level of effective deprotection, but instead 
resulted in extensive degradation. In contrast to methyl ester 138, storage of 142 under air 
resulted in some desilylation, along with recovery of starting material and marked 
degradation. Therefore this route to C-6 alcohols was not pursued further. 
 
Table 9. Selective deprotection of persilylated 142. 
 
 
Entry Conditions Time Temp (°C) Yield (%) 
1 5% HF/MeCN 30 min -42 to -20 degradation 
2 K2CO3, MeOH 1h rt degradation 
3 citric acid (10 mol%), MeOH 1h rt degradation
 
4 Ambient storage 14d rt 23
b 
a) 45% recovery of SM. 
 
4.3 Allylic acetate rearrangement 
 
According to previous results (Scheme 71), allylic acetates 140 and 143 could undergo 
rearrangement to adducts 166 and 167 respectively. This led to the synthetic strategy 
outlined in Scheme 73, whereby hydration across the acrylate olefin and oxidation of the 
C-6/7 olefin of 170 could be facially controlled, based on previous conformational 
analysis. 
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Scheme 73. Synthetic strategy from acetates 140 and 143 to thapsigargin 1. 
 
The C-8 acetate rearranged product 166 is expected to be thermodynamically favoured due 
to increased π-bond conjugation, 138  indeed some rearrangement was noticed during 
prolonged contact with silica gel during chromatographic purification of the preceding 
metathesis reaction, and this has been noted before during the synthesis of analogous 
allylic acetates.
139
 By stirring 140 in a slurry of silica gel, the rearranged acetate 166 could 
be isolated via preparative thin layer chromatography upon complete consumption of 
starting material, alongside numerous other unidentified rearrangement and decomposition 
products in complex mixtures (Scheme 74). 
 
 
Scheme 74. SiO2-mediated allylic rearrangement. 
 
When Nolan's silver-free (NHC)-Au(I) pre-catalyst 168, synthesised from commercially 
available (IPr)AuCl 171,
137
 was used, the previously reported outcomes could 
unfortunately not be reproduced (Scheme 75). Under both microwave and conventional 
heating, substrate 140 produced a complex mixture of products from which adduct 166 
could be isolated in poor yield and surprisingly as a mixture of C-8 diasteromers (dr 3:1). 
The proposed [3,3]-sigmatropic rearrangement reaction mechanism for Au(I)-catalysed 
                                           
138
 Oehlschlager, C.; Mishra, P.; Dhami, S. Can. J. Chem. 1984, 62, 791. 
139
 Serra-Muns, A.; Guérinot, A.; Reymond, S.; Cossy, J. Chem. Commun. 2010, 46, 4178. 
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allylic acetate rearrangement should proceed with transfer of stereochemical information 
between the starting and product allylic sites,
140
 so isolation of an isomeric mixture 
indicates a possible competing general acid catalysed reaction pathway under the reaction 
conditions. 
 
 
Scheme 75. Rearrangement under Nolan's silver-free conditions. 
 
A further small screening of earlier conditions employed by Nolan et al.
141
 also produced 
disappointing yields and diasteromeric mixtures (Table 10). The tert-butyl ester 143 
reacted to give only complex mixtures and the product could not be isolated. 
 
 
 
 
 
 
 
 
 
 
 
                                           
140
 a) Freindorf, M.; Cremer, D.; Kraka, E. Mol. Phys. 2018, 116, 611. b) Gourlaouen, C.; Marion, N.; Nolan, 
S. P.; Maseras, F. Org. Lett. 2009, 11, 81. 
141
 Marion, N.; Gealageas, R.; Nolan, S. P. Org. Lett. 2007, 9, 2653. 
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Table 10. Screening of allylic acetate rearrangement conditions. 
 
 
Entry Substrate Additive Time Temp (°C) Product Yield (%) 
1 140 AgOTf (2 mol%) 1h 80, μW 166 degradation 
2 140 AgBF4 (2 mol%) 30 min 80, μW 166 28 (dr 3:1) 
3 140 AgBF4 (2 mol%) 30 min 80 166 degradation
 
4 143 AgBF4 (2 mol%) 30 min 80, μW 167 complex mixture 
5 143 AgBF4 (2 mol%) 30 min 80 167 complex mixture
 
  
Overman's Pd(II) allylic ester rearrangement
142
 of adduct 140 resulted only in product 172 
(Scheme 76), the mechanism of which will be explored later. A similar apparent [1,4]-
hydride shift/elimination has been reported before under Pd(II) catalysis during the 
synthesis of (–)-shikimic acid.143 
 
 
Scheme 76. Rearrangement under Overman conditions. 
 
Attempts to lactonise acetate 166 under standard conditions also met with failure and 
produced complex mixtures (Scheme 77). 
 
 
                                           
142
 a) Overman, L. E.; Knoll, F. M. Tetrahedron Lett. 1979, 20, 321. 
 b) Golding, B. T.; Pierpoint, C.; Aneja, R. J. Chem. Soc. Chem. Commun. 1981, 1030. 
143
 Yoshida, N.; Ogasawara, K. Org. Lett. 2000, 2, 1461. 
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Scheme 77. Attempted lactonisation of rearranged acetate 166. 
 
4.4 Chemoselective oxidation of the C-7/8 alkene 
 
All of the bicycles that had been made so far contain three alkene functional group sites, 
which are differentiated by their substitution patterns and electronic properties. The C-
11/13 olefin is considerably electron-deficient, while the C-4/5 olefin is electron-rich but 
also tetrasubstituted, differentiating it from the C-7/8 double bond. The C-6 alcohol is 
allylic to both of these alkenes and so the correct oxidative conditions are critical to the 
selective oxidation the C-7/8 alkene. Scheme 78 shows the new proposed strategy towards 
the fully oxygenated thapsigargin core. First, oxidation of the C-7/8 olefin can fix the 
pendent C-11/13 olefin into an orientation that favours hydration across the correct face of 
lactone 173, which can then be taken on to thapsigargin 1. 
 
 
Scheme 78.  Proposed oxidation strategy towards thapsigargin 1. 
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4.4.1 Chemoselective dihydroxylation 
 
4.4.1.1 Osmium(VIII) dihydroxylation 
 
The catalytic use of osmium tetroxide for the dihydroxylation of alkenes is prolific in 
natural product synthesis, as the vicinal-diol motif is a common building block for many 
classes of compounds, including sesquiterpenes.
144
 All three previous total syntheses of 
thapsigargin have included the use of either Sharpless asymmetric dihydroxylation or 
catalytic Upjohn dihydroxylation in order to access the highly oxidised core structure. 
Ley's approach to ketone 174 included the use of commercial AD-mix α to access the 
crucial C-8 stereochemistry (Scheme 79), while it was noted that AD-mix β resulted in a 
mixture of products.  
 
 
Scheme 79. Dihydroxylation during Ley's total synthesis of thapsigargin. 
 
Bulky non-acidic allylic stereocentres generally direct dihydroxylation towards the 
opposite face, as is the case with substrate 43. However, wider substrate control can also 
control the dihydroxylation stereochemistry; during the total synthesis of Gabosine J, 
Figueredo et al. obtained a mixture of diols 175/176 from silyl ether 177.
145
 The influence 
of the pseudoaxial thioether partially directed the osmylation to the opposite face, despite 
the influence of the preconfigured allylic TBS ether (Figure 21). Based upon these results, 
it was surmised that 139 could undergo at least partial dihydroxylation on the β-face in 
order to install the correct stereochemistry of the C-7 tertiary alcohol (Figure 21), as the 
allylic TMS ether is predicted to lie pseudoequatorially in order to minimise transannular 
strain, alleviating some of the steric hindrance of the β-face. 
 
                                           
144
 Heravi, M. M.; Zadsirjan, V.; Esfandyari, M.; Lashaki, T. B. Tetrahedron: Asymmetry 2017, 28, 987. 
145
 Fresneda, M. Á.; Alibés, R.; Font, J.; Bayón, P.; Figueredo, M. J. Org. Chem. 2012, 77, 5030. 
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Figure 21. Dihydroxylation during the synthesis of Gabisone J and proposed configuration 
of silyl ether 139. 
 
Unfortunately, subjecting silyl ether 139 to Sharpless asymmetric dihydroxylation 
conditions promoted by methylsulfonamide
146
 did not result in any detectable conversion, 
giving only recovered starting material (Scheme 80).  
 
 
Scheme 80. Attempted dihydroxylation using AD-mix α. 
 
Under more forcing conditions, a higher loading of osmium precatalyst K2OsO4·2H2O (2 
mol%) was added under Sharpless biphasic conditions.
147
 This led to a complex mixture of 
products (Scheme 81), as well as recovery of most of the starting material. These products 
were difficult to isolate due to separation issues and low quantities, but crude NMR 
analysis combined with mass spectrometry pointed to the formation of a diasteromeric 
                                           
146
 Junttila, M. H.; Hormi, O. O. E. J. Org. Chem. 2009, 74, 3038. 
147
 Hoi-Lun, K.; Sorato, C.; Ogino, Y.; Hou, C.; Sharpless, B. K. Tetrahedron Lett. 1990, 31, 2999. 
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mixture of diol 178, as well as the concurrent deprotection of the TMS-ether and 
dihydroxylation/lactonisation to give tetrol 179. 
 
 
Scheme 81. Osmylation under Sharpless biphasic conditions. 
 
4.4.1.2 Prévost reaction 
 
The Prévost reaction and the related Woodward reaction (or modification) also allows for 
the synthesis of vicinal diols, in an anti and cis selective manner, respectively. The 
classical Prévost reaction conditions involve the stoichiometric use of a silver carboxylate 
and molecular iodine. The reaction operates by the initial formation of RCOOI, which 
forms a transient cyclic iodonium ion 180 on the target alkene (Scheme 82). This 
intermediate can be trapped by internal or external nucleophiles. Anchimeric assistance 
then liberates iodide by forming oxonium 181. This can be trapped once more by a 
nucleophile to generate the anti-configured product 182. The addition of water to this 
reaction decomposes the intermediate oxonium 181 directly to the syn-substituted product 
and this is called the Woodward modification.
148
 
 
 
Scheme 82. Model Prévost reaction scheme. 
 
                                           
148
 Woodward, R. B.; Brutcher, F. V. J. Am. Chem. Soc. 1958, 80, 209. 
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Although not as popular as other dihydroxylation methods due to the use of large amounts 
of silver carboxylates and molecular halides, the method has found a continuing use in 
total synthesis. During the synthesis of the C-58/71 fragment of palytoxin, Nelson et al. 
took advantage of an interrupted Prévost reaction of substrate 183 when the intermediate 
iodonium was trapped by a neighbouring para-methoxybenzoate to an oxonium ion which 
is apparently stable under the reaction conditions, yielding syn-hydroxy p-
methoxybenzoate 184 as the major product upon aqueous workup (Scheme 83).
149
 This 
iodide could be converted into the 1,2-anti-heptaacetate palytoxin C-58/C-71 fragment  
185. 
 
 
Scheme 83. Interrupted Prévost reaction during the synthesis of the C-58/71 fragment of 
palytoxin. 
 
Clarke et al. used the Prévost reaction conditions to affect a transannular cyclisation of  
ketone precursor 186 during synthetic studies towards the D,E,F rings of FR182877 and 
hexacyclinic acid (Scheme 84).
150
 The cyclisation reaction was rationalised by the 
quenching of intermediate oxonium ion 187 by the acetic acid solvent.  
 
                                           
149
 a) Hodgson, R.; Nelson, A. Org. Biomol. Chem. 2004, 2, 373. 
 b) Hodgson, R.; Mahid, T.; Nelson, A. Chem. Commun. 2001, 1, 2076. 
150
 Clarke, P. A.; Grist, M.; Ebden, M.; Wilson, C.; Blake, A. J. Tetrahedron 2005, 61, 353. 
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Scheme 84. Transannular cyclisation under Prévost conditions. 
 
The double inversion approach of the Prévost reaction is well suited to the more readily 
accessible α-face of bicyclic substrates 138-144. As the iodonium intermediate forms on 
the α-face, initial nucleophilic attack is expected to occur on the C-7 position as the partial 
positive charge is stabilised by the adjacent vinyl group (Scheme 85). Neighbouring group 
assistance then provides the desired 1,2 anti-configured vicinal diester 188. 
 
 
Scheme 85. Proposed Prévost pathway for bicylic substrates 138-144. 
 
Subjecting TMS ether 139 to dry Prévost conditions did not lead to product 189 and only 
recovered starting material was isolated upon workup (Scheme 86). 
 
 
Scheme 86. Trial dry Prévost reaction. 
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Inclusion of a large excess of acetic acid led to allyl-substituted acetate 190 as the only 
isolated product in poor yield (Scheme 87), and crude NMR revealed the presence of traces 
of product 191. Perhaps the most surprising outcome was that the apparent SN2' 
substitution reaction proceeded with syn-selectivity, as confirmed by an NOE between the 
C-8 proton and the C-14 methyl.  
 
 
Scheme 87. Modified dry Prevost reaction conditions and observed NOE interactions in 
acetate 190. 
 
Direct SN2' substitution reactions of allylic ethers are rare in literature, and are typically 
mediated by transition metal catalysts which can activate the electron-rich ethers towards 
substitution.
151
 Acid-mediated carbocation formation after in situ deprotection of the TMS 
ether might account for this behaviour, and the intermediate allylic carbocation would be 
expected to undergo nucleophilic addition on the convex face of 192 (Scheme 88). Ethers 
are known hydride shift donors to under Brønsted acid conditions.
152
 Analogous to the 
previous Overman-Pd(II) conditions, two consecutive [1,3]-hydride shifts to vinyl 
oxocarbenium ion 193 can be considered a possible explanation for the formation of 
product 191, as intermediate 193 is heteroatom and conjugation stabilised.
153
 
 
                                           
151
 a) Lalic, G.; Krinsky, J. L.; Bergman, R. G. J. Am. Chem. Soc. 2008, 130, 4459. 
 b) Didiuk, M. T.; Morken, J. P.; Hoveyda, A. H. J. Am. Chem. Soc. 1995, 117, 7273. 
152
 Bolte, B.; Gagosz, F. J. Am. Chem. Soc. 2011, 133, 7696. 
153
 Harmata, M.; Jones, D. E. J. Org. Chem. 1997, 62, 1578. 
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Scheme 88. Possible mechanism to acetate 190 and product 191. 
 
Although the use of silver(I) acetate led to the formation of acetate 190, the use of sodium 
acetate led to the isolation of extended conjugated adduct 194 and trace amounts of 191 
were present in the crude reaction mixture (Scheme 89). The exact mechanism for this 
reaction is not clear but the absence of silver acetate precludes preformed iodonium acetate 
in the reaction mixture, and the free molecular I2 could potentially participate in concurrent 
halogenation/dehydrohalogenation of product 191.
154
  
 
 
Scheme 89. Elimination under I2/NaOAc. 
 
No reaction was observed before the addition of iodine, therefore variation of the Lewis 
acid in the reaction was tested. Zn(OTf)2 without acetic acid led to a small conversion to 
adduct 191, while reintroduction of the protic acid source led to quick conversion at room 
temperature, and produced a complex mixture with 191 visible in the crude NMR as a 
major product (Scheme 90). 
 
                                           
154
 a) Jimenez-Aleman, G. H.; Schöner, T.; Montero-Alejo, A. L.; Brandt, W.; Boland, W. Arkivoc 2012, 371. 
 b) Rule, N. G.; Detty, M. R.; Kaeding, J. E.; Sinicropi, J. A. J. Org. Chem. 1995, 60, 1665. 
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Scheme 90. Lewis acid mediated elimination. 
 
Analogous to the interrupted Prévost reaction during the synthesis of palytoxin (Scheme 
83), attempts to access the desired reactivity from the Prévost reaction involved the use of 
anchimeric assistance from the preformed C-6 acetate in adduct 140. However, none of the 
desired iodoacetate 195 was obtained when 140 was subjected to standard acetic acid 
mediated Prévost conditions (Scheme 91). 
 
Scheme 91. Attempted use of pre-installed anchimeric assistance. 
 
4.4.1.3 Modified substrates for C-7/8 oxidation 
 
From previous experiments, it was determined that the methyl acrylate moiety presented 
many reactivity problems. As a relatively unhindered Michael acceptor, it is expected to be 
reactive under a wide range of acidic and basic conditions. In order to regulate this 
reactivity, it was decided to explore functionalisation of the pendent methyl acrylate. 
Direct lactonisation with catalytic acetyl chloride
155
 did not furnish any of the desired 
adducts (Scheme 92). Similarly, attempts to perform lactonisation and concurrent addition 
of an oxygen nucleophile under basic conditions
156
 yielded no identifiable products. 
 
                                           
155
 Hon, Y. S.; Liu, Y. W.; Hsieh, C. H. Tetrahedron 2004, 60, 4837. 
156
 Jia, Q. Q.; Wang, J. C.; Long, J.; Zhao, Y.; Chen, S. J.; Zhai, J. D.; Wei, L. B.; Zhang, Q.; Chen, Y.; Long, 
H. B. Molecules 2013, 18, 13061. 
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Scheme 92. Lactonisation attempts. 
 
Michael addition of p-thiocresol to the thioether adduct 196 did succeed,
157
 albeit in 
modest yield, and a mixture of inseparable diastereomers was obtained. However, 
subsequent lactonisation once again proved fruitless (Scheme 93). The relative 
configuration of the major diastereomer could not be established at this point. 
 
 
Scheme 93. Michael addition/lactonisation. 
 
Reduction of acetate 140 followed by selective oxidation of the primary alcohol 197 
according to Massanet's protocol also failed to deliver the desired lactone (Scheme 94).
67
 
 
 
Scheme 94. Reduction/oxidation protocol. 
 
Finally, attempts to perform the hydration across the conjugated alkene did not yield any 
discernible products either, despite the reported selective nature of the mild conditions 
employed (Scheme 95).
158
 
 
                                           
157
 Yang, H.; Gao, Y.; Qiao, X.; Xie, L.; Xu, X. Org. Lett. 2011, 13, 3670. 
158
 a) Magnus, P.; Payne, A. H.; Waring, M. J.; Scott, D. A.; Lynch, V. Tetrahedron Lett. 2000, 41, 9725. 
  b) Wang, X.; Sun, W. Bin; Zou, J. P.; Lin, G. Q.; Sun, B. F. Org. Biomol. Chem. 2016, 14, 10581. 
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Scheme 95. Attempted hydration across methyl acrylate 140. 
 
4.4.2 Chemoselective epoxidation and derivativation of the epoxide 
 
4.4.2.1 Directed epoxidation 
 
Many oxidants can be used for the epoxidation of simple alkenes. However, hydroxyl-
assisted epoxidation is commonly performed in the context of natural product synthesis 
with the use of metal catalysts as these reactions can be performed under mild conditions 
and often very selectively. To illustrate, during the synthesis of the clavularanes by Henry 
et al., vanadium(IV)-catalysed epoxidation was able to distinguish between three separate 
olefins, as well as between the allylic and homoallylic positions in 198 (Scheme 96).
159
 
 
 
Scheme 96. Late-stage directed epoxidation during the total syntehsis of the clavularanes. 
 
In another, perhaps even more remarkable, selective epoxidation reaction, Nicolaou et al. 
were able to differentiate between two separate trisubstituted allylic alcohols in 199 as well 
as control α/β facial selectivity to a great degree (Scheme 97).160 This reaction was entirely 
substrate controlled, therefore careful substrate selection beforehand was needed to ensure 
the right outcome.  
 
                                           
159
 Williams, D. R.; Coleman, P. J.; Henry, S. S. J. Am. Chem. Soc. 1993, 115, 11654. 
160
 Nicolaou, K. C.; Baran, P. S.; Zhong, Y. L.; Fong, K. C.; Choi, H. S. J. Am. Chem. Soc. 2002, 124, 2190. 
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Scheme 97. Directed epoxidation during the total synthesis of CP-263,114. 
 
Many more approaches to this versatile selective transformation exist, for instance the use 
of Ti(IV)
161
, Ti(III)
162
 and Mo(0)
163
 catalysts. The substrate scope has also been expanded 
to include homoallylic
164
 and other proximal hydroxyl-assisted epoxidations, and extensive 
developments of enantioselective versions have also been undertaken.
165
 
 
Directed epoxidation of the methyl ester substrate 138, starting with R. Bonepally's 
conditions (Table 11, Entry 1), gave encouraging results. A quick solvent screen showed 
that the reaction was best performed in benzene, with dichloromethane (Entries 3 and 8)  
reducing yields  and toluene giving mixtures of epoxides (Entry 2), the majority of which 
is bis-epoxide.  Similarly, the epoxidation of tert-butyl ester 142 led exclusively to the bis-
epoxidised product (Entry 6). The outcome of these reactions seem to be independent of 
the amount of terminal oxidant used; a substoichiometric use of tert-butylhydroperoxide 
still resulted in exclusive formation of the tert-butyl ester bis-epoxide as the only 
identifiable product. The use of vanadium(V) oxytriisopropoxide as a catalyst was 
beneficial in the case of methyl ester 138 (Entry 4) but seemingly made little difference in 
the case of benzyl ester analogue 144, possibly due to the changing steric interactions 
decreasing selectivity for the C-7/8 olefin. 
 
 
 
 
 
 
                                           
161
 Nicolaou, K. C.; Bulger, P. G.; Brenzovich, W. E. Org. Biomol. Chem. 2006, 4, 2158. 
162
 Botubol-Ares, J. M.; Hanson, J. R.; Hernández-Galán, R.; Collado, I. G. ACS Omega 2017, 2, 3083. 
163
 Kobayashi, K.; Kunimura, R.; Takagi, H.; Hirai, M.; Kogen, H.; Hirota, H.; Kuroda, C. J. Org. Chem. 
2018, 83, 703. 
164
 Zhang, W.; Yamamoto, H. J. Am. Chem. Soc. 2007, 129, 286. 
165
 Johnson, R. . A.; Sharpless, K. B. Catalytic Asymmetric Synthesis, Second Edition; John Wiley & Sons, 
Inc. 2000, 231. 
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Table 11. Epoxidation conditions. 
 
 
Entry R
 
Cat. [mol%] Oxidant [equiv]          T °C
 
solvent Yield A[B] 
1
 
Me VO(acac)2 [2.5] 
t
BuOOH [1.5] rt PhH 67 [
a
] 
2
 
Me VO(acac)2 [2.5] 
t
BuOOH [1.5] rt PhMe 0 [20]
 
3
 
Me VO(acac)2 [2.5] 
t
BuOOH [1.5] rt CH2Cl2 31 [n.d.] 
4 Me
 
VO(O
i
Pr)3 [2.5] 
t
BuOOH [1.5] rt PhH 83 [0] 
5 Me
 
Ti(O
i
Pr)4 [100] 
t
BuOOH [1.5] -15 CH2Cl2 n.r. 
6
 t
Bu VO(acac)2 [2.5] 
t
BuOOH [1.5] rt PhH 0 [73]
 
7
 
Bn VO(acac)2 [2.5] 
t
BuOOH [1.5] rt PhH 39 [n.d.] 
8 Bn VO(acac)2 [2.5] 
t
BuOOH [1.5] rt CH2Cl2 23 [n.d.] 
9
 
Bn VO(acac)2 [2.5] CumeneOOH [1.5] rt PhH 
b
 
10
 
Bn VO(O
i
Pr)3 [1.0] 
t
BuOOH [1.5] rt PhH 41 [n.d.] 
11 Bn VO(O
i
Pr)3 [2.5] 
t
BuOOH [1.5]
 
rt PhH 8 [n.d.] 
a) variable yield. b) Complex mixture of epoxides and starting material.  
 
4.4.2.1 Inversion at C-8 
 
It was envisioned that the correct stereochemical configuration at the C-7/8 stereocentres 
could be accomplished via an SN2 nucleophilic attack on the C-8 site of epoxide 169 
(Figure 22). 
 
 
Figure 22. Envisaged nucleophilic attack on C-8. 
 
This could potentially be accomplished with either an internal or external nucleophile. 
Externally, the simple addition of a nucleophile could result in regioisomers 205-207, 
(Scheme 98), and this is known to be highly dependent on the steric encumbrance of the 
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various reactive sites, the nature of the nucleophile and the stereoelectronic properties of 
the vinyl epoxide.
166
  
 
 
Scheme 98. Possible sites for nucleophilic attack on vinyl epoxides 
 
Sharpless et al. has reported that 2,3-epoxy alcohols can be substituted regioselectively 
with a wide range of heteroatom nucleophiles using titanium isopropoxide as a Lewis acid 
mediator.
167
 Under Sharpless' conditions, epoxide 169 is resistant to nucleophilic 
substitution (Scheme 99). Surprisingly, when more forceful conditions are applied (DMF, 
reflux), an unexpected semi-pinacol rearrangement occurs, with a 1,2-migration of the C-
5/6 bond to the C-7 position to form aldehyde 208.  
 
 
Scheme 99. Titanium isopropoxide mediated semi-pinacol rearrangement. 
                                           
166
 He, J.; Ling, J.; Chiu, P. Chem. Rev. 2014, 114, 8037. 
167
 Caron, M.; Sharpless, K. B. J. Org. Chem. 1985, 50, 1557. 
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An unusual example of epoxide opening has been reported by Ducrot et al. whereby 
epoxide 209 undergoes Lewis acid-mediated ring opening with inversion of configuration 
on the less stable carbocationic site (Scheme 100) in the presence of triethylsilane.
168
 This 
was in contrast to Brønsted acid conditions which furnished the expected inverted anti-
diol. The mechanism for this unusual behaviour has not been elaborated, but hydrogenation 
of the C-4/4a olefin had no effect on the course of the reaction.  
 
 
Scheme 100. Epoxide cleavage by Ducrot et al. 
 
Unfortunately, epoxide cleavage of substrate 169 under Ducrot's conditions did not yield 
the expected adduct, but instead furnished an unidentified adduct. The presence of a clear 
aldehyde signal (
1
H δ 9.82 ppm, dd J = 3.7, 2.5 Hz, CDCl3) suggested that the reaction had 
once again proceeded along a semi-pinacol type rearrangement. However, the unusual 
splitting pattern and a nominal mass peak of m/z 276 pointed to a either a different 
mechanistic pathway or a more extensive rearrangement, and the corresponding coupling 
signals could not be identified in the spectrum. Unfortunately, analysis was hampered by 
the rapid decomposition of the product during standard purification techniques and 
prolonged storage in deuterated chloroform. 
 
Water has been known to act as a general acid catalyst and nucleophile in epoxide cleavage 
reactions,
169
 and has been used by Nicolaou et al. to great effect during the synthesis of the 
QRSTU domain of maitotoxin to promote the intramolecular cyclisation of epoxy alcohol 
210 when traditional Brønsted acid catalysis failed to give the product in acceptable yields 
(Scheme 101).
170
 The high temperatures are not only required to promote the reaction but 
also to ensure sufficient amounts of the usually non-polar substrates are dissolved in the 
aqueous media for the reaction to occur. 
 
                                           
168
 Beauhaire, J.; Ducrot, P. H.; Simon, I. Synth. Commun. 1995, 25, 3015. 
169
 Wang, Z.; Cui, Y. T.; Xu, Z. B.; Qu, J. J. Org. Chem. 2008, 73, 2270. 
170
 Nicolaou, K. C.; Gelin, C. F.; Seo, J. H.; Huang, Z.; Umezawa, T. J. Am. Chem. Soc. 2010, 132, 9900. 
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Scheme 101. Hot water promoted epoxide cleavage. 
 
Unfortunately, none of the water/base conditions tested were sufficient to effect epoxide 
cleavage, except when organic solvents are included. However, these conditions degrade 
the starting material, with nothing being recovered (Table 12), 
 
Table 12. Hot water promoted epoxide opening. 
 
 
Entry Conditions Temp (°C) Yield (%) 
1 H2O 60 n.r. 
2 H2O  100 n.r. 
3 H2O, NaHCO3 100 n.r.
 
4 H2O, KOH 100 n.r. 
5 H2O, DMSO, KOH 100 degradation
 
 
A final attempt at external nucleophilic opening of epoxide 169 was made using benzyl 
alcohol and sodium hydride (Scheme 102). This gave a rather complex mixture of products 
but crude NMR analysis indicated that the SN2' nucleophilic attack had predominated, 
consistent with a sterically hindered vinyl epoxide, as a mixture of E/Z isomers.  
 
 
Scheme 102. Benzyl alcohol external nucleophilic opening of epoxide 169. 
 
In order to hopefully limit the reactive site to C-8, internal nucleophiles centred on C-12 
were then explored. Balme et al. had shown that epoxy-diester could undergo cyclisation 
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mediated by either trimethylsilyliodide or p-toluenesulfonic acid (PTSA) to the 
corresponding δ-hydroxy-γ-lactones (Scheme 103).171 
 
 
Scheme 103. Dealkylative cyclisation of epoxy-diesters. 
 
Subjecting epoxide 169 to both these conditions did not result in recovery of the desired 
adduct (Scheme 104). While the in situ formation of trimethylsilyl iodide resulted in 
complete degradation of the starting material, the use of catayltic amounts of PTSA 
resulted in the formation of byproduct 211 in poor yield after column chromatography. 
This derivative also proved to be rather unstable under atmospheric conditions and did not 
survive long enough to be fully analysed, having decomposed after several hours in 
deuterated solvent, Thus, the proposed structure is based on incomplete spectroscopic 
analysis.  
 
 
Scheme 104. Attempted delalkylative cyclisation into epoxide 169. 
 
Internal nucleophilic attack onto the C-7/8 epoxide was attempted using an alcohol as a 
nucleophile. Selective reduction of the epoxyester 169 provided diol 212 in low yield 
(Scheme 105). A cursory solvent screen (CH2Cl2, hexane, toluene) showed that toluene 
was the superior solvent for this reaction, but optimisation of these conditions is needed. 
                                           
171
 Pehlivan, L.; Jacolot, M.; Coia, N.; Monteiro, N.; Bouyssi, D.; Balme, G. Tetrahedron Lett. 2011, 52, 
4716. 
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Scheme 105. Reduction of the ester moiety and attempted temporary silyl protection of the 
C-6 alcohol. 
 
The low yield of this reaction is likely attributable to adjacent C-6 alcohol to the C-7/8 
epoxide, directing the incoming Al-hydride reagent to reduce the epoxide instead,
 172
 
causing unwanted side-reactions. An attempt to temporarily protect the C-6 alcohol of 169 
failed (TESCl, imidazole, CH2Cl2), most likely due to another semi-pinacol type reaction, 
as silyl halides are known promoters of the rearrangement of 2,3-epoxy alcohols.
173
 
Although the mass spectrum analysis indicated the addition of a triethylsilyl group (m/z 
calc 675.3903, found 675.3895), assignment of spectroscopic data was difficult due to the 
appearance of a mixture of inseparable isomeric products.  
 
Alcohol 212 was then subjected to standard deprotonation conditions (NaH, DMF) to try 
and effect cyclisation to the desired ether. However, when the reaction was heated, a 
complex mixture of products was formed. It should be noted that the NaH and DMF 
reagent/solvent combination has previously been found to be problematic under certain 
circumstances.
174
 The use of rhodium carbonyl chloride dimer
175
 as the reagent also gave 
intractable mixtures. 
 
Under mild acidic conditions, however, a diastereomeric mixture of oxetane 213 is 
obtained, presumably through the formation of a stabilised vinyl carbocation intermediate 
which is attacked by the free pendent alcohol (Scheme 106). Oxetane 213 was difficult to 
separate and characterise, but derivatisation to give the persilylated adduct 214 provided a 
clean sample after chromatography that could be identified. Unfortunately the 
configuration at C-7 of the major product could not be established. 
 
                                           
172
 Krishna, P. R.; Kadiyala, R. R. Tetrahedron Lett. 2010, 51, 4981. 
173
 Song, Z. L.; Fan, C. A.; Tu, Y. Q. Chemical Reviews. 2011, 111, 7523. 
174
 Hesek, D.; Lee, M.; Noll, B. C.; Usher, J. F.; Mobashery, S. J. Org. Chem. 2009, 74, 2567. 
175
 Ha, J. Du; Shin, E. Y.; Kang, S. K.; Ahn, J. H.; Choi, J. K. Tetrahedron Lett. 2004, 45, 4193. 
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Scheme 106. Oxetane formation under acidic conditions. 
 
Our attention then turned to the hydrolysis of ester 169 as a means of obtaining the free 
acid 215, which could hopefully be used to affect epoxide cleavage (Scheme 107).  
 
 
Scheme 107. Proposed route to lactonisation using free acid x213. 
 
A range of hydrolysis conditions were explored on methyl ester 169 (Table 12). Common 
basic conditions using sodium and lithium hydroxide (Entries 1 and 2), proved too harsh to 
affect the desire transformation, resulting only in decomposition. The use of non-basic in 
situ formed lithium hydroperoxide has previously been found to effect epoxide cleavage 
and de-esterification through anchimeric assistance of an ester moiety.
176
 However, these 
conditions only resulted in decomposition of adduct 169 (Entry 3). Mild anhydrous de-
esterification with dimethylaluminium methyltellurate
177
 or trimethyltin hydroxide
161
 also 
did not effect the desired cleavage (Entries 4 and 5).  
 
 
 
 
 
 
 
 
 
                                           
176
 Morzycki, J. W.; Gryszkiewicz, A.; Jastrz, I. Tetrahedron 2001, 57, 2185. 
177
 Reddy, B. V. S.; Reddy, L. R.; Corey, E. J. Tetrahedron Lett. 2005, 46, 4589. 
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Table 12. Hydrolysis conditions. 
 
 
Entry Conditions Temp (°C) Time Yield (%) 
1 NaOH, THF/H2O 0 1h degradation 
2 LiOH, THF/H2O 0 1h degradation 
3 LiOH, H2O2, EtOH rt 1h degradation
 
4 (Me2AlTeMe)2, toluene rt 5h degradation. 
5 Me3SnOH (10 equiv), toluene 80 72h n.r.
 
 
Additionally, a hydrolysis attempt was made to cleave the ester in epoxide precursor 139 
with potassium trimethylsilanolate.
178
 Although this reaction did not cleave the ester to 
give the acid, it did effect an unusual epoxidation reaction of the C-11/13 olefin (Scheme 
108) to epoxide 216. A literature search revealed no comparable transformation, but it is 
possible that the reagent had oxidised to the corresponding peroxide at some point, 
although a potassium iodide test of the reagent proved negative. 
 
 
Scheme 108. Unusual epoxide formation using trimethylsilanolate. 
 
Finally, our attention turned to epoxy benzyl ester 201 as a substrate that would allow de-
esterification under mild and neutral conditions, primarily through hydrogenolysis, as 
harsher conditions such as the use of FeCl3
179
 resulted in decomposition. 
 
Many different catalytic systems exist for the hydrogenolysis of benzyl ethers and esters, 
and many were developed to allow the desired transformation to be accomplished in 
complex poly-functionalised systems. For the synthesis of spongistatin 1, Smith III et al. 
                                           
178
 Gilbert, B. A.; Tan, E. W.; Pérez-Sala, D.; Rando, R. R. J. Am. Chem. Soc. 1992, 114, 3966. 
179
 Davies, T. J.; Jones, R. V. H.; Lindsell, W. E.; Miln, C.; Preston, P. N. Tetrahedron Lett. 2002, 43, 487. 
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employed a transfer hydrogenation system that successfully cleaved a primary benzyl ether 
in the presence of many sensitive functional groups (Scheme 109).
180
 
 
 
Scheme 109. Selective hydrogenolysis during the synthesis of spongistatin 1. 
 
During the synthesis of the C-10/17 unit of FK-506, Rupprecht et al. used homogeneous 
palladium catalysis to affect hydrogenolysis of adduct 217 as part of a multi-step sequence  
and these conditions are known to be compatible with simple olefins (Scheme 110).
181,182 
 
 
Scheme 110. Homogeneous hydrogenolysis conditions. 
 
When heterogeneous conditions were employed at room temperature, the substrate 201 
failed to react and reactivity was only observed at higher temperatures (Scheme 111). The 
sole isolable product from this reaction was assigned as lactone 218, although this could 
not be confirmed by mass spectrometry due to a fault.  
 
                                           
180
 Smith III, A. B.; Sfouggatakis, C.; Risatti, C. A.; Sperry, J. B.; Zhu, W.; Doughty, V. A.; Tomioka, T.; 
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Scheme 111. Heterogeneous transfer hydrogenation. 
 
Under homogeneous conditions, two major products are formed (Scheme 112). The first 
product is the aforementioned lactone 218, but the second (major) product could not be 
identified. The crude product spectra were complex and no mass spectrometry was 
available. High loading of palladium chloride (50 mol%) is needed for this product to 
appear as the major product in an otherwise complex mixture, and based on the reactivity 
pattern that forms lactone 218 a tentative assignment of 219 was made.  
 
 
Scheme 112. Homogenous reduction conditions. 
 
The reason for this assignement was that reductive epoxide ring openings catalysed by 
Pd(0) and Pd(II) are known to occur with selectivity for substitution at the allylic position 
to generate homoallylic alcohols in the absence of significant steric encumbrance.
183
 
However, since 218 was obtained as the major product under heterogeneous conditions, it 
indicated that significant steric interaction forced the SN2' reduction pathway, and that 
therefore the direct SN2 hydrogenolysis at the homoallylic position also became more 
likely. Associated 
1
H signals were those of the methylene protons (δ 6.33, 5.68). The 
disappearance of the benzylic protons, the appearance of H-6 (δ 4.84, s), 184  and the 
                                           
183
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remaining H-3 (δ 4.39, d app) indicated that the C-4/5 olefin was still intact. Any attempt 
at standard purification resulted only in recovery of lactone 218, presenting difficulty in 
analysing the small quantity of material that had been synthesised.  
 
4.5 Conclusions 
 
An array of oxidative procedures were applied to the bicyclic adducts 138-144 in order to 
target the C-7/8 olefin chemoselectively. Vanadium-catalysed directed epoxidation proved 
to be suitable for diastereoselective epoxidation of the allylic alcohols 138 and 144. 
Elaboration on epoxy alcohols 169 and 201 was generally hampered by the high reactivity 
of the vinyl epoxide in combination with a good Michael acceptor, and the most promising 
conditions for further study are those that involve mild hydrogenolysis of 201 as 
demonstrated through heterogeneous Pd-catalysed formation of [5,7,5] tricyclic lactone 
218. 
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Chapter 5: [5,8] thapsigargin analogues 
 
5.1 Synthesis of a [5,8] bicyclic structure 
 
An efficient enantioselective synthesis of common ketone intermediate 84 had been 
established and so a route could now be devised to exemplify the flexibility of the chosen 
synthetic strategy in the context of varying ring sizes. The first challenge was to install the 
C-10 stereocentre with hopefully a similar efficiency compared with the allyl homologue. 
Subjecting ketone 84 to Grignard reagent 220 in the presence of dry cerium(III) chloride 
resulted in a disappointing yield and diastereomeric ratio of adduct 221 in contrast to 
previous results (Scheme 113).  
 
 
Scheme 113. Synthesis of homoallyl homologue 221. 
 
This reaction has scope for optimisation as the nature of the allylmagnesium Grignard 
reagent is markedly different compared to non-allylic reagents.
102
 The presence of β-
hydrogens on Grignard reagents is known to cause many side reactions as the substrates 
and nucleophiles become more hindered, and therefore the reaction might benefit more 
from Hatano's conditions developed for such systems (Scheme 54).
110
 The direct addition 
of Grignard 220 to Weinreb amide 83 did not proceed to give the expected product 222 
(Scheme 114). 
 
 
Scheme 114. Attempted nucleophilic attack onto Weinreb amide 83. 
 
Mono-protection of diol 221 proceeded without incident, but the two epimeric products 
could not be separated by standard chromatographic techniques and compound 223 was 
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elaborated as a mixture of diastereomers for the rest of the synthesis (Scheme 115). The 
protection of the C-10 tertiary alcohol 223 also proceeded efficiently. The configuration at 
the C-10 stereocentre of the major diastereomer of 221 could not be definitively 
established at this point and is proposed based on the reaction of ketone 84 to give the 
allylated homologue 103. Definitive NOE correlations have also not yet been established 
on later cyclised derivatives. 
 
 
Scheme 115. Sequential double protection of diol 221. 
 
This synthetic intermediate 224 is stable to long term storage under ambient atmosphere 
and is therefore a good synthetic platform for subsequent exploration of the synthesis of 
further [5,8] bicyclic systems. Nitrile reduction followed by the previous mild hydrolysis 
conditions furnished the crude aldehyde 225 quantitatively and with sufficient purity for 
continuation of the synthesis (Scheme 116). 
 
 
Scheme 116. Nitrile reduction under mild hydrolysis. 
 
Gratifyingly, alkynyl addition to aldehyde 225 proceeded as expected with near complete 
stereocontrol for both diastereomers. At this stage the diastereomers of free alcohols 226 
and 227 could be separated using standard chromatographic methods. However, the TMS 
protected variant 228 was still an inseparable mixture (Scheme 117). 
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Scheme 117. Protected and unprotected alkynylation products. 
 
The RCEYM protocol was then attempted on the free alcohol 226, but this did not proceed 
to give the expected bicycle 229, and only degradation products were obtained (Scheme 
118).  
 
 
Scheme 118. RCEYM failure with propargylic alcohols. 
 
8-Membered carbocycles are known to be difficult to synthesise by RCM due to the 
development of increased ring strain in the product and transannular interactions in the 
cyclisation transition state.
185
 This problem, in addition to the earlier explored effect of the 
propargylic alcohol, can reasonably explain the near complete failure of the expected 
reaction. However, when the metathesis reaction conditions were applied to protected 
adduct 228, the cyclisation proceeded smoothly to the desired bicyclic triene 230 (Scheme 
119).  
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Scheme 119. Successful application of RCYEM conditions to the synthesis of [5,8] 
bicycles. 
 
The use of normal catalyst loading and temperatures was surprising considering the general 
use of high loadings in eight-membered rings to combat reactivity problems. The presence 
of a pre-existing ring system is likely to a major factor in the relative ease of cyclisation as 
it physically forces the reactive alkene and alkyne in close proximity to each other.
186
 The 
removal of the coordinating ability of the propargyl alcohol and the introduction of a 
Thorpe-Ingold effect due to the bulky silyl ether also likely assisted the reaction.
187
  
 
Albeit unexpected, a welcome reactivity difference was observed between the two starting 
isomers, leading to an increased diastereomeric ratio. Numerous examples of such effects 
exist in literature and especially natural product synthesis. For instance during the 
synthesis of the taxoid A,B-ring fragments, Blechert et al. constructed bicyclic structure 
231 as one stereoisomer after reacting the starting diastereomeric mixture 232 under 
Grubbs metathesis conditions (Scheme 120), while the undesired diastereomer underwent 
dimerisation. 
 
 
Scheme 120. Ring-closing metathesis during the synthesis of taxoid fragments by Blechert 
et al. 
 
Carrying out the earlier reaction of TMS ether 228 at a lower temperature and interrupting 
the incomplete reaction formation resulted in the isolation of product 230 with an even 
                                           
186
 Miller, S. J.; Kim, S.-H.; Chen, Z.-R.; Grubbs, R. H. J. Am. Chem. Soc. 1995, 117, 2108. 
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higher diastereomeric ratio as well as recovery of a depleted ratio of starting material 
diastereomers (Scheme 121) 
 
 
Scheme 121. Lower temperature RCEYM reaction showing an increased dr. 
 
5.2 Conclusions 
 
Unnatural thapsigargin core-structural homologue 230 has been synthesised in 6 steps from 
common ketone intermediate 84 using the key ring-closing ene-yne metathesis step with 
similar efficiency compared to the natural core structures in previous chapters (Scheme 
122).  
 
 
Scheme 122. Completion of a [5,8] thapsigargin core homologue. 
 
This is the first foray into the bicyclic core modification of thapsigargin, taking advantage 
of a pre-installed five-membered ring to easily access the otherwise challenging [5,8] fused 
bicyclic system. 
 
 
 
 
 
 
 
 
Conclusions and perspectives 
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Building on previous methodology, this work has expanded the scope of the synthetic 
strategy towards versatile cyclopentenol building block 84 to include an entantioselective 
pathway towards the (1S,3R) natural thapsigargin configuration (Scheme 123). 
 
 
Scheme 123. Summary of results towards ketone 84. 
 
The key allylation reaction of ketone 84 and subsequent steps have been markedly 
improved and have also furnished several new [5,7]-bicyclic structures. The protected C-6 
allylic alcohol analogues were the most efficient way to rapidly construct the guaianolide 
carbon skeleton (Scheme 124) as the free alkynyl alcohols suffered from a large drop in 
yield during RCEYM reactions. 
 
 
Scheme 124. Construction of [5,7]-bicycles. 
 
These bicyclic adducts were then used to explore a range of synthetic strategies towards 
the fully oxidised skeleton of thapsigargin 1 and nortrilobolide 19. Unfortunately, many of 
the substrates used in these processes proved highly sensitive and so precise modulation of 
reaction conditions were necessary to obtain any desired reactivity. The general conclusion 
is that epoxides of type 233 (Figure 23) are sensitive to acidic conditions and can be 
expected to exhibit unexpected reactivity and probable decomposition under such 
conditions. They are, however, generally unreactive to mildly basic conditions, and near 
neutral conditions can also be applied to effect desired transformations, as is the case with 
hydrogenolysis of 201 to give the adduct 218.  
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Figure 23. Possible intermediates towards the total synthesis of Tg 1. 
 
From here we can envisage a route to the desired natural compounds. Building on the work 
of Massanet,
188
 unsaturated lactone 218 could be converted into either epoxide 234 or 235 
under basic conditions, depending on facial selectivity (Scheme 125). In the event that 
epoxide 235 is the major stereochemical outcome of the epoxidation, it can be envisaged 
that access to the correct configuration of the C-7/8 hydroxyls could be provided by a 
Payne rearrangement to epoxyalcohol isomer 236 followed by nucleophilic opening at the 
less substituted C-8 position to an advanced intermediate 237.
189
 Although epoxide 235 is 
favoured in the equilibrium under basic isomerisation conditions, steric factors would 
favour nucleophilic opening of isomer 236, thus the reaction would be expected be under 
Curtin-Hammett conditions, assuming isomerisation is fast compared to epoxide opening.  
 
 
Scheme 125. Suggested approaches to Tg 1 from unsaturated lactone 218. 
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Base-mediated elimination and opening of the opposite epoxylactone 234 could be used to 
access methelene lactone 238. The relatively flat conformation of methylene lactone 236 
could allow for hydration across the desired face of the methylene lactone to the C-11 
tertiary alcohol 239, which could be taken on to Tg 1 after establishing the correct C-8 
stereochemistry via a sequential oxidation-procedure to tetrol 240, analogous to the 
strategy previously employed by Evans (Scheme 126).
69
 
 
 
Scheme 126. Alternative strategy to Tg 1. 
 
The scope of the synthetic strategy towards Tg 1 has also been expanded to include 
unnatural core-modified [5,8]-bicyclic analogue 230, with the succesful formation of the 8-
membered carbocycle serving as proof of the versatility of the key ring-closing ene-yne 
metathesis reaction in our synthetic approach (Scheme 127). The configuration at the C-10 
stereogenic centre still needs to be established. 
 
 
Scheme 127. Synthesis of an unnatural [5,8]-bicylic core. 
 
By analogy to the natural [5,7]-bicyclic homologues, the 8-membered allylic alcohol 241 is 
predicted to exhibit facial selectivity during C-7/8 oxidation to epoxyalcohol 242 because 
reaction at the convex β-face is thought to minimise transannular strain (Scheme 128). 
Following the previously suggested strategy towards natural Tg 1, epoxyalcohol 242 could 
121 
 
be converted into either of two epoxylactones 243 and 244 from unsaturated lactone 245 
via hydrogenolysis, and then hopefully taken to [5,8,5] thapsigargin homologue 246. Like 
methylene lactone 238, compound 247 is predicted to allow access to the correct face for 
hydration across the C-11/13 olefin.                                                                                                   
 
  
 Scheme 128. Envisaged development towards a [5,8,5] thapsigargin homologue. 
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Experimental 
General experimental 
Nuclear magnetic resonance spectra were recorded on a Bruker DPX-400 spectrometer and 
a Bruker DPX-500 spectrometer at ambient temperature; chemical shifts are quoted in 
parts per million (ppm) and were referenced as follows: chloroform-d, 7.26 ppm for 
1
H 
NMR; chloroform-d, 77.0 ppm for 
13
C NMR. Coupling constants (J) are quoted in Hertz. 
Carbon numbering system is used according to the structure of thapsigargin. High 
resolution mass spectra were recorded under FAB and CI conditions by the University of 
Glasgow analytical service. IR spectra were recorded using a Golden Gate TM attachment, 
utilizing a type IIa diamond as a single reflection element. Thin layer chromatography was 
performed on aluminium-backed plates coated with Merck Silica gel 60 F254. The plates 
were developed using ultraviolet light, ethanolic anisaldehyde, ceric ammonium molybdate 
or KMnO4. Liquid chromatography was performed using forced flow (flash column) with 
the solvent systems indicated. The stationary phase was Merck KGaA Guduran silica gel 
60. CH2Cl2, Toluene, and THF were all purified using Innovative Technology Solvent 
Purification System; Ac2O was distilled from quinoline under reduced pressure; all other 
solvents and reagents were used as received from commercial suppliers unless stated 
otherwise. Air or moisture sensitive reactions were carried out in pre-dried glassware; 
either overnight in an oven (130 °C) or by flame drying in vacuo. Argon was used to create 
an inert atmosphere. 
 
123 
 
Experimental procedures 
Benzyl methoxy(methyl)carbamate (88) 
 
 
 
To a solution of MeO(Me)NH·HCl (1.00 g, 10.3 mmol) in acetonitrile (20 mL) was added 
a saturated aqueous solution of K2CO3 (20 mL) and benzyl chloroformate (1.46 mL, 10.3 
mmol, 1 equiv) at room tempterature. The mixture was stirred at the same temperature for 
18 h. The reaction mixture was extracted with CH2Cl2 (x3) and the combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
90:10) to give 88 as a colourless oil (2.00 g, 99%).  
 
1
H NMR (400 MHz, CDCl3): δ 7.42-7.29 (m, 5H, H-2), 5.19 (s, 2H, H-1), 3.70 (s, 3H, H-
4), 3.17 (s, 3H, H-3) ppm.  
 
13
C NMR (101 MHz, CDCl3): δ 157.1 (C-5), 136.2 (C-6), 128.6 (C-Ar), 128.2 (C-Ar), 
128.1 (C-Ar), 67.6 (C-1), 61.7 (C-4), 35.7 (C-3) ppm. 
 
IR (thin film): 2935, 1703, 1456,1411, 1388, 1340, 1153, 1045 cm
-1
. 
 
HRMS (ESI): m/z calculated for C10H13NO3 (M + Na)
+
 218.0788, found 218.0785. 
 
N-Methoxy-N-methyl-1H-pyrrole-1-carboxamide (87) 
 
 
Ref: Angew. Chemie Int. Ed. 2015, 54, 9839. 
 
To a saturated aqueous solution of NaHCO3 (100 mL) was added ice (100 g) and solid 
MeO(Me)NH·HCl (20.0 g, 205 mmol) portionwise at 0 °C. Then solid N,N'-
carbonyldiimidazole (43.2 g, 267 mmol, 1.3 equiv) was added portionwise over the course 
124 
 
of 15 min and the mixture was left to stir at the same temperature for 30 min. The reaction 
mixture was then extracted with CH2Cl2 (x3) and the combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give the crude 
product as a yellow oil (26.7 g). The residue was redissolved in dry acetonitrile (400 mL) 
and pyrrole (12.5 mL, 180 mmol, 1.05 equiv) was added dropwise at room temperature. 
Then DBU (25.7 mL, 172 mmol, 1 equiv) was added dropwise and stirring maintained for 
3 h, after which the solvent was removed in vacuo and the residue partitioned between 1M 
HCl and EtOAc and the aqueous layer was extracted with EtOAc (x3). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (petroleum ether/ethyl 
acetate, 90:10) to give 87 as a colourless oil (19.9 g, 63% over 2 steps). 
 
1
H NMR (400 MHz, CDCl3): δ 7.40 (dd, 2H, J = 5.1, 2.8 Hz, H-1), 6.25 (dd, 2H, J = 5.1, 
2.8 Hz, H-2), 3.66 (s, 3H, H-4), 3.35 (s, 3H, H-3) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 152.2 (C-5), 121.4 (C-2), 111.3 (C-1), 60.9 (C-4), 35.3 
(C-3) ppm. 
 
HRMS (ESI): m/z calculated for C7H10N2O2 (M + Na)
+
 177.0639, found 177.0641. 
 
3-Methoxy-2-methylcyclopent-2-enone (78)
  
 
 
Ref: Eur. J. Org. Chem. 2017, 23, 3362-3372. 
 
To a solution of dione 77 (10.0 g, 89.2 mmol) in dry acetone (100 mL) was added K2CO3 
(13.6 g, 98.1 mmol, 1.1 equiv) and Me2SO4 (10.2 mL, 107 mmol, 1.2 equiv) at room 
temperature. The mixture was heated to reflux and stirred for 4 h, after which the reaction 
was cooled to rt, quenched with saturated aqueous NaHCO3 and the aqueous phase was 
extracted with CH2Cl2 (x3). The combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo to give 78 as a yellow oil (11.2 g, 99%). 
The crude product was used for the next step without purification.  
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1
H NMR (400 MHz, CDCl3): δ 3.96 (s, 3H, OMe), 2.65 (m, 2H, H-2a), 2.45 (m, 2H, H-
2b), 1.64 (t, 3H, J = 1.7 Hz, H-15) ppm.  
 
13
C NMR (101 MHz, CDCl3): δ 205.3 (C-3), 184.4 (C-5), 116.2 (C-4), 56.4 (OMe), 33.4 
(C-2), 24.7 (C-3), 6.0 (C-15) ppm. 
 
HRMS (ESI): m/z calculated for C7H10O2 (M + H)
+
 127.0759, found 127.0756. 
 
Methyl 2-methoxy-3-methyl-4-oxocyclopent-2-enecarboxylate (79)  
 
 
 
To a solution of HMDS (21.6 mL, 103 mmol, 1.3 equiv) in dry THF (500 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (41.2 mL, 103 mmol, 1.3 equiv, 2.5 M in hexanes). 
After stirring for 5 min, the temperature was lowered to -78 ºC and cyclopentenone 78 
(10.00 g, 79.2 mmol) in THF (50 mL) was added dropwise. The reaction mixture was 
stirred at the same temperature for 1 h, after which methylchloroformate (6.42 mL, 83.1 
mmol, 1.05 equiv) was added slowly dropwise over the course of 5 min. The reaction was 
stirred for 1 h, then warmed up to 0 °C, quenched with saturated aqueous NaHCO3 and the 
aqueous phase was extracted with ethyl acetate (x3). The combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (petroleum ether/ethyl acetate, 80:20 up to 
60:40) to give 79 as a yellow oil (12.5 g, 86%).   
 
1
H NMR (400 MHz, CDCl3): δ 4.02 (3H, s, COOMe), 3.76 (s, 3H, OMe), 3.71-3.75 (m, 
1H, H-1), 2.71 (dd, 1H, J = 17.9, 7.7 Hz, H-2a), 2.55 (dd, 1H, J = 17.9, 2.5 Hz, H-2b), 2.25 
(d, 3H, J = 0.9 Hz, H-15) ppm. 
 
 
 
13
C NMR (101 MHz, CDCl3): δ 203.0 (C-3), 179.1 (C-10), 171.6 (C-5), 116.6 (C-4), 58.0 
(OMe), 52.5 (COOMe), 43.9 (C-1), 38.3 (C-2), 7.1 (C-15) ppm. 
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IR (thin film): 2967, 1735, 1692, 1471, 1375, 1342, 1240, 1160 cm
-1
. 
 
HRMS (ESI): m/z calculated for C9H12O4 (M + Na
+
) 207.0628, found 207.0626. 
 
Ethyl 2-methoxy-3-methyl-4-oxocyclopent-2-enecarboxylate (90a) 
 
 
To a solution of HMDS (1.66 mL, 7.92 mmol, 1 equiv) in dry THF (5 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (3.17 mL, 7.92 mmol, 1 equiv, 2.5 M in hexanes) and 
stirred for 5 min. The solution was transferred via cannula to a solution of cyclopentenone 
78 (1.00 g, 7.92 mmol) in dry THF (50 mL) at -78 ºC. The reaction mixture was stirred at 
the same temperature for 1 h, after which ethylchloroformate (0.790 mL, 8.32 mmol, 1.05 
equiv) was added slowly dropwise over the course of 5 min. The reaction was stirred for 1 
h, then warmed up to 0 °C, quenched with saturated aqueous NaHCO3 and the aqueous 
phase was extracted with ethyl acetate (x3). The combined organic layers were washed 
with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (petroleum ether/ethyl acetate, 80:20 up to 60:40) to give 
90a as a yellow oil (1.05g, 67%). 
 
1
H NMR (400 MHz, CDCl3): δ 4.21 (q, 2H, J = 7.1 Hz, H-6), 4.01 (s, 3H, OMe), 3.74 – 
3.69 (m, 1H, H-1), 2.70 (dd, 1H, J = 17.9, 7.7 Hz, H-2a), 2.54 (dd, 1H, J = 17.9, 2.6 Hz, H-
2b), 1.79 (d, 3H, J = 1.4 Hz, H-15), 1.27 (t, 3H, J = 7.1 Hz, H-7) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 203.3 (C-3), 179.4 (C-10), 171.4 (C-5), 116.9 (C-4), 61.7 
(C-6), 58.0 (OMe), 44.1 (C-1), 38.5 (C-2), 14.1 (C-6), 7.2 (C-15) ppm. 
 
IR (thin film): 2978, 1728, 1697, 1627, 1458, 1381, 1327, 1249, 1165 cm
-1
. 
 
HRMS (ESI): m/z calculated for C10H14O4 (M + Na
+
) 221.0784, found 221.0782 
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Methyl 2-cyano-3-methyl-4-oxocyclopent-2-enecarboxylate (81)  
 
 
ZnI2 (1.38 g, 4.33 mmol, 0.1 equiv) was dried under vaccuum for 4 h, after which ketoester 
79 (7.97 g, 43.3 mmol) in dry CH2Cl2 (25 mL) was added. TMSCN (5.98 mL, 47.6 mmol, 
1.1 equiv) was added dropwise and the solution was stirred for 24 h at rt, after which the 
solution was concentrated in vacuo using a trap filled with a NaClO/KOH solution. The 
residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
80:20) to give 81 as a yellow oil (5.25 g, 68%).  
 
1
H NMR (400 MHz, CDCl3): δ 3.93-3.87 (m, 1H, H-1), 3.84 (s, 3H, OCH3), 2.87 (dd, 1H, 
J = 19.3, 2.9 Hz, H-2a), 2.76 (dd, 1H, J = 19.3, 7.4 Hz, H-2b), 2.05 (d, 3H, J = 2.2 Hz, H-
15) ppm.
 
 
13
C NMR (101 MHz, CDCl3): δ 203.5 (C-3), 169.7 (C-10), 154.7 (C-4), 133.3 (C-5), 114.0 
(C-6), 53.3 (COOMe), 44.5 (C-2), 37.1 (C-1), 10.6 (C-15) ppm. 
 
IR (thin film): 2956, 2836, 2223, 1738, 1647, 1436, 1343, 1338, 1244, 1162 cm
-1
. 
 
HRMS (ESI): m/z calculated for C9H9NO3 (M + Na)
+
 202.0480, found 202.0471. 
 
(1S*,4R*)-Methyl 2-cyano-4-hydroxy-3-methylcyclopent-2-enecarboxylate (82)  
 
 
Method 1: 
 
To a solution of ketoester 81 (6.65 g, 37.1 mmol) in dry methanol (120 mL) at -78 ºC was 
added solid NaBH4 (1.42 g, 37.5 mmol, 1.01 equiv) portion-wise. The mixture was left to 
stir at -78 ºC for 2 h, followed by the addition of brine at -78 ºC. After 30 min the 
temperature was raised to rt and stirring continued for a further 30 min. The mixture was 
extracted with ethyl acetate (x3). The combined organic layers were washed with brine, 
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dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 60:40) to give 82 as a colourless 
oil (6.16 g, 92%, dr 4:1).  
 
Method 2: 
 
To a solution of [Ru(p-cymene)Cl2]2 (414 mg, 0.677 mmol, 0.01 equiv) in CH2Cl2 (340 
mL, distilled from CaH2) was added (R,R)-TsDPEN (494 mg, 1.35 mmol, 0.02 equiv) and 
the mixture was left to stir for 3 h at rt. Ketoester 81 (12.1 g, 67.7 mmol) was then added 
followed by a mixture of Et3N/HCOOH (2:5, 11.52 mL). The temperature was raised to 30 
°C and the reaction was stirred for 18 h.  Aqueous HCl (1 M) was added and the two layers 
separated. The organic layer was washed with further 1 M aqueous HCl (x2), saturated 
aqueous NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
60:40) to give 82 as a colourless oil (9.93 g, 81%, dr 9:1, 98.9% ee).  
 
Chiral HPLC: Chiralpak AD-H, hexane/iPrOH 88:12, T = 25°C, λ = 214 nm, retention 
time: trans-82 10.573 min and 11.682 min; cis-82 12.448 min and 14.031 min. HPLC 
traces are included in Appendix C. 
 
1
H NMR (400 MHz, CDCl3): δ 4.56 (ddd, 1H, J = 10.5, 7.3, 2.3 Hz, H-3), 3.81 (s, 3H, 
OCH3), 3.62 (dtd, 1H, J = 6.5, 4.3, 1.8 Hz, H-1), 2.74 (d, 1H, J = 10.5 Hz, OH), 2.46 (ddd, 
1H, J = 14.5, 7.9, 7.3 Hz, H-2a), 2.12 (dd, 3H, J = 1.8, 0.7 Hz, H-15), 2.10-2.04 (m, 1H, H-
2b) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 174.1 (C-10), 164.1 (C-4), 114.8 (C-6), 109.7 (C-5), 78.0 
(C-3), 53.1 (COOMe), 49.6 (C-2), 36.4 (C-1), 14.3 (C-15) ppm. 
 
IR (thin film): 3456, 2959, 2225, 1735, 1646, 1433, 1380, 1341, 1206, 1050 cm
-1
. 
 
HRMS (ESI): m/z calculated for C9H11NO3 (M + Na)
+
 204.0637, found 204.0630. 
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(1R,4S)-2-Cyano-4-hydroxy-N-methoxy-N,3-dimethylcyclopent-2-enecarboxamide 
(83)  
 
 
To a solution of MeONHMe.HCl (9.62 g, 98.6 mmol, 1.8 equiv) in dry CH2Cl2 (300 mL) 
at 0 ºC was added dropwise a solution of AlMe3 (32.9 mL, 98.6 mmol, 1.8 equiv, 3.0 M in 
toluene). The mixture was stirred for 1 h, after which a solution of 82 (9.93 g, 54.8 mmol, 
dr 9:1) in dry CH2Cl2 (25 mL) was added dropwise at 0 ºC. The mixture was allowed to 
warm up to rt and left to stir for 18 h. The reaction was quenched with saturated aqueous 
Rochelle’s salt and the aqueous phase was extracted with CH2Cl2 (x3). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (petroleum ether/ethyl 
acetate, 70:30 up to 50:50) to give 83 as a yellow oil (10.6 g, 92%, dr 27:1) 
 
1
H NMR (400 MHz, CDCl3): δ 4.47 (dd, 1H, J = 11.5, 7.8 Hz, H-3), 4.25 (d, 1H, J = 7.8 
Hz, OH), 4.15 (d, 1H, J = 11.5 Hz, H-1), 3.84 (s, 3H, OCH3), 3.27 (s, 3H, NCH3), 2.34-
2.26 (m, 1H, H-2a), 2.13 (d, 3H, J = 1.2 Hz, H-15), 1.97 (d, 1H,  J = 14.2 Hz, H-2b) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 173.3 (C-10), 164.9 (C-4), 115.6 (C-5), 109.6 (C-6), 77.9 
(C-3), 62.2 (OMe), 46.2 (C-2), 36.9 (C-1), 32.55 (NMe), 14.5 (C-15) ppm. 
 
IR (thin film): 3426, 2943, 2217, 1641, 1438, 1390, 1175, 1080, 1045, 1001 cm
-1
. 
 
HRMS (ESI): m/z calculated for C10H14N2O3 (M + Na)
+
 233.0902, found 233.0896. 
 
[α]25D -238.1 (c 1.0, CHCl3) 
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(3R,5S)-5-Acetyl-3-hydroxy-2-methylcyclopent-1-enecarbonitrile (84)  
 
 
To a solution of amide 83 (5.32 g, 25.3 mmol) in dry THF (20 mL) at 0 ºC was added 
dropwise a solution of MeMgBr (21.1 mL, 63.3 mmol, 2.5 equiv, 3.0 M in Et2O). The 
reaction was stirred for 1 h at 0 ºC, after which it was quenched with saturated aqueous 
NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. The crude yellow oil 84 (4.18 g) was used without further purification. A small 
sample was taken and recrystallised via slow vapour diffusion of hexane into EtOAc. 
 
m.p. : 94-96 °C 
 
1
H NMR (400 MHz, CDCl3): δ 4.55-4.47 (m, 1H), 3.87-3.80 (m, 1H), 2.88 (d, 1H, J = 
10.6 Hz), 2.41 (s, 3H), 2.39-2.31 (m, 1H), 2.11-2.08 (m, 3H), 1.96 (dt, 1H, J = 14.3, 2.2 
Hz) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 208.6 (C-10), 164.2 (C-4), 115.2 (C-6), 109.4 (C-5), 77.8 
(C-3). 57.1 (C-1), 35.8 (C-2), 30.4 (C-14), 14.4 (C-15) ppm. 
 
IR (thin film): 3432, 2220, 1706, 1640, 1438, 1362, 1176, 1085, 1039 cm
-1
. 
 
HRMS (ESI): m/z calculated for C9H11NO2 (M + Na)
+
 188.0687, found 188.0683. 
 
[α]25D -157.1 (c 1.0, CHCl3) 
 
X-ray data is included in Appendix A. 
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(3R,5S)-3-Hydroxy-5-((S)-2-hydroxypent-4-en-2-yl)-2-methylcyclopent-1-
enecarbonitrile (103) 
 
 
CeCl3.7H2O (22.7g, 60.9 mmol, 2.2 equiv) was dried under vaccuum at 60 °C (4 h), 80 °C 
(4 h), 120 °C (12 h), 140 °C (4 h), in that order. Dry THF (275 mL) was added and the 
white suspension was sonicated at rt for 1 h. The suspension was then cooled to -78 °C and 
allylmagnesium chloride (30.5 mL, 60.9 mmol, 2.2 equiv, 2 M in THF) was added 
dropwise. The solution was stirred for 1 h at the same temperature, after which a solution 
of ketone 84 (4.57 g, 27.7 mmol) in dry THF (25 mL) was added dropwise and left to stir 
for 2 h. The reaction was quenched with saturated aqueous NH4Cl and the aqueous phase 
was extracted with ethyl acetate (x3). The combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography (petroleum ether/ethyl acetate, 60:40 up to 40:60) to give 
103 as a colourless oil (5.31 g, 93% over 2 steps, dr 6:1). Major isomer signals reported.  
 
1
H NMR (400 MHz, CDCl3): δ 5.91-5.78 (m, 1H, H-8), 5.28-5.13 (m, 2H, H-8’), 4.41-
4.30 (m, 1H, H-3), 3.47 (d, 1H, J = 10.8 Hz, OH), 2.88-2.82 (m, 1H, H-1), 2.37-2.21 (m, 
3H, H-2a + H-9), 2.13-2.08 (m, 3H, H-15), 1.99-1.89 (m, 1H, H-2b), 1.45 (s, 3H, H-14) 
ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 164.3 (C-4), 132.6 (C-8), 120.3 (C-8'), 117.5 (C-6), 111.1 
(C-5), 76.9 (C-3), 72.6 (C-10), 53.9 (C-9), 46.2 (C-1), 34.9 (C-2), 25.8 (C-14, 14.6 (C-15) 
ppm. 
 
IR (thin film): 3435, 2221, 1707, 1642, 1439, 1364, 1177, 1087, 1040 cm
-1
. 
 
HRMS (ESI): m/z calculated for C12H17NO2 (M + Na)
+
 230.1157, found 230.1153. 
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(3R,5S)-3-(tert-Butyldimethylsilyloxy)-5-((S)-2-hydroxypent-4-en-2-yl)-2- 
methylcyclopent-1-carbonitrile (125) 
 
 
To a solution of diol 103 (5.31 mg, 25.6 mmol) in dry DMF (40 mL) was added imidazole 
(6.95 g, 102 mmol, 4 equiv) and TBDMSCl (7.72 g, 51.2 mmol, 2 equiv). The reaction was 
heated to 40 ºC and stirred for 18 h. The reaction was quenched with saturated aqueous 
NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (petroleum ether/ethyl 
acetate, 99:1 up to 95:5) to give 125 as a colourless oil and a single diastereomer (6.87 g, 
83%), and minor diastereomer 125a in variable yields. 
 
1
H NMR (400 MHz, CDCl3): δ 5.88 (ddt app, 1H, J = 17.8, 10.3, 7.5 Hz, H-8), 5.22-5.13 
(m, 2H, H-8’), 4.56-4.50 (m, 1H, H-3), 2.95-2.87 (m, 1H, H-1), 2.38-2.26 (m, 3H, H-2a + 
H-9), 2.01 (dd, 3H, J = 2.1, 0.9 Hz, H-15), 1.69 (ddd, 1H, J = 13.7, 5.7, 4.7 Hz, H-2b), 
1.21 (s, 3H, H-14), 0.90 (s, 9H, CH3-TBS), 0.11 (s, 3H, CH3-TBS), 0.11 (s, 3H, CH3-TBS) 
ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 163.4 (C-6), 133.3 (C-8), 119.5 (C-8'), 117.2 (C-6), 111.3 
(C-5), 77.3 (C-3), 72.7 (C-10), 53.6 (C-1), 44.9 (C-9), 35.6 (C-2), 25.7 (Me3C-TBS), 25.0 
(C-14), 18.0 (Me3C-TBS), 14.4 (C-15), -4.6 (Me-TBS), -4.7 (Me-TBS) ppm.  
 
IR (thin film): 3432, 3080, 2957, 2930, 2215, 1640, 1460, 1257, 1100 cm
-1
. 
 
HRMS (ESI): m/z calculated for C18H31NO2Si (M + Na)
+
 344.2022, found 344.2020. 
 
[α]25D +3.0 (c 1.0, CHCl3) 
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(3R,5S)-3-(tert-Butyldimethylsilyloxy)-5-((S)-2-hydroxypent-4-en-2-yl)-2-
methylcyclopent-1-carbonitrile (125a) 
 
 
1
H NMR (400 MHz, CDCl3): δ 5.90 (ddt app, 1H, J = 17.0, 10.5, 7.4 Hz, H-8), 5.25-5.10 
(m, 2H, H-8'), 4.58-4.52 (m, 1H, H-3), 2.92-2.83 (m, 1H, H-1), 2.38-2.31 (m, 1H, H-2a), 
2.38-2.23 (m, 2H, H-9), 1.99 (dd, 3H, J = 2.1, 1.0 Hz, H-15), 1.50 (ddd, 1H, J = 13.2, 6.7, 
5.6 Hz, H-2b), 1.20 (s, 3H, H-14), 0.90 (s, 9H, CH3-TBS), 0.10 (s, 3H, CH3-TBS), 0.09 (s, 
3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 163.4 (C-6), 133.3 (C-8), 119.5 (C-8'), 117.2 (C-6), 111.0 
(C-5), 77.6 (C-3), 73.2 (C-10), 53.4 (C-1), 44.8 (C-9), 36.1 (C-2), 25.7 (Me3C-TBS), 24.0 
(C-14), 18.0 (Me3C-TBS), 14.2 (C-15), -4.6 (Me-TBS), -4.9 (Me-TBS) ppm.  
 
IR (thin film): 3471, 2931, 2854, 2214, 1643, 1465, 1257, 1096, 833 cm
-1
. 
 
HRMS (ESI): m/z calculated for C18H31NO2Si (M + Na)
+
 344.2022, found 344.2019. 
 
[α]25D -0.75 (c 1.0, CHCl3) 
 
(3R*,5S*)-3-(tert-Butyldimethylsilyloxy)-2-methyl-5-((S)-2-triethylsilyloxy)pent-4-en-
2-yl)cyclopent-1-enecarbonitrile (104) 
 
 
To a solution of alcohol 125 (5.90 g, 18.4 mmol) in dry DMF (30 mL) was added 
imidazole (12.5 g, 184 mmol, 10 equiv) and TESCl (15.4 mL, 91.8 mmol, 5 equiv). The 
reaction was heated to 80 ºC and stirred for 24 h. The reaction was quenched with saturated 
aqueous NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). The 
combined organic layers were washed with 1 M aqueous HCl, brine (x4), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
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chromatography (petroleum ether/ethyl acetate, 99:1) to give 104 as a colourless oil (7.84 
g, 98%).  
 
1
H NMR (400 MHz, CDCl3): δ 5.86 (ddt app, 1H, J = 17.7, 10.4, 7.3 Hz, H-8), 5.15-5.07 
(m, 2H, H-8'), 4.55-4.50 (m, 1H, H-3), 2.88-2.80 (m, 1H, H-1), 2.43-2.21 (m, 3H, H-2a + 
H-9), 1.95 (dd, 3H, J = 2.3, 1.2 Hz, H-15), 1.63 (ddd, 1H, J = 13.1, 7.8, 6.8 Hz, H-2b), 
1.31 (s, 3H, H-14), 0.95 (t, 9H, J = 7.9 Hz, CH3-TBS) 0.90 (s, 9H, CH3-TES), 0.66-0.58 (m, 
6H, CH2-TES), 0.09 (s, 3H, CH3-TBS), 0.08 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 164.0 (C-6), 134.3 (C-8), 118.1 (C-8'), 117.4 (C-6), 110.7 
(C-5), 77.5 (C-3), 76.0 (C-10), 53.2 (C-1), 45.4 (C-9), 35.9 (C-2), 25.7 (Me3C-TBS), 25.5 
(C-14), 18.0 (Me3C-TBS), 14.1 (C-15), 7.1 (CH2-TES), 6.8 (CH3-TES), -4.5 (Me-TBS), -4.9 
(Me-TBS) ppm. 
 
IR (cm
-
1): 2950, 2881, 1640, 1460, 1340, 1250, 1058, 1002, 903. 
 
HRMS (ESI): m/z calculated for C24H45NO2Si2 (M + Na)
+
 458.2887, found 458.2869. 
 
[α]25D -5.6 (c 1.0, CHCl3) 
 
(3R,5S)-3-(tert-Butyldimethylsilyloxy)-2-methyl-5-((S)-2-triethylsilyloxy)pent-4-en-2-
yl)cyclopent-1-enecarbaldehyde (105)  
 
 
To a solution of nitrile 104 (1.00 g, 2.29 mmol) in dry hexane at -78 ºC was added 
dropwise a solution of DIBAL-H (3.44 mL, 3.44 mmol, 1.5 equiv, 1 M in hexane). The 
mixture was warmed to 0 
o
C for 20 min then cooled back down to -78 ºC. Ethyl acetate (5 
mL) was added to quench the excess DIBAL-H and the reaction mixture was left to stir for 
10 min, after which SiO2 (10g) was added and the temperature raised to rt and stirring 
maintained for a further 4 h. The reaction was filtered and concentrated in vacuo to give 
crude aldehyde 105 as a colourless oil (1.01g, 100%). The residue was taken on into the 
next reaction without further purification.  
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1
H NMR (400 MHz, CDCl3): δ 9.91 (s, 1H, H-6), 5.86 (dddd, 1H, J = 17.0, 10.3, 7.6, 6.8 
Hz, H-8), 5.07-4.98 (m, 2H, H-8’), 4.49-4.43 (m, 1H, H-3), 3.13-3.06 (m, 1H, H-1), 2.37-
2.12 (m, 3H, H-2a + H-9), 2.01 (dd, 3H, J = 2.0, 1.0 Hz, H-15), 1.57-1.47 (m, 1H, H-2b), 
1.19 (s, 3H, H-14), 0.94 (t, 9H, J = 7.9 Hz, CH3-TES) 0.91 (s, 9H, CH3-TBS), 0.64-0.56 (m, 
6H, CH2-TES), 0.10 (s, 3H, CH3-TBS), 0.09 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 192.8 (C-6), 157.5 (C-4), 137.4 (C-5), 135.0 (C-8), 117.4 
(C-8'), 78.5 (C-3), 77.6 (C-10), 53.7 (C-9), 44.2 (C-1), 35.3 (C-2), 26.3 (C-14), 25.8 
(Me3C-TBS), 18.1 (Me3C-TBS), 13.0 (C-14), 7.2 (CH2-TES), 7.0 (CH3-TES), -4.5 (Me-
TBS), -4.9 (Me-TBS) ppm. 
 
IR (thin film): 2942, 2885, 1680, 1632, 1456, 1360, 1231, 1128, 1068, 1012 cm
-1
. 
 
HRMS (ESI): m/z calculated for C24H46O3Si2 (M + Na)
+
 461.2883, found 461.2863. 
 
[α]25D -43.3 (c 1.0, CHCl3) 
 
(R)-Methyl 4-((3R,5S)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S)-2- 
(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (128) 
 
 
CeCl3.7H2O (2.56 g, 6.88 mmol, 3 equiv) was dried under vaccuum at 60 °C (4 h), 80 °C 
(4 h), 100 °C (12 h), 140 °C (4 h), in that order. Dry THF (50 mL) was added and the white 
suspension was sonicated for 1 h then cooled to -78 ºC. To a separate solution of HMDS 
(1.44 mL, 6.88 mmol, 3 equiv) in dry THF (5 mL) at 0 ºC was added dropwise a solution 
of 
n
BuLi (2.75 mL, 6.88 mmol, 3 equiv, 2.5 M in hexanes), stirred for 5 min and 
transferred via cannula to the reaction mixture. Methyl propiolate (0.61 mL, 6.88 mmol, 3 
equiv) was added dropwise and after stirring at -78 ºC for 10 min, aldehyde 105 (1.01 g, 
2.29 mmol) in dry THF (2 mL) was added dropwise and the reaction mixture was stirred at 
-78 ºC for 1 h. The reaction was quenched with saturated aqueous NH4Cl, diluted with 
brine and the aqueous phase was extracted with ethyl acetate (x3). The combined organic 
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layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 99:1) 
to give 128 as a colourless oil (1.08 g, 90%).  
 
1
H NMR (400 MHz, CDCl3): δ 5.98-5.85 (m, 1H, H-8), 5.27 (d, 1H, J = 9.1 Hz, H-6), 
5.10-5.02 (m, 2H, H-8’), 4.79 (d, 1H, J = 9.1 Hz, OH), 4.41 (dd, 1H, J = 7.6, 4.1 Hz, H-3), 
3.76 (s, 3H, COOMe), 2.94 (t, 1H, J = 6.1 Hz, H-1), 2.52 (dd, 1H, J = 14.4, 7.3 Hz, H-2a), 
2.45-2.25 (m, 2H, H-9), 1.76 (d, 3H, J = 1.3 Hz, H-15), 1.36-1.29 (m, 1H, H-2b), 1.26 (s, 
3H, H-14), 0.98 (t, 9H, J = 7.9 Hz, CH3-TES) 0.89 (s, 9H, CH3-TBS), 0.75-0.66 (m, 6H, 
CH3-TES), 0.08 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 154.0 (C-12), 142.7 (C-4), 135.2 (C-5), 134.9 (C-8), 117.9 
(C-8'), 87.8 (C-7), 80.1 (C-11), 78.2 (C-3), 76.2 (C-10), 59.5 (COOMe), 57.4 (C-1), 52.6 
(C-6), 42.1 (C-9), 36.5 (C-2), 26.3 (C-14), 25.8 (Me3C-TBS), 18.1 (Me3C-TBS), 12.5 (C-
15), 7.0 (CH2-TES), 6.9 (CH3-TES), -4.5 (Me-TBS), -4.8 (Me-TBS) ppm. 
 
IR (thin film): 3396, 2954, 2875, 2222, 1703, 1360, 1257, 1160, 1058, 1002 cm
-1
. 
 
HRMS (ESI): m/z calculated for C28H50O5Si2 (M + Na)
+
 545.3094, found 545.3086. 
 
[α]25D -22.0 (c 1.0, CHCl3) 
 
(R*)-Methyl 4-((3R*,5S*)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S*)-2- 
(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (129) 
 
 
To a solution of HMDS (71 μL, 0.34 mmol, 1.5 equiv) in dry THF (5 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (0.14 mL, 0.35 mmol, 3 equiv, 2.5 M in hexanes), 
stirred for 5 min and transferred via cannula to a solution of methyl propiolate (30 μL, 0.34 
mmol, 1.5 equiv) in dry THF (5 mL) at -78 ºC. After stirring for 10 min, aldehyde 105 
(100 mg, 0.23 mmol) in dry THF (2 mL) was added dropwise to the reaction mixture and 
stirred at -78 ºC for 1 h. TMSCl (86 μL, 0.69 mmol, 3 equiv) was added dropwise and 
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reaction was allowed to warm up to room temperature and stirred for 18 h. The reaction 
was then quenched with saturated aqueous NaHCO3 and the aqueous phase was extracted 
with ethyl acetate (x3). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 99:1) to give 129 as a colourless oil (136 
mg, 100%).  
 
1
H NMR (400 MHz, CDCl3): 5.91 (dddd, 1H, J = 16.3, 10.2, 8.5, 6.0 Hz, H-8), 5.82 (s, 
1H, H-6), 5.07-4.97 (m, 2H, H-8'), 4.39 (t, 1H, J = 6.7 Hz, H-3), 3.75 (s, 3H, COOMe), 
2.80-2.69 (m, 1H, H-1), 2.31-2.05 (m, 3H, H-9 + H-2a), 1.86 (d, 3H, J = 1.5 Hz, H-15), 
1.24 (ddd, 1H, J = 13.7, 7.7, 6.1 Hz, H-2b), 1.15 (d, 3H J = 11.0 Hz, H-14), 0.98 (t, 9H, J = 
7.9 Hz, CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.66 (q, 6H, J = 7.5 Hz, CH2-TES), 0.19 (s, 9H, 
CH3-TMS), 0.08 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 154.1 (C-12), 143.8 (C-4), 135.2 (C-5), 134.8 (C-8), 117.2 
(C-8'), 88.9 (C-7), 78.8 (C-11), 78.4 (C-3), 75.8 (C-10), 60.3 (C-6), 55.3 (COOMe), 52.5 
(C-1), 41.9 (C-9), 37.0 (C-2), 26.2 (C-14), 25.9 (Me3C-TBS), 18.2 (Me3C-TBS), 12.7 (C-
15), 7.4 (CH2-TES), 7.1 (CH3-TES), 0.1 (Me-TMS), -4.4 (Me-TBS), -4.7 (Me-TBS) ppm. 
 
IR (thin film): 2954, 2876, 2230, 1721, 1359, 1250, 1080, 840 cm
-1
. 
 
HRMS (ESI): m/z calculated for C31H58O5Si3 (M + Na)
+
 617.3490, found 617.3462. 
 
(R*)-Methyl 4-acetoxy-4-((3R*,5S*)-3-(tert-butyldimethylsilyloxy)-2-methyl-5- 
((S*)-2-(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)but-2-ynoate (130) 
 
 
To a solution of HMDS (270 μL, 1.29 mmol, 3 equiv) in dry THF (10 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (516 μL, 1.29 mmol, 3 equiv, 2.5 M in hexanes), 
stirred for 5 min and transferred via cannula to a solution of methyl propiolate (114 μL, 
1.29 mmol, 3 equiv) in dry THF (10 mL) at -78 ºC. After stirring for 10 min, aldehyde 105 
(188 mg, 0.430 mmol) in dry THF (2 mL) was added dropwise  and the reaction mixture 
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was stirred at -78 ºC for 1 h. Ac2O (243 μL, 2.57 mmol, 6 equiv) was added dropwise, the 
reaction was allowed to warm up to room temperature and stirred for 18 h. The reaction 
was then quenched with saturated aqueous NaHCO3 and the aqueous phase was extracted 
with ethyl acetate (x3). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 99:1) to give 130 as a colourless oil (179 
mg, 74%). 
 
1
H NMR (500 MHz, CDCl3): δ 6.73 (s, 1H, H-6), 5.88 (dddd, 1H, J = 16.8, 10.2, 8.1, 6.5 
Hz, H-8), 5.06-4.95 (m, 2H, H-8'), 4.43 (dd, 1H, J = 7.2, 6.3 Hz, H-3), 3.75 (s, 3H, 
COOMe), 2.85-2.75 (m, 1H, H-1), 2.26 (dt app, 1H, J = 13.1, 7.9 Hz, H-2a), 2.17 (dd, 1H, 
J = 14.1, 6.5 Hz, H-9a), 2.11 (s, 3H, OAc), 2.10 – 2.06 (m, 1H, H-9b), 1.87 (dd, 3H, J = 
2.0, 0.7 Hz, H-15), 1.28 (ddd, 1H, J = 10.0, 8.0, 4.2 Hz, H-2b), 1.17 (s, 3H, H-14), 0.97 (t, 
9H, J = 7.9 Hz, CH3-TES), 0.91 (s, 9H, CH3-TBS), 0.70-0.63 (m, 6H, CH2-TES), 0.09 (s, 
3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 169.2 (Ac), 153.7 (C-12), 146.2 (C-5), 134.9 (C-5), 131.2 
(C-8), 117.4 (C-8'), 84.5 (C-7), 78.5 (C-11), 78.1 (C-3), 76.3 (C-10), 60.6 (C-6), 55.8 
(COOMe), 52.6 (C-1), 41.9 (C-9), 36.9 (C-2), 26.3 (C-14), 25.9 (Me3C-TBS), 20.8 (Ac), 
18.1 (Me3C-TBS), 13.0 (C-15), 7.2 (CH2-TES), 7.0 (CH3-TES), -4.4 (Me-TBS), -4.8 (Me-
TBS) ppm. 
 
IR (thin film): 2955, 2877, 2237, 1720, 1249, 1219, 1064, 1002, 833 cm
-1
. 
 
HRMS (ESI): m/z calculated for C30H52O6Si2 (M + Na)
+
 587.3195, found 587.3172. 
 
(R*)-tert-Butyl 4-((3R*,5S*)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S*)-2- 
(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (131) 
 
 
CeCl3.7H2O (127 mg, 0.34 mmol, 3 equiv) was dried under vaccuum at 60 °C (4 h), 80 °C 
(4 h), 100 °C (12 h), 140 °C (4 h), in that order. Dry THF (2 mL) was added and the white 
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suspension was sonicated for 1 h then cooled to -78 ºC. To a separate solution of HMDS 
(71 μL, 0.34 mmol, 3 equiv) in dry THF (2 mL) at 0 ºC was added dropwise a solution of 
n
BuLi (136 μL, 0.34 mmol, 3 equiv, 2.5 M in hexanes), stirred for 5 min and transferred 
via cannula to the reaction mixture. tert-Butyl propiolate (43.1 mg, 0.34 mmol, 3 equiv) 
was then added dropwise at -78 ºC and after stirring for 10 min, aldehyde 105 (50 mg, 0.11 
mmol) in dry THF (2 mL) was added dropwise and the reaction mixture was stirred at -78 
ºC for 1 h. Saturated aqueous NH4Cl was slowly added and the reaction was warmed to 
room temperature and the aqueous phase was extracted with ethyl acetate (x3). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petroleum ether/ethyl acetate, 97:3) to give 131 as a colourless oil (48 mg, 75%).  
 
1
H NMR (500 MHz, CDCl3): δ 5.91 (ddt app, 1H, J = 17.5, 10.2, 7.5 Hz, H-8), 5.23 (d, 
1H, J = 9.3 Hz, H-6), 5.10-5.02 (m, 2H, H-8'), 4.74 (d, 1H, J = 9.3 Hz, OH), 4.40 (dd, 1H, 
J = 7.5, 4.5 Hz, H-3), 2.93 (t app, 1H, J = 6.2 Hz, H-1), 2.57 (dd, 1H, J = 14.5, 7.2 Hz, H-
2a), 2.35 (dd, 1H, J = 14.5, 7.2 Hz, H-2b), 2.29 (dt app, 1H, J = 13.7, 8.4 Hz, H-9a), 1.75 
(d, 3H, J = 1.3 Hz, H-15), 1.46 (s, 9H, COO
t
Bu), 1.34-1.28 (m, 1H, H-9b), 1.27 (s, 3H, H-
14), 0.98 (t, 9H, J = 7.9 Hz, CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.70 (q, 6H, J = 7.9 Hz, 
CH2-TES), 0.07 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS)  ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 152.7 (C-12), 142.4 (C-4), 135.3 (C-5), 135.0 (C-8), 117.8 
(C-8'), 84.9 (C-7), 83.0 (C-11), 80.1 (C-3), 78.2 (C-10), 77.8 (Me3C-
t
Bu), 59.5 (C-1), 57.4 
(C-6), 42.0 (C-9), 36.5 (C-2), 28.0 (Me3C-
t
Bu), 26.3 (C-14), 25.8 (Me3C-TBS), 18.1 
(Me3C-TBS), 12.4 (C-15), 7.1 (CH2-TES), 6.9 (CH3-TES), -4.5 (Me-TBS), -4.8 (Me-TBS) 
ppm. 
 
IR (cm
-1
): 2954, 2877, 2222, 1705, 1257, 1157, 1056, 1002, 840. 
 
HRMS (ESI): m/z calculated for C31H56O5Si2 (M + Na)
+
 587.3558, found 587.3532. 
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(R*)-tert-Butyl 4-((3R*,5S*)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S*)-2- 
(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)-4-(trimethylsilyloxy)but-2-ynoate 
(132) 
 
 
To a solution of HMDS (193 μL, 0.92 mmol, 3 equiv) in dry THF (5 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (368 μL, 0.92 mmol, 3 equiv, 2.5 M in hexanes), 
stirred for 5 min and transferred via cannula to a solution of tert-butyl propiolate (116 mg, 
0.920 mmol, 3 equiv) in dry THF (5 mL) at -78 ºC. After stirring for 10 min, aldehyde 105 
(135 mg, 0.310 mmol) in dry THF (2 mL) was added dropwise and the reaction mixture 
was stirred at -78 ºC for 1 h. TMSCl (389 μL, 3.08 mmol, 10 equiv) was added dropwise 
and reaction was allowed to warm up to room temperature and stirred for 18 h. The 
reaction was then quenched with saturated aqueous NaHCO3 and the aqueous phase was 
extracted with ethyl acetate (x3). The combined organic layers were washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 99:1) to give 132 as a colourless 
oil (62 mg, 32%).  
 
1
H NMR (400 MHz, CDCl3): δ 5.97-5.86 (m, 1H, H-8), 5.78 (s, 1H, H-6), 5.08-4.98 (m, 
2H, H-8'), 4.39 (t app, 1H, J = 6.7 Hz, H-3), 2.75 (t app, 1H, J = 7.8 Hz, H-1), 2.30-2.17 
(m, 2H, H-9), 2.12 (dd, 1H, J = 14.2, 8.4 Hz, H-2a), 1.86 (d, 3H, J = 1.3 Hz, H-15), 1.47 
(s, 9H, COO
t
Bu), 1.29-1.20 (m, 1H, H-2b), 1.16 (s, 3H, H-14), 0.98 (t, 9H, J = 7.9 Hz, 
CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.67 (q, 6H, J = 7.7 Hz, CH2-TES), 0.19 (s, 9H, CH3-
TMS), 0.08 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS)  ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 153.6 (C-12), 144.0 (C-4), 136.0 (C-5), 135.8 (C-8), 117.9 
(C-8'), 86.7 (C-7), 83.6 (C-11), 79.6 (C-3), 79.1 (C-10), 78.2 (Me3C-
t
Bu), 61.3 (C-1), 56.1 
(C-6), 42.7 (C-9), 37.7 (C-2), 28.8 (Me3C-
t
Bu), 27.0 (C-14), 26.7 (Me3C-TBS), 19.0 
(Me3C-TBS), 13.5 (C-15), 8.1 (CH2-TES), 7.8 (CH3-TES), 0.0 (Me-TMS), -4.5 (Me-TBS), -
4.8 (Me-TBS) ppm. 
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IR (thin film):2968, 2950, 2234, 1720, 1660, 1472, 1432, 1375, 1347, 1242, 1083, 1016 
cm
-1
. 
 
HRMS (ESI): m/z calculated for C34H64O5Si3 (M + Na)
+
 659.4062, found 659.4063. 
 
(R*)-tert-Butyl 4-acetoxy-4-((3R*,5S*)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S*)-
2-(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)but-2-ynoate (133) 
 
 
To a solution of HMDS (170 μL, 0.810 mmol, 3 equiv) in dry THF (5 mL) at 0 ºC was 
added dropwise a solution of 
n
BuLi (324 μL, 0.810 mmol, 3 equiv, 2.5 M in hexanes), 
stirred for 5 min and transferred via cannula to a solution of tert-butyl propiolate (102 mg, 
0.810 mmol, 3 equiv) in dry THF (5 mL) at -78 ºC After stirring for 10 min, aldehyde 105 
(118 mg, 0.270 mmol) in dry THF (2 mL) was added dropwise and the reaction mixture 
was stirred at -78 ºC for 1 h. Ac2O (153 μL, 1.61 mmol, 6 equiv) was added dropwise and 
the reaction was allowed to warm up to room temperature and stirred for 18 h. The reaction 
was then quenched with saturated aqueous NaHCO3 and the aqueous phase was extracted 
with ethyl acetate (x3). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 99:1) to give 133 as a colourless oil (131 
mg, 80%). 
 
1
H NMR (500 MHz, CDCl3): δ 6.73 (s, 1H, H-6), 5.89 (dddd, 1H, J = 16.8, 10.2, 8.1, 6.4 
Hz, H-8), 5.08-4.93 (m, 2H, H-8'), 4.44 (t app, 1H, J = 6.7 Hz, H-3), 2.86-2.74 (m, 1H, H-
1), 2.30-2.13 (m, 2H, H-9a + H-2a), 2.11 (s, 3H, OAc), 2.09-2.04 (m, 1H, H-9b), 1.87 (d, 
3H, J = 1.4 Hz, H-15), 1.47 (s, 9H, COO
t
Bu), 1.31-1.24 (m, 1H, H-2b), 1.17 (s, 3H, H-14), 
0.98 (t, 9H, J = 7.9 Hz, CH3-TES), 0.91 (s, 9H, CH3-TBS), 0.70-0.64 (m, 6H, CH2-TES), 
0.09 (s, 3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 169.2 (Ac), 152.4 (C-12), 145.6 (C-4), 135.0 (C-5), 131.4 
(C-8), 117.3 (C-8'), 83.3 (C-7), 81.5 (C-11), 78.6 (C-3), 78.3 (C-10), 77.8 (Me3C-
t
Bu), 
60.8 (C-1), 55.7 (C-6), 41.8 (C-9), 36.8 (C-2), 27.9 (Me3C-
t
Bu), 26.2 (C-14), 25.8 (Me3C-
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TBS), 20.8 (Ac) 18.1 (Me3C-TBS), 13.0 (C-15), 7.3 (CH2-TES), 6.9 (CH3-TES), -4.4 (Me-
TBS), -4.7 (Me-TBS) ppm. 
 
IR (thin film): 2954, 2887, 2360, 1751, 1712, 1373, 1257, 1219, 1157, 1064, 1002, 840, 
740 cm
-1
. 
 
HRMS (ESI): m/z calculated for C33H58O6Si2 (M + Na)
+
 629.3664, found 629.3636. 
 
(R)-Benzyl 4-((3R,5S)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S)-2- 
(triethylsilyloxy)pent-4-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (134) 
 
 
CeCl3.7H2O (1.28 g, 3.44 mmol, 3 equiv) was dried under vaccuum at 60 °C (4 h), 80 °C 
(4 h), 100 °C (12 h), 140 °C (4 h), in that order. Dry THF (50 mL) was added and the white 
suspension was sonicated for 1 h then cooled to -78 ºC. To a separate solution of HMDS 
(721 μL, 3.44 mmol, 3 equiv) in dry THF (5 mL) at 0 ºC was added dropwise a solution of 
n
BuLi (1.38 mL, 3.44 mmol, 3 equiv, 2.5 M in hexanes), stirred for 5 min and transferred 
via cannula to the reaction mixture. Benzyl propiolate (0.44 mL, 3.44 mmol, 3 equiv) was 
added dropwise and after stirring at -78 ºC for 10 min, aldehyde 105 (503 mg, 1.15 mmol) 
in dry THF (2 mL) was added dropwise and the reaction mixture was stirred at -78 ºC for 1 
h. The reaction was quenched with saturated aqueous NH4Cl, diluted with brine and the 
aqueous phase was extracted with ethyl acetate (x3). The combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (petroleum ether/CH2Cl2, 50:50 to remove 
benzyl propiolate, then petroleum ether/ethyl acetate, 95:5) to give 134 as a colourless oil 
(645 mg, 92%).  
 
1
H NMR (400 MHz, CDCl3): δ 7.41-7.28 (m, 5H, Ar), 5.89 (ddt app, 1H, J = 17.5, 10.2, 
7.5 Hz, H-8), 5.27 (d, 1H, J = 9.2 Hz, H-6), 5.19 (s, 2H, PhCH2), 5.09-4.95 (m, 2H, H-8'), 
4.77 (d, 1H, J = 9.2 Hz, OH), 4.41 (dd, 1H, J = 7.7, 4.1 Hz, H-3), 2.94 (t app, 1H, J = 6.1 
Hz, H-1), 2.53 (dd, 1H J = 14.5, 7.2 Hz, H-9a), 2.42-2.23 (m, 2H, H-2a + H-9b), 1.76 (d, 
3H, J = 1.3 Hz, H-15), 1.33 (ddd, 1H J = 13.8, 5.8, 4.4 Hz, H-2b), 1.27 (s, 3H, H-14), 0.96 
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(t, 9H, J = 7.9 Hz, CH3-TES), 0.90 (s, 9H CH3-TBS), 0.69 (q, 6H, J = 7.9 Hz, CH2-TES), 
0.08 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 153.3 (C-12), 142.6 (C-4), 135.1 (C-5), 134.9 (C-8), 134.9 
(C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 117.8 (C-8'), 88.0 (C-7), 80.0 (C-11), 
78.2 (C-3), 76.3 (C-10), 67.4 (PhCH2), 59.5 (C-1), 57.3 (C-6), 42.1 (C-9), 36.4 (C-2), 26.2 
(C-14), 25.8 (Me3C-TBS), 18.0 (Me3C-TBS), 12.5 (C-15), 7.0 (CH2-TES), 6.9 (CH3-TES), -
4.5 (Me-TBS), -4.8 (Me-TBS) ppm. 
 
IR (thin film): 3361, 2955, 2875, 1712, 1456, 1375, 1229, 1054, 1003, 747 cm
-1
. 
 
HRMS (ESI): m/z calculated for C34H54O5Si2 (M + Na)
+
 621.3402, found 621.3392. 
 
[α]25D -9.7 (c 1.0, CHCl3) 
 
tert-Butyl propiolate (135) 
 
 
Ref:  Chem. Commun. 2015, 51, 13004. 
 
To a suspension of anhydrous MgSO4 (6.87 g, 57.1 mmol, 4 equiv) in dry CH2Cl2 (60 mL) 
was added H2SO4 (0.76 mL, 14.3 mmol, 1 equiv) and the resulting mixture was stirred 
vigorously for 15 min.  Propiolic acid (0.88 mL, 14.3 mmol) was added, after which tert-
butanol (6.78 mL, 71.3 mmol, 5 equiv) was slowly added and the reaction flask tightly 
stoppered. The reaction was left stirring for 24 h, after which saturated aqueous NaHCO3 
(100 mL) was added and the resulting mixture was stirred until all MgSO4 had dissolved. 
The organic phase was collected, washed with brine, dried over MgSO4 and concentrated 
in vacuo to give tert-butyl propiolate as a yellow oil (1.42 g, 79%). 
 
1
H NMR (400 MHz, CDCl3): δ 2.68 (s, 1H, H-1), 1.44 (s, 9H, COO
t
Bu) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 151.7 (C-3), 84.1 (Me3C-
t
Bu), 76.0 (C-1), 72.2 (C-2), 
27.9 (Me3C-
t
Bu) ppm. 
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Benzyl propiolate (137) 
 
 
Ref: ChemBioChem 2011, 12, 1193. 
 
To a solution of propiolic acid (3.52 mL, 58 mmol, 1 equiv) in acetone (180 mL) was 
added K2CO3 (8.15 g, 59.0 mmol, 1.01 equiv) and NaI (870 mg, 5.80 mmol, 0.1 equiv). 
Benzyl bromide (6.88 mL, 58.0 mmol, 1 equiv) was added rapidly dropwise and the 
reaction mixture heated to reflux. The reaction mixture was left stirring at reflux for 24 h, 
after which it was cooled to rt and volatiles were removed in vacuo. The residue was 
partitioned between Et2O and water, and the aqueous phase was extracted with Et2O (x3). 
The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petroleum ether/ethyl acetate, 95:5) to give 137 as a colourless oil (8.48 g, 91%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.51-7.34 (m, 5H, Ar), 5.25 (s, 2H, PhCH2), 2.92 (s, 1H, 
H-1) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 152.5 (C-3), 134.6 (C-Ar), 128.7 (C-Ar), 128.7 (C-Ar), 
128.6 (C-Ar), 75.0 (C-1), 74.6 (C-2), 67.9 (PhCH2) ppm. 
 
(E)-di-tert-Butyl hex-2-en-4-ynedioate (136) 
 
 
To a solution of propiolic acid (1.00 g, 14.3 mmol) in tert-butanol (5 mL) was added di-
tert-butyl carbonate (6.56 mL, 28.5 mmol, 2 equiv) and DMAP (0.520 g, 4.28 mmol, 0.3 
equiv). The solution was left to stir for 12 h at room temperature. The solvent was 
evaporated and the residue was purified by flash column chromatography (petroleum 
ether/ethyl acetate, 99:1) to give 136 as a yellow oil (1.37 g, 76%). 
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1
H NMR (400 MHz, CDCl3): δ 7.94 (d, 1H, J = 12.4 Hz, H-3), 5.54 (d, 1H, J = 12.4 Hz, 
H-5), 1.46 (s, 9H, COO
t
Bu), 1.41 (s, 9H, COO
t
Bu) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 165.4 (C-1), 150.6 (C-6), 149.7 (C-3), 107.1 (C-2), 84.9 
(C-4), 81.0 (C-5), 80.7 (Me3C-
t
Bu), 77.2 (Me3C-
t
Bu), 28.2 (Me3C-
t
Bu), 27.6 (Me3C-
t
Bu) 
ppm. 
 
IR (thin film): 2978, 1766, 1712, 1257, 1111 cm
-1
. 
 
General procedure for ring-closing ene-yne metathesis. 
 
A solution of enyne in dry toluene [0.02 M] was degassed using the freeze-pump-thaw 
cycle (x3). Grubbs second-generation catalyst was added in one portion. The reaction was 
heated to 80 ºC and left to stir overnight under an ethylene atmosphere. The solution was 
cooled to rt and concentrated in vacuo. The title compound was obtained after purification 
as indicated. 
 
Methyl 2-((2R,4S,8S,8aS)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-3,8-dimethyl-8- 
(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate (138) 
 
Method 1 
 
After following the general RCYEM procedure with enyne 128 (100 mg, 0.190 mmol), the 
crude residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
98:2) to give 138 as a colourless oil (63 mg, 63%).  
 
Method 2 
 
To a solution of ester 139 (25 mg, 0.042 mmol) in dry MeOH (1 mL) at -78 °C was added 
a solution of I2 (0.53 mg, 0.0021 mmol, 0.05 equiv) in MeOH (0.2 mL) and stirred for 3.5 
h. The reaction was quenched with saturated aqueous Na2S2O3 and the aqueous phase was 
extracted with ethyl acetate (x3). The combined organic layers were washed with brine, 
146 
 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 99:1) to give 138 as a colourless 
oil (16 mg, 73%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.15 (d, 1H, J = 1.7 Hz, H-13a), 5.78 (d, 1H, J = 1.7 Hz, 
H-13b), 5.54 (dd, 1H, J = 8.1, 3.0 Hz, H-8) 4.95 (d, 1H, J = 10.6 Hz, H-6), 4.51 (d, 1H, J = 
10.6 Hz, OH), 4.53-4.44 (m, 1H, H-3), 3.76 (s, 3H, COOMe), 3.03-2.95 (m, 1H, H-1), 2.52 
(dd, 1H, J = 17.1, 3.0 Hz, H-9a), 2.34-2.16 (m, 3H, H-2 + H-9b), 1.69 (dd, 3H, J = 2.1, 1.0 
Hz, H-15), 1.26 (s, 3H, H-14), 0.97 (t, 9H, J = 7.9 Hz, CH3-TES) 0.90 (s, 9H, CH3-TBS), 
0.65 (q, 6H, J = 7.9 Hz, CH2-TES), 0.09 (s, 3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 167.4 (C-12), 142.9 (C-11), 140.5 (C-4), 137.5 (C-7), 
136.1 (C-5), 130.9 (C-8), 125.1 (C-13), 79.5 (C-3), 77.8 (C-10), 68.8 (C-6), 57.8 (C-1), 
52.1 (COOMe), 42.1 (C-9), 34.4 (C-2), 25.9 (Me3C-TBS), 22.2 (C-14), 18.1 (Me3C-TBS), 
12.1 (C-15), 7.2 (CH2-TES), 6.9 (CH3-TES), -4.4 (Me-TBS), -4.8 (Me-TBS) ppm. 
 
IR (thin film): 3320, 2957, 2929, 1728, 1460, 1380, 1229, 1023 cm
-1
. 
 
HRMS (ESI): m/z calculated for C28H50O5Si2 (M + Na)
+
 545.3094, found 545.3100 
 
[α]25D -44.9 (c 1.0, CHCl3) 
 
Methyl 2-((2R*,4S*,8S*,8aS*)-2-(tert-butyldimethylsilyloxy)-3,8-dimethyl-8- 
(triethylsilyloxy)-4-(trimethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate 
(139) 
 
 
After following the general RCYEM procedure with enyne 129 (102 mg, 0.17 mmol), the 
crude residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
98:2) to give 139 as a colourless oil (102 mg, 100%).  
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1
H NMR (400 MHz, CDCl3): δ 6.04 (d, 1H, J = 1.7 Hz, H-13a), 5.84 (ddd, 1H, J = 9.6, 
5.2, 1.3 Hz, H-8), 5.55 (d, 1H, J = 1.7 Hz, H-13b), 4.86 (d, 1H, J = 1.3 Hz, H-6), 4.42 (d, 
1H, J = 6.9 Hz, H-3), 3.78 (s, 3H, COOMe), 3.28 (d, 1H, J = 9.1 Hz, H-1), 3.22 (dd, 1H, J 
= 13.2, 5.2 Hz, H-9a), 2.22-2.06 (m, 2H, H-2 + H-9b), 1.77-1.71 (m, 1H, H-2b), 1.59 (d, 
3H, J = 1.4 Hz, H-15), 1.07 (s, 3H, H-14), 0.98 (t, 9H J = 7.9 Hz, CH3-TES), 0.90 (s, 9H, 
CH3-TBS), 0.62 (q, 6H, J = 8.0 Hz, CH2-TES) 0.10-0.07 (m, 15H, CH3-TBS + CH3-TMS)  
ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 167.4 (C-12), 143.0 (C-11), 140.5 (C-4), 137.5 (C-7), 
136.0 (C-5), 131.0 (C-8), 125.0 (C-13), 79.5 (C-3), 77.2 (C-10), 68.8 (C-6), 57.8 (C-1), 
52.1 (COOMe), 42.1 (C-9), 34.3 (C-2), 25.8 (Me3C-TBS), 22.2 (C-14), 18.1 (Me3C-TBS), 
12.0 (C-15), 7.1 (CH2-TES), 6.9 (CH3-TES), 0.1 (Me-TMS), -4.4 (Me-TBS), -4.9 (Me-TBS) 
ppm. 
 
IR (thin film): 2956, 2930, 1727, 1435, 1379, 1360, 1245, 1093, 1020 cm
-1
. 
 
HRMS (ESI): m/z calculated for C31H58O5Si3 (M + Na)
+
 617.3489, found 617.3489. 
 
Methyl 2-((2R*,4S*,8S*,8aS*)-4-acetoxy-2-(tert-butyldimethylsilyloxy)-3,8- 
dimethyl-8-(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate (140) 
 
 
After following the general RCYEM procedure with enyne 130 (179 mg, 0.320 mmol), the 
reaction was filtered over celite and the filtrate concentrated in vacuo to give 140 as a 
colourless oil (179 mg, 100%).  
 
1
H NMR (500 MHz, CDCl3): δ 6.08 (d, 1H, J = 1.1 Hz, H-13a), 6.01 (d, 1H, J = 1.1 Hz, 
H-13b), 5.97 (ddd, 1H, J = 9.6, 5.0, 0.9 Hz, H-8), 5.62 (d, 1H, J = 0.9 Hz, H-6), 4.43 (dd, 
1H, J = 8.0, 2.0 Hz, H-3), 3.74 (s, 3H, COOMe), 3.09 (d, 1H, J = 8.4 Hz, H-1), 3.00 (dd, 
1H, J = 13.9, 5.1 Hz, H-9a), 2.27 (dd, 1H, J = 13.9, 9.6 Hz, H-9b), 2.21 – 2.13 (m, 1H, H-
2a), 2.07 (s, 3H, OAc), 1.74-1.69 (m, 1H, H-2b), 1.68 (d, 3H, J = 1.7 Hz, H-15), 1.09 (s, 
148 
 
3H, H-14), 0.96 (t, 9H J = 7.9 Hz, CH3-TES), 0.88 (s, 9H, CH3-TBS), 0.60 (q, 6H J = 7.9 
Hz, CH2-TES), 0.07 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 170.0 (Ac), 166.8 (C-12), 142.3 (C-11), 140.8 (C-4), 
137.1 (C-7), 133.2 (C-5), 132.4 (C-8), 125.8 (C-13), 78.9 (C-3), 76.3 (C-10), 70.0 (C-6), 
58.2 (C-1), 52.1 (COOMe), 42.4 (C-9), 34.7 (C-2), 25.8 (Me3C-TBS), 22.2 (C-14), 21.1 
(Ac), 18.1 (Me3C-TBS), 12.2 (C-15), 7.1 (CH2-TES), 6.9 (CH3-TES), -4.4 (Me-TBS), -4.9 
(Me-TBS) ppm. 
 
IR (thin film): 2954, 2877, 1735, 1234, 1111, 1010, 833 cm
-1
. 
 
HRMS (ESI): m/z calculated for C30H52O6Si2 (M + Na)
+
 587.3195, found 587.3168. 
 
tert-Butyl 2-((2R*,4S*,8S*,8aS*)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-3,8- 
dimethyl-8-(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate (141) 
 
 
After following the general RCYEM procedure with enyne 131 (50 mg, 0.097 mmol) at 
100 °C, the crude residue was purified by flash column chromatography (petroleum 
ether/ethyl acetate, 97:3) to give 141 as a colourless oil (11.5 mg, 23%).  
 
1
H NMR (400 MHz, CDCl3): δ 5.94 (d, 1H, J = 1.8 Hz, H-13a), 5.69 (d, 1H, J = 1.8 Hz, 
H-13b), 5.59 (dd, 1H, J = 7.6, 3.8 Hz, H-8), 4.92 (d, 1H, J = 9.6 Hz, H-6), 4.46 (t app, 1H, 
J = 6.7 Hz, H-3), 4.31 (d, 1H, J = 9.6 Hz, OH), 3.02 (t app, 1H, J = 7.2 Hz, H-1), 2.48 (dd, 
1H, J = 16.7, 3.8 Hz, H-9a), 2.37-2.20 (m, 2H, H-9b +H-2a), 1.68 (dd, 3H, J = 2.0, 0.9 Hz, 
H-15), 1.51 (s, 9H, COO
t
Bu), 1.46-1.39 (m, 1H, H-2b), 1.23 (s, 3H, H-14), 0.97 (t, 9H, J = 
7.9 Hz, CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.64 (q, 6H J = 8.0 Hz, CH2-TES), 0.07 (s, 3H, 
CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 166.5 (C-12), 144.7 (C-11), 141.4 (C-4), 139.3 (C-7), 
137.2 (C-5), 128.2 (C-8), 124.2 (C-13), 81.0 (C-3), 78.9 (C-10), 77.9 (Me3C-
t
Bu), 67.8 (C-
6), 55.0 (C-1), 38.6 (C-9), 37.6 (C-2), 28.0 (Me3C-
t
Bu), 26.8 (C-14), 25.9 (Me3C-TBS), 
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18.1 (Me3C-TBS), 11.4 (C-15), 7.0 (CH2-TES), 6.6 (CH3-TES), -4.4 (Me-TBS), -4.8 (Me-
TBS) ppm. 
 
IR (thin film): 3726, 3626, 2924, 1712, 1458, 1429, 1149, 1002, 840, 671 cm
-1
. 
 
HRMS (ESI): m/z calculated for C31H56O5Si2 (M + Na)
+
 587.3581, found 587.3593. 
 
tert-Butyl 2-((2R*,4S*,8S*,8aS*)-2-(tert-butyldimethylsilyloxy)-3,8-dimethyl-8- 
(triethylsilyloxy)-4-(trimethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate 
(142) 
 
 
After following the general RCYEM procedure with enyne 132 (62 mg, 0.097 mmol) the 
crude residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
99:1) to give 142 as a colourless oil (47 mg, 76%).  
 
1
H NMR (500 MHz, CDCl3): δ 5.84 (d, 1H, J = 1.6 Hz, H-13a), 5.80 (ddd, 1H, J = 9.8, 
5.1, 1.1 Hz, H-8), 5.47 (d, 1H, J = 1.5 Hz, H-13b), 4.86 (d, 1H, J = 1.1 Hz, H-6), 4.40 (d, 
1H, J = 6.8 Hz, H-3), 3.25 (d, 1H, J = 8.9 Hz, H-1), 3.17 (dd, 1H, J = 13.3, 5.1 Hz, H-9a), 
2.18-2.06 (m, 2H, H-9b + H-2a), 1.74-1.68 (m, 1H, H-2b), 1.60 (d, 3H, J = 1.1 Hz, H-15), 
1.48 (s, 9H, COO
t
Bu), 1.06 (s, 3H, H-14), 0.96 (t, 9H, J = 7.9 Hz, CH3-TES), 0.88 (s, 9H, 
CH3-TBS), 0.59 (q, 6H, J = 7.9 Hz, CH2-TES), 0.08-0.04 (m, 15H, CH3-TBS + CH3-TMS) 
ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 166.3 (C-12), 144.8 (C-11), 140.3 (C-4), 137.7 (C-7), 
135.8 (C-5), 130.4 (C-8), 122.1 (C-13), 80.8 (C-3), 79.4 (C-10), 76.8 (Me3C-
t
Bu), 68.8 (C-
6), 57.5 (C-1), 42.1 (C-9), 34.3 (C-2), 28.0 (Me3C-
t
Bu), 25.6 (Me3C-TBS), 22.3 (C-14),  
18.0 (Me3C-TBS), 12.1 (C-15), 7.1 (CH2-TES), 6.8 (CH3-TES), 0.0 (Me-TMS), -4.4 (Me-
TBS), -4.8 (Me-TBS) ppm. 
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IR (thin film): 2954, 2877, 2360, 1712, 1458, 1365, 1249, 1141, 1111, 1018, 887, 840, 740 
cm
-1
. 
 
HRMS (ESI): m/z calculated for C34H64O5Si3 (M + Na)
+
 659.3954, found 659.3921. 
 
tert-Butyl 2-((2R*,4S*,8S*,8aS*)-4-acetoxy-2-(tert-butyldimethylsilyloxy)-3,8- 
dimethyl-8-(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate (143) 
 
 
After following the general RCYEM procedure with enyne 133 (131 mg, 0.220 mmol) the 
crude residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
99:1) to give 143 as a colourless oil (122 mg, 93%).  
 
1
H NMR (400 MHz, CDCl3): δ 5.98 (s, 1H, H-6), 5.94 (d, 1H, J = 1.5 Hz, H-13a), 5.97-
5.91 (m, 1H, H-8), 5.53 (d, 1H, J = 1.4 Hz, H-13b), 4.43 (d, 1H, J = 6.1 Hz, H-3), 3.04 (t 
app, 1H, J = 8.6 Hz, H-1), 2.99 (d, 1H, J = 5.1 Hz, H-9a), 2.32-2.11 (m, 2H, H-9b + H-2a), 
2.06 (s, 3H, OAc), 1.68 (d, 3H, J = 1.5 Hz, H-15), 1.72-1.64 (m, 1H, H-2b), 1.48 (s, 9H, 
COO
t
Bu), 1.09 (s, 3H, H-14), 0.96 (t, 9H, J = 7.8 Hz, CH3-TES), 0.87 (s, 9H, CH3-TBS), 
0.60 (q, 6H, J = 7.9 Hz, CH2-TES), 0.06 (s, 3H, CH3-TBS), 0.05 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 170.0 (Ac), 165.9 (C-12), 144.0 (C-11), 140.6 (C-4), 
137.1 (C-7), 132.5 (C-5), 132.5 (C-8), 124.3 (C-13), 81.4 (C-3), 78.9 (C-10), 76.4 (Me3C-
t
Bu), 70.3 (C-6), 58.2 (C-1), 42.4 (C-9), 34.6 (C-2), 28.0 (Me3C-
t
Bu), 25.8 (Me3C-TBS), 
22.3 (C-14), 21.2 (Ac), 18.1 (Me3C-TBS), 12.3 (C-15), 7.2 (CH2-TES), 6.9 (CH3-TES), -4.5 
(Me-TBS), -4.9 (Me-TBS) ppm. 
 
IR (thin film): 2954, 2877, 2160, 1735, 1720, 1458, 1365, 1234, 1149, 1111, 1064, 1010, 
956, 840 cm
-1
. 
 
HRMS (ESI): m/z calculated for C33H58O6Si2 (M + Na)
+
 629.3664, found 629.3659. 
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Benzyl 2-((2R,4S,8S,8aS)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-3,8-dimethyl-8- 
(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)acrylate (144) 
 
 
After following the general RCYEM procedure with enyne 134 (645 mg, 1.08 mmol) the 
crude residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 
95:5) to give 144 as a colourless oil (300 mg, 47%).  
 
1
H NMR (400 MHz, CDCl3): δ 7.43-7.26 (m, 5H, Ar), 6.16 (d, 1H, J = 1.6 Hz, H-13a), 
5.82 (d, 1H, J = 1.6 Hz, H-13b), 5.59 (dd, 1H, J = 8.0, 3.3 Hz, H-8), 5.22 (s, 2H, PhCH2), 
4.97 (d, 1H, J = 10.1 Hz, H-6), 4.46 (t app, 1H, J = 6.8 Hz, H-3), 4.40 (d, 1H, J = 10.1 Hz, 
OH), 3.00 (t app, 1H, J = 7.2 Hz, H-1), 2.50 (dd, 1H, J = 16.9, 3.3 Hz, H-9a), 2.33-2.21 
(m, 2H, H-2a + H-9b), 1.63 (dd, 3H, J = 1.9, 0.9 Hz, H-15), 1.29-1.18 (m, 4H, H-14 + H-
2b), 0.96 (t, 9H, J = 7.9 Hz, CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.64 (q, J = 7.7 Hz, 6H, 
CH2-TES), 0.08 (s, 3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS). 
 
13
C NMR (101 MHz, CDCl3): δ 166.8 (C-12), 142.9 (C-11), 140.8 (C-4), 139.4 (C-7), 
137.3 (C-5), 135.9 (C-Ar), 128.6 (C-8), 128.5 (C-Ar), 128.2 (C-Ar), 128.2 (C-Ar), 126.3 
(C-13), 79.0 (C-3), 77.8 (C-10), 67.7 (C-6), 66.6 (PhCH2), 54.7 (C-1), 38.30 (C-9), 37.8 
(C-2), 27.1 (C-14), 25.9 (Me3C-TBS), 18.2 (Me3C-TBS), 11.3 (C-15), 6.9 (CH2-TES), 6.6 
(CH3-TES), -4.4 (Me-TBS), -4.8 (Me-TBS) ppm. 
 
IR (thin film): 3452, 2953, 2875, 1716, 1456, 1249, 1136, 1002, 835 cm
-1
. 
 
HRMS (ESI): m/z calculated for C34H54O5Si2 (M + Na)
+
 621.3402, found 621.3380. 
 
[α]25D -28.1 (c 1.0, CHCl3) 
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1,4-bis(3-Isocyanopropyl)piperazine (163) 
 
 
Ref: ChemSusChem, 2015, 8, 4139. 
 
To a solution of ethyl formate (8.25 mL, 100 mmol, 5 equiv) in ethyl acetate (12.5 mL)  at 
room temperature was added dropwise 1,4-bis(3-aminopropyl)piperazine 165 (4.12 mL, 
20.0 mmol, 1 equiv). The reaction mixture was stirred for 2 h at room temperature, after 
which ethyl acetate (10 mL) was added and the white precipitate filtered off. The residue 
was washed with ethyl acetate and dried in vacuo. The residue was then redissolved in 
CH2Cl2 (100 mL), and Et3N (33.4 mL, 240 mmol, 12 equiv) was added dropwise at room 
temperature. The solution was then cooled down to 0 °C and phosphoryl chloride (5.59 
mL, 60.0 mmol, 3 equiv) added dropwise. The reaction was stirred at 0 °C for 15 min, after 
which the temperature was raised to room temperature and stirring maintained for a further 
1 h. Under ice-cooling, saturated aqueous K2CO3 (150 mL) was slowly added and the 
resulting mixture stirred for 30 min. The aqueous phase was then extracted with CH2Cl2 
(x3) and the combined organic layers were washed with brine, dried over MgSO4, filtered 
and concentrated in vacuo. The residue was transferred to a pad of silica and washed with a 
solution of CH2Cl2 and Et3N (100:2). The solvent was removed in vacuo and the residue 
recrystallised from cyclohexane to give 163 as a white crystalline solid (775 mg, 18% over 
two steps). 
 
m.p. 74-76 °C (ref: 79-81 °C) 
 
1
H NMR (400 MHz, CDCl3): δ 3.62-3.34 (m, 4H, H-4), 2.72-2.15 (m, 12H, H-1 + H-2), 
1.94-1.76 (m, 4H, H-3) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 156.0 (C-5), 54.4 (C-1), 53.1 (C-2), 39.5 (C-4), 26.4 (C-3) 
ppm. 
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Methyl 2-((2R*,6R*,8S*,8aS*)-6-acetoxy-2-(tert-butyldimethylsilyloxy)-3,8- 
dimethyl-8-(triethylsilyloxy)-1,2,6,7,8,8a-hexahydroazulen-5-yl)acrylate (166) 
 
 
To a solution of (IPr)AuCl (0.82 mg, 0.0013 mmol, 0.03 equiv) in dry 1,2-dichloroethane 
(0.5 mL) was added AgBF4 (0.17 mg, 0.00089 mmol, 0.02 equiv) in 1,2-dichloroethane 
(0.5 mL). The solution was left to stir for 1 minute at room temperature, after which a 
solution of 140 (25 mg, 0.044 mmol) in 1,2-dichloroethane (0.5 mL) was added and the 
sealed vial placed in a scientific microwave reactor. The reaction mixture was stirred at 80 
°C for 30 min and allowed to cool to room temperature. The solution was diluted with 
pentane and filtered over celite, the filtrate concentrated in vacuo and the residue purified 
by flash column chromatography (petroleum ether/ethyl acetate, 98:2) to give 166 as a 
colourless oil (6.9 mg, 28% dr 3:1). 
 
1
H NMR (400 MHz, CDCl3): δ 6.37 (s, 1H, H-6), 6.06 (d, 1H, J = 1.5 Hz, H-13a), 5.68 
(dd, 1H, J = 10.7, 3.8 Hz, H-8), 5.62 (d, 1H, J = 1.5 Hz, H-13b), 4.50 (t app, 1H, J = 6.6 
Hz, H-3), 3.72 (s, 3H, COOMe), 2.84 (t app, 1H, J = 7.6 Hz, H-1), 2.37-2.21 (m, 2H, H-2a 
+H-9a), 2.06-1.93 (m, 4H, H-2b + Ac), 1.74 (s, 3H, H-15), 1.64-1.57 (m, 1H, H-9b), 1.21 
(s, 3H, H-14), 0.94 (t, 9H, J = 7.9 Hz, CH3-TES), 0.91 (s, 9H, CH3-TBS), 0.58 (q, 6H, J = 
7.9 Hz, CH2-TES), 0.10 (s, 3H, CH3-TBS), 0.09 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 169.7 (Ac), 167.1 (C-12), 146.9 (C-5), 144.0 (C-11), 
137.0 (C-7), 132.2 (C-4), 125.8 (C-13), 125.1 (C-6), 78.0 (C-3), 74.4 (C-10), 70.8 (C-8), 
57.3 (C-1), 52.0 (COOMe), 48.3 (C-9), 35.9 (C-2), 25.9 (Me3C-TBS), 21.5 (C-14), 21.0 
(Ac), 18.2 (Me3C-TBS), 12.2 (C-15), 7.1 (CH2-TES), 6.8 (CH3-TES), -4.4 (Me-TBS), -4.8 
(Me-TBS) ppm. 
 
IR (thin film): 2957, 2880, 1736, 1458, 1230, 1111, 1012 cm
-1
. 
 
HRMS (ESI): m/z calculated for C30H52O6Si2 (M + Na)
+
 587.3195, found 587.3192. 
 
 
154 
 
Methyl 2-((8S*,8aS*)-3,8-dimethyl-2-oxo-8-(triethylsilyloxy)-1,2,4,7,8,8a- 
hexahydroazulen-5-yl)acrylate (172) 
 
 
To a solution of acetate 140 (25 mg, 0.044 mmol) in dry 1,2-dichloroethane (2 mL) was 
added (MeCN)2PdCl2 (0.22 mg, 0.00089 mmol, 0.02 equiv) in 1,2-dichloromethane (2 
mL). The solution was stirred at room temperature for 2.5 h, after which the solution was 
concentrated in vacuo and the residue purified by flash column chromatography 
(petroleum ether/ethyl acetate, 90:10) to give 172 as a yellow oil (11.0 mg, 64%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.03 (d, 1H, J = 1.5 Hz, H-13a), 5.87 (dd, 1H, J = 7.9, 6.0 
Hz, H-8), 5.58 (d, 1H, J = 1.5 Hz, H-13b), 3.78 (s, 3H, COOMe), 3.35 (d, 1H, J = 14.1 Hz, 
H-6a), 3.26 (d, 1H, J = 14.1 Hz, H-6b), 3.06 (br s app, 1H, H-1), 2.70 (dd, 1H, J = 13.3, 
5.1 Hz, H-2a), 2.45-2.31 (m, 3H, H-2a + H-9), 1.64 (s, 3H, H-15), 1.25 (s, 3H, H-14), 
1.03-0.77 (m, 9H, CH2-TES), 0.69-0.49 (m, 9H, CH2-TES) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 209.5 (C-3), 166.9 (C-12), 166.8 (C-5), 143.3 (C-11), 
137.1 (C-7), 135.9 (C-4), 128.8 (C-13), 124.77 (C-8), 76.5 (C-10), 57.4 (C-1), 52.2 
(COOMe), 42.8 (C-9), 38.3 (C-2), 33.2 (C-6), 21.5 (C-14), 8.1 (C-15), 7.1 (CH3-TES), 6.8 
(CH3-TES) ppm. 
 
IR (thin film): 2952, 2878, 1713, 1642, 1137, 1107, 1010 cm
-1
. 
 
HRMS (ESI): m/z calculated for C22H34O4Si (M + Na)
+
 413.2119, found 413.2115. 
 
 
 
 
 
 
 
 
155 
 
Methyl 2-((8S*,8aS*)-3,8-dimethyl-2-oxo-8-(triethylsilyloxy)-1,2,8,8a- 
tetrahydroazulen-5-yl)acrylate (194) 
 
 
To a solution of silyl ether 139 (100 mg, 0.168 mmol) in dry benzene (10 mL) was added 
glacial acetic acid (1 mL), iodine (85.3 mg, 0.336 mmol, 2 equiv) and sodium acetate (27.6 
mg, 0.336 mmol, 2 equiv) in that order. The reaction mixture was heated to reflux and 
stirred in the absence of light for 30 min. The reaction mixture was cooled to rt after which 
the solution was concentrated in vacuo and the residue purified by flash column 
chromatography (petroleum ether/ethyl acetate, 90:10) to give 194 as a yellow oil (9.2 mg, 
14%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.68 (s, 1H, H-6), 6.30 (dd, 1H, J = 12.4, 0.5 Hz, H-8), 
6.29 (d, 1H, J = 1.0 Hz, H-13a), 5.85-5.78 (m, 2H, H-9 + H-13b), 3.81 (s, 3H, COOMe), 
3.31 (br s app, 1H, H-1), 2.52-2.46 (m, 2H, H-2), 1.85 (d, J = 2.1 Hz, 3H, H-15), 1.01 (s, 
3H, H-14), 0.98 (t, 9H, J = 7.9 Hz, CH2-TES), 0.65 (q, 5H, J = 7.8 Hz, CH2-TES) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 208.2 (C-3), 166.5 (C-12), 161.1 (C-5), 146.1 (C-11), 
144.0 (C-7), 140.0 (C-4), 139.2 (C-8), 127.2 (C-6), 125.2 (C-13), 122.6 (C-9), 75.7 (C-10), 
52.4 (COOMe), 48.7 (C-1), 37.3 (C-2), 20.0 (C-14), 8.5 (C-15), 7.1 (CH3-TES), 6.7 (CH3-
TES) ppm. 
 
IR (thin film): 2953, 2875, 1726, 1695, 1381, 1139, 1006, 727 cm
-1
. 
 
HRMS (ESI): m/z calculated for C22H32O4Si (M + Na)
+
 411.1962, found 411.1946. 
 
 
 
 
 
 
 
156 
 
Methyl 2-((2R*,4R*,8S*,8aS*)-4-acetoxy-2-(tert-butyldimethylsilyloxy)-3,8- 
dimethyl-8-(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)-3-(p-
tolylthio)propanoate (196) 
 
 
To a solution of acetate 140 (100 mg, 0.177 mmol) in dry methanol (10 mL) was added p-
thiocresol (44.0 mg, 0.354 mmol, 2 equiv), and triethylamine (24 μL, 0.177 mmol, 1 
equiv). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture 
was diluted with ethyl acetate and washed with 1 M aqueous HCl (x2), brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/diethyl ether, 95:5) to give 196 as a colourless oil (59 
mg, 48%, dr 3:1). Major diastereomer peaks reported. 
 
1
H NMR (500 MHz, CDCl3): δ 7.31-7.23 (m, 2H, Ar), 7.15-7.05 (m, 2H, Ar), 5.81-5.75 
(m, 2H, H-8 + H-6), 4.44-4.36 (m, 1H, H-3), 3.61 (s, 3H, COOMe), 3.37-3.21 (m, 2H, H-
13a + H-11), 3.13-3.01 (m, 2H, H-1 + H-13b), 2.90 (dd, 1H, J = 13.8, 4.9 Hz, H-9a), 2.32 
(s, 3H, ArMe), 2.24-2.10 (m, 2H, H-9a + H-2a), 2.03 (s, 1H, Ac), 1.71-1.64 (m, 4H, H-2b 
+ H-15), 1.02 (s, 3H, H-14), 0.96 (t, 4H, J = 7.9 Hz, CH3-TES), 0.87 (s, 9H, CH3-TBS), 
0.59 (q, 6H, J = 7.9 Hz, CH2-TES), 0.06 (s, 3H, CH3-TBS), 0.05 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 172.4 (C-12), 170.0 (Ac), 140.4 (C-4), 136.5 (C-7), 136.4 
(Ar), 132.3 (C-5), 131.7 (C-8), 131.6 (Ar), 130.5 (Ar), 129.8 (Ar), 79.0 (C-3), 76.2 (C-10), 
71.5 (C-6), 58.4 (C-1), 52.5 (COOMe), 51.9 (C-11), 41.9 (C-9), 35.3 (C-13), 34.5 (C-2), 
25.8 (Me3C-TBS), 22.0 (C-14), 21.0 (Ac), 21.0 (ArMe), 18.0 (Me3C-TBS), 12.3 (C-15), 7.1 
(CH2-TES), 6.9 (CH3-TES), -4.5 (Me-TBS), -4.9 (Me-TBS) ppm. 
 
IR (thin film): 2950, 2876, 1743, 1697, 1381, 1141, 1008 cm
-1
. 
 
HRMS (ESI): m/z calculated for C37H60O6SSi2 (M + Na)
+
 711.3547, found 711.3523. 
 
 
157 
 
(2R*,4R*,8S*,8aS*)-2-(tert-Butyldimethylsilyloxy)-5-(3-hydroxyprop-1-en-2-yl)-3,8-
dimethyl-8-(triethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-4-ol (197) 
 
 
To solution to acetate 140 (90 mg, 0.159 mmol) in CH2Cl2 (10 mL) at -78 °C was added 
dropwise a solution of DIBAL-H (700 μL, 0.700 mmol, 4.4 equiv). The reaction mixture 
was stired at -78 for 2 h. The reaction was quenched with the addition of MeOH (2 mL) 
followed by a saturated aqueous solution of Rochelle's salt. The aqueous phase was 
extracted with CH2Cl2 (x3) and the combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/diethyl ether, 90:10) to give 197 as a colourless oil (39.1 
mg,  50%). 
 
1
H NMR (500 MHz, CDCl3): δ 5.63 (dd, 1H, J = 8.4, 2.3 Hz, H-8), 5.21-5.11 (m, 2H, H-
13a + H-6), 5.04 (d, 1H, J = 1.0 Hz, H-13b), 4.96 (d, 1H, J = 11.1 Hz, OH), 4.48 (br t app, 
1H, J = 7.0 Hz, H-3), 4.41 (dd, 1H, J = 13.4, 4.7 Hz, H-12a), 4.22 (dd, 1H, J = 13.4, 7.4 
Hz, H-12b), 3.02-2.89 (m, 1H, H-1), 2.83 (dd, 1H, J = 7.4, 5.6 Hz, OH), 2.48 (dd, 1H, J = 
17.3, 2.1 Hz, H-9a), 2.30 (dt app, 1H J = 12.2, 6.7 Hz, H-2a), 2.22 (ddd, 1H, J = 17.3, 8.4, 
1.8 Hz, H-9b), 1.61 (dd, 3H, J = 2.1, 1.1 Hz, H-15), 1.29 (s, 3H, H-14), 1.16 (ddd, 1H, J = 
12.2, 10.0, 7.8 Hz, H-2b), 0.95 (t, 9H, J = 7.9 Hz, CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.65 
(q, 6H, J = 7.8 Hz, CH2-TES), 0.09 (s, 3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 150.1 (C-4), 141.3 (C-7), 138.9 (C-5), 137.7 (C-8), 125.8 
(C-11), 111.8 (C-13), 79.4 (C-3), 77.7 (C-10), 67.4 (C-12), 65.5 (C-6), 54.4 (C-1), 38.3 (C-
9), 37.8 (C-2), 27.8 (C-14), 25.9 (Me3C-TBS), 18.2 (Me3C-TBS), 11.3 (C-15), 6.9 (CH2-
TES), 6.4 (CH3-TES), -4.4 (Me-TBS), -4.7 (Me-TBS) ppm. 
 
IR (thin film): 3381, 2948, 2870, 1427, 1372, 1105, 1005 cm
-1
. 
 
HRMS (ESI): m/z calculated for C27H50O4Si2 (M + Na)
+
 517.3140, found 517.3114. 
 
158 
 
Methyl 2-((1aS,2S,4R,5aS,6S,7aR)-4-(tert-butyldimethylsilyloxy)-2-hydroxy-3,6-
dimethyl-6-(triethylsilyloxy)-1a,2,4,5,5a,6,7,7a-octahydroazuleno[5,6-b]oxiren-1a-
yl)acrylate (169) 
 
To a solution of 138 (29.0 mg, 0.0550 mmol) in dry benzene (0.5 mL) was added 
VO(O
i
Pr)3 (0.315 μL, 0.00139 mmol, 0.025 equiv) in benzene (0.5 mL) and 
t
BuOOH (15.0 
μL, 0.0833 mmol, 1.5 equiv, 5.5M in decane) in benzene (0.5 mL) and the reaction mixture 
was stirred for 2 h. The reaction mixture was filtered through celite with 80:20 petroleum 
ether/ethyl acetate and the filtrate was concentrated in vacuo. The residue was purified by 
flash column chromatography (petroleum ether/ethyl acetate, 95:5) to give 169 as a 
colourless oil (24.8 mg, 83%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.34 (s, 1H, H-13a), 5.72 (s, 1H, H-13b), 4.81 (s, 1H, H-6), 
4.40 (d, 1H, J = 7.7 Hz, H-3), 3.84 (s, 3H, CH3 ester), 3.10 (dd, 1H, J = 7.1, 3.9 Hz, H-8), 
3.09 (d, 1H, J = 7.7 Hz, H-1), 2.57 (br s, 1H, OH), 2.38 (dd, 1H, J = 13.2, 7.7 Hz, H-9a), 
2.22 (dd, 1H, J = 13.2, 7.7 Hz, H-9b), 2.11 (ddd, 1H, J = 15.0, 9.1, 7.1 Hz, H-2a), 1.76-
1.70 (m, 1H, H-2b), 1.53 (d, 3H J = 1.8 Hz, H-15), 1.26 (s, 3H, H-14), 0.95 (t, 9H, J = 7.7 
Hz, CH3-TES), 0.88 (s, 9H, CH3-TBS), 0.59 (q, 6H, J = 7.7 Hz, CH2-TES), 0.08 (s, 3H, 
CH3-TBS), 0.06 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ
 
165.4 (C-12), 141.0 (C-4), 138.8 (C-11), 135.3 (C-5), 
128.9 (C-13), 79.4 (C-3), 76.1 (C-10), 65.8 (C-6), 62.3 (C-7), 58.7 (C-8), 56.6 (C-1), 52.2 
(COOMe), 43.1 (C-9), 34.1 (C-2), 25.8 (Me3C-TBS), 22.9 (C-14), 18.0 (Me3C-TBS), 12.6 
(C-15), 7.1 (CH2-TES), 6.8 (CH3-TES), -4.5 (Me-TBS), -5.0 (Me-TBS) ppm. 
  
IR (thin film): 3357, 2925, 2855, 1727, 1444, 1110, 1003, 756 cm
-1
. 
 
HRMS (ESI): m/z calculated for C28H50O6Si2 (M + Na)
+
 561.3038, found 561.3013. 
 
[α]25D +64.1 (c 1.0, CHCl3) 
 
 
159 
 
Methyl 2‐((1S*,2R*,3S*,5R*,7S*,8S*,10R*,11S*)‐10‐(tert‐butyldimethylsilyloxy)‐2‐ 
hydroxy‐7,11‐methyl‐7‐(triethylsilyloxy)‐4,12‐dioxatetracyclo[6.4.0.01,11.03,5]dodecan‐
3‐yl)acrylate (202) 
 
 
To a solution of 138 (63.0 mg, 0.120 mmol) in dry toluene (2 mL) was added VO(acac)2 
(0.795 mg, 0.00300 mmol, 0.025 equiv) in toluene (0.5 mL) and 
tBuOOH (18.1 μL, 0.0833 
mmol, 1.5 equiv, 5.5M in decane) in toluene (0.5 mL) and the reaction mixture was stirred 
for 1 h. The reaction mixture was filtered through celite with 80:20 petroleum ether/ethyl 
acetate and the filtrate was concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 95:5) to give 202 as a colourless 
oil (13.0 mg, 20%). 
 
1
H NMR (500 MHz, CDCl3): δ 6.45 (s, 1H, H-13a), 5.84 (s, 1H, H-13b), 4.09 (d, 1H, J = 
6.6 Hz, H-3), 3.96 (s, 1H, H-6), 3.82 (s, 3H, COOMe), 3.29 (br t app, 1H, J = 7.2 Hz, H-8), 
2.78 (d, 1H, J = 9.2 Hz, H-1), 2.66 (s, 1H, OH), 2.40 (dd, 1H, J = 13.2, 6.9 Hz, H-9a), 2.34 
(dd, 1H, J = 13.2, 8.0 Hz, H-9b), 1.86 (ddd, 1H, J = 15.0, 9.4, 6.7 Hz, H-2a), 1.64 (dd, 1H, 
J = 15.0, 0.9 Hz, H-2b), 1.38 (s, 3H, H-15), 1.22 (s, 3H, H-14), 0.94 (t, 9H, J = 7.9 Hz, 
CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.58 (q, 6H, J = 7.9 Hz, CH2-TES), 0.09 (s, 3H, CH3-
TBS), 0.07 (s, 3H, CH3-TBS ) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 165.1 (C-12), 138.1 (C-11), 129.4 (C-13), 75.5 (C-3), 74.4 
(C-6), 71.3 (C-4), 70.8 (C-7), 70.6 (C-10), 59.5 (C-5), 58.3 (C-8), 53.6 (C-1), 52.5 
(COOMe), 42.2 (C-9), 33.0 (C-2), 26.0 (C-14), 25.8 (Me3C-TBS), 18.0 (Me3C-TBS), 14.0 
(C-15), 7.1 (CH2-TES), 6.7 (CH3-TES), -4.5 (Me-TBS), -5.2 (Me-TBS) ppm. 
 
IR (thin film): 3350, 2924, 2854, 1728, 1442, 1110, 1002 cm
-1
. 
 
HRMS (ESI): m/z calculated for C28H50O7Si2 (M + Na)
+
 577.2987, found 577.2961. 
 
 
 
160 
 
tert-Butyl 2‐((1S*,2R*,3S*,5R*,7S*,8S*,10R*,11S*)‐10‐(tert‐butyldimethylsilyloxy) 
‐2‐hydroxy‐7,11‐methyl‐7‐(triethylsilyloxy)‐4,12‐dioxatetracyclo[6.4.0.01,11.03,5]dodeca
n‐3‐yl)acrylate (203) 
 
To a solution of 142 (4.70 mg, 0.00900 mmol) in dry benzene (1 mL) was added 
VO(acac)2 (0.06 mg, 0.00022 mmol, 0.01 equiv) in benzene (0.5 mL) and 
t
BuOOH (1.46 
μL, 0.0130 mmol, 1.5 equiv, 5.5M in decane) in benzene (0.5 mL) and the reaction mixture 
was stirred for 1 h. The reaction mixture was filtered through celite with 80:20 petroleum 
ether/ethyl acetate and the filtrate was concentrated in vacuo. The residue was purified by 
flash column chromatography (petroleum ether/ethyl acetate, 95:5) to give 203 as a 
colourless oil (3.6 mg, 73%). 
 
1
H NMR (400 MHz, CDCl3): δ 6.36 (d, 1H, J = 0.7 Hz, H-13a), 5.73 (d, 1H, J = 0.7 Hz, 
H-13b), 4.10 (d, 1H, J = 6.5 Hz, H-3), 3.95 (s, 1H, H-6), 3.27 (br t app, 1H, J = 7.2 Hz, H-
8), 2.77 (d, 1H, J = 9.1 Hz, H-1), 2.63 (s, 1H, OH), 2.38 (dd, 1H, J = 13.2, 7.0 Hz, H-9a), 
2.32 (dd, 1H, J = 13.2, 8.0 Hz, H-9b), 1.86 (ddd, 1H, J = 15.0, 9.4, 6.7 Hz, H-2a), 1.63 (dd, 
1H, J = 15.0, 0.9 Hz, H-2b), 1.52 (s, 9H, COO
t
Bu), 1.37 (s, 3H, H-15), 1.22 (s, 3H, H-14), 
0.94 (t, 9H, J = 7.9 Hz, CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.58 (q, 6H, J = 7.9 Hz, CH2-
TES), 0.09 (s, 3H, CH3-TBS), 0.07 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 163.6 (C-12), 139.6 (C-11), 128.3 (C-13), 82.2 (Me3C-
t
Bu), 75.5 (C-3), 74.5 (C-6), 71.3 (C-4), 70.8 (C-7), 70.7 (C-10), 59.5 (C-5), 58.2 (C-8), 
53.6 (C-1), 42.2 (C-9), 33.0 (C-2), 28.1 (Me3C-
t
Bu) 26.0 (C-14), 25.8 (Me3C-TBS), 18.0 
(Me3C-TBS), 14.0 (C-15), 7.1 (CH2-TES), 6.7 (CH3-TES), -4.5 (Me-TBS), -5.1 (Me-TBS) 
ppm. 
 
IR (thin film): 2924, 2877, 1720, 1458, 1080, 1010, 671 cm
-1
. 
 
HRMS (ESI): m/z calculated for C31H56O7Si2 (M + Na)
+
 619.3462, found 619.3424. 
 
 
 
161 
 
Benzyl 2-((1aS,2S,4R,5aS,6S,7aR)-4-(tert-butyldimethylsilyloxy)-2-hydroxy-3,6- 
dimethyl-6-(triethylsilyloxy)-1a,2,4,5,5a,6,7,7a-octahydroazuleno[5,6-b]oxiren-1a-
yl)acrylate (201) 
 
 
To a solution of 144 (50 mg, 0.0834 mmol) in dry benzene (2 mL) was added VO(O
i
Pr)3 
(0.21 μL, 0.000834 mmol, 0.01 equiv) in benzene (0.5 mL) and tBuOOH (22.7 μL, 0.0130 
mmol, 1.5 equiv, 5.5M in decane) in benzene (0.5 mL) and the reaction mixture was stirred 
for 1 h. The reaction mixture was filtered through celite with 80:20 petroleum ether/ethyl 
acetate and the filtrate was concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 95:5) to give 201 as a colourless 
oil (21.0 mg, 41%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.45-7.28 (m, 5H, Ar), 6.38 (d, 1H, J = 0.5 Hz, H-13a), 
5.71 (d, 1H, J = 0.5 Hz, H-13b), 5.32 (d, 1H, J = 12.4 Hz, ArCH
1
H
2
), 5.26 (d, 1H, J = 12.4 
Hz, ArCH
1
H
2
), 4.82 (s, 1H, H-6), 4.38 (d, 1H, J = 7.5 Hz, H-3), 3.16-3.04 (m, 2H, H-1 + 
H-8), 2.51 (d, 1H, J = 0.8 Hz, OH), 2.37 (dd, 1H, J = 13.2, 7.1 Hz, H-9a), 2.22 (dd, 1H, J = 
13.2, 7.7 Hz, H-9b), 2.10 (ddd, 1H, J = 14.9, 9.1, 7.9 Hz, H-2a), 1.76-1.70 (m, 1H, H-2b), 
1.49 (d, 3H, J = 1.7 Hz, H-15), 1.24 (s, 3H, H-14), 0.95 (t, 9H, J = 7.9 Hz, CH3-TES), 0.87 
(s, 9H, CH3-TBS), 0.58 (q, 6H, J = 7.9 Hz, CH2-TES), 0.07 (s, 3H, CH3-TBS), 0.05 (s, 3H, 
CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 164.8 (C-12), 141.1 (C-4), 138.7 (C-11), 135.65 (C-5), 
135.2 (Ar), 129.30 (Ar), 128.65 (Ar), 128.34 (C-13), 128.03 (Ar), 79.3 (C-3), 76.1 (C-10), 
66.9 (PhCH2) 65.7 (C-6), 62.3 (C-7), 58.6 (C-8), 56.6 (C-1), 43.0 (C-9), 34.0 (C-2), 25.8 
(Me3C-TBS), 23.0 (C-14), 18.0 (Me3C-TBS), 12.7 (C-15), 7.1 (CH2-TES), 6.8 (CH3-TES), -
4.4 (Me-TBS), -5.0 (Me-TBS) ppm. 
 
IR (thin film): 3401, 2953, 2873, 1726, 1462, 1379, 1255, 1112, 1055, 1001, 835 cm
-1
. 
 
 
 
162 
 
HRMS (ESI): m/z calculated for C31H56O7Si2 (M + Na)
+
 637.3357, found 637.3331. 
 
[α]25D +23.3 (c 1.0, CHCl3) 
 
(3aR,5S,5aS,7R,8bR)-7-(tert-Butyldimethylsilyloxy)-5,8-dimethyl-1-methylene-2-oxo-
5-(triethylsilyloxy)-2,3a,4,5,5a,6,7,8b-octahydro-1H-indeno[5,4-b]furan-8b-
carbaldehyde (208) 
 
 
To a solution of epoxide 169 (35.0 mg, 0.0649 mmol) in dry THF (3 mL) was added DMF 
(1 mL), ammonium acetate (10.0 mg, 0.130 mmol, 2 equiv), sodium acetate (10.7 mg, 
0.130 mmol, 2 equiv) and a solution of titanium isopropoxide (38.5 μL, 0.130 mmol, 2 
equiv) in THF (0.5 mL) in that order. The reaction mixture was heated to 70 °C and stirred 
for 30 minutes. The reaction mixture was allowed to cool to rt and then quenched with 
saturated aqueous NH4Cl. The aqueous phase was extracted with ethyl acetate (x3) and the 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petroleum ether/diethyl ether, 90:10) to give 208 as a white crystalline  film (5.0 mg, 
26%).  
 
1
H NMR (400 MHz, CDCl3): δ 9.65 (s, 1H, H-6), 6.54 (s, 1H, H-13a), 5.55 (s, 1H, H-13b), 
4.69 (dd, 1H, J = 11.3, 6.1 Hz, H-8), 4.62 (t app, 1H, J = 7.0 Hz, H-3), 2.52-2.41 (m, 2H, 
H-1 + H-9a), 2.33 (dt app, 1H, J = 12.7, 7.3 Hz, H-2a), 1.67 (dd, 3H, J = 2.4, 0.9 Hz, H-
15), 1.54-1.51 (m, 1H, H-9b), 1.46 (ddd, 1H, J = 12.7, 8.6, 7.3 Hz, H-2b), 1.12 (s, 3H, H-
14), 1.00-0.83 (m, 18H, CH3-TES + CH3-TBS), 0.57 (q, 6H, J = 7.9 Hz, CH2-TES), 0.11 (s, 
3H, CH3-TBS), 0.10 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 196.1 (C-6), 167.9 (C-12), 143.6 (C-4), 134.1 (C-11), 
129.8 (C-5), 125.9 (C-13), 79.4 (C-3), 75.8 (C-8), 72.4 (C-10), 60.5 (C-7), 52.9 (C-1), 45.8 
(C-9), 34.2 (C-2), 25.8 (Me3C-TBS), 22.0 (C-14), 18.1 (Me3C-TBS), 13.0 (C-15), 7.0 
(CH2-TES), 6.7 (CH3-TES), -4.3 (Me-TBS), -4.8 (Me-TBS) ppm. 
 
163 
 
IR (thin film): 2952, 2870, 1726, 1720, 1455, 1099, 1042, 1003 cm
-1
. 
 
HRMS (ESI): m/z calculated for C27H46O5Si2 (M + Na)
+
 529.2781, found 529.2753. 
 
[α]25D -62.9 (c 0.25, CHCl3) 
 
Methyl 2-((2R*,4S*,5S*,8S*,8aS*)-2,4,5,8-tetrahydroxy-3,8-dimethyl-1,2,4,5,8,8a- 
hexahydroazulen-5-yl)acrylate (211) 
 
To a solution of epoxide 169 (10.0 mg, 0.0190 mmol) in CH2Cl2 (1 mL) was added p-
TsOH.H2O (0.64 mg, 0.00370 mmol, 0.2 equiv) at rt. The solution was stirred for 8 h and 
the reaction quenched with saturated aqueous NaHCO3 and the aqueous phase was 
extracted with ethyl acetate (x3). The combined organic layers were washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (petroleum ether/ethyl acetate, 50:50) to give 211 as a colourless 
oil (4 mg, 40%).  
 
1
H NMR (400 MHz, CDCl3): δ 6.51 (d, 1H, J = 5.3 Hz, H-9), 6.41 (s, 1H, H-13a), 6.32 (d, 
1H, J = 5.3 Hz, H-8), 5.59 (s, 1H, H-13b), 4.70 (m, 1H, OH), 4.46 (tdd app, 1H, J = 7.7, 
4.8, 1.1 Hz, H-3), 3.81 (s, 3H, CH3 ester), 3.63 (d, 1H, J = 7.8 Hz, H-6), 3.51-3.41 (m, 1H, 
H-1), 2.82 (dd, 1H, J = 18.5, 7.7 Hz, H-2a), 2.62 (dd, 1H, J = 18.7, 4.7 Hz, H-2b), 2.15 (s, 
3H, H-15), 1.85 (s, 3H, H-14) ppm. 
 
Further data was not obtained due to rapid degradation of substrate. 
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(1aS,2S,4R,5aS,6S,7aR)-4-(tert-Butyldimethylsilyloxy)-1a-(3-hydroxyprop-1-en-2-yl)-
3,6-dimethyl-6-(triethylsilyloxy)-1a,2,4,5,5a,6,7,7a-octahydroazuleno[5,6-b]oxiren-2-ol 
(212) 
 
 
To a solution of epoxide 169 (166 mg, 0.308 mmol) in dry toluene (10 mL) was added 
dropwise DIBAL-H (1.08 mL, 1.08 mmol, 3.5 equiv, 1 M in hexane) at -78°C and the 
resulting mixture was stirred for 30 min. The excess DIBAL-H was quenched with ethyl 
acetate and saturated aqueous NH4Cl was added. The aqueous phase was extracted with 
ethyl acetate (x3) and the combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 80:20) to give 212 as a colourless oil (41 
mg, 26%). 
 
1
H NMR (400 MHz, CDCl3): δ 5.27 (d, 1H, J = 0.5 Hz, H-13a), 5.18 (d, 1H, J = 0.5 Hz, 
H-13b), 4.80 (s, 1H, H-6), 4.41 (dd, 1H, J = 7.6, 1.2 Hz, H-3), 4.20 (d, 2H, J = 5.5 Hz, H-
12), 3.10 (m, 2H, H-1 + H-8), 2.61 (s, 1H, OH), 2.39 (dd, 1H, J = 13.2, 7.3 Hz, H-9a), 
2.20-2.09 (m, 2H, H-2a + H-9b), 1.91 (t, 1H, J = 5.5 Hz, OH), 1.78-1.69 (m, 1H, H-2a), 
1.66 (d, 3H, J = 1.8 Hz, H-15), 1.23 (s, 3H, H-14), 0.95 (t, 9H, J = 7.9 Hz, CH3-TES), 0.88 
(s, 9H, CH3-TBS), 0.58 (q, 6H, J = 7.9 Hz, CH2-TES), 0.08 (s, 3H, CH3-TBS), 0.07 (s, 3H, 
CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 146.0 (C-4), 141.5 (C-11), 135.6 (C-5), 114.7 (C-13), 79.3 
(C-3), 76.2 (C-10), 65.9 (C-7), 63.5 (C-6), 63.4 (C-12), 59.6 (C-1), 56.7 (C-8), 43.1 (C-9), 
34.2 (C-2), 25.8 (Me3C-TBS), 22.8 (C-14), 18.1 (Me3C-TBS), 13.1 (C-15), 7.1 (CH2-TES), 
6.8 (CH3-TES), -4.4 (Me-TBS), -5.0 (Me-TBS) ppm. 
 
IR (thin film): 3417, 2954, 2931, 2877, 1458, 1381, 1249, 1111, 1049, 1002 cm
-1
. 
 
HRMS (ESI): m/z calculated for C27H50O5Si2 (M + Na)
+
 533.3089, found 533.3064. 
 
[α]25D +50.7 (c 1.0, CHCl3) 
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(2R*,4S*,6R*,8S*,8aS*)-2-(tert-Butyldimethylsilyloxy)-3,8-dimethyl-3'-methylene-4,8-
bis(triethylsilyloxy)-2,4,6,7,8,8a-hexahydro-1H-spiro[azulene-5,2'-oxetan]-6-ol (214) 
 
To a solution of epoxide 212 (27.0 mg, 0.0530 mmol in dry CH2Cl2 (5 mL) at rt was added 
solid p-touenesulfonate (13.3 mg, 0.0530 mmol, 1 equiv). The reaction mixture was stirred 
at rt for 3 h and the reaction quenched with saturated aqueous NaHCO3. The aqueous phase 
was extracted with ethyl acetate (x3) and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. The crude residue (18.4 mg) 
was redissolved in dry CH2Cl2 (2 mL) and imidazole (6.0 mg, 0.0880 mmol, 2.5 equiv) 
was added followed by the dropwise addition of TESCl (11.0 μL, 0.528 mmol, 2 equiv) at 
rt. The reaction mixture was stirred at rt for 8 h and the reaction was quenched with 
saturated aqueous NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). 
The combined organic layers were washed with 1 M aqueous HCl, brine, dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 95:5) to give 214 as a colourless oil (3 mg, 
9% over 2 steps).  
 
1
H NMR (400 MHz, CDCl3): δ 5.47 (s, 1H, H-6), 5.31 (br t app, 1H, J = 1.9 Hz, H-13a), 
5.23 (br t app, 1H, J = 2.4 Hz, H-13b), 4.66 (dt app, 1H, J = 13.2, 2.3 Hz, H-12a), 4.60 (dt 
app, 1H, J = 13.2, 2.2 Hz, H-12b), 4.50 (d, 1H, J = 10.5 Hz, OH), 4.42-4.36 (m, 1H, H-3), 
3.79 (ddd, 1H, J = 12.8, 10.5, 3.9 Hz, H-8), 2.58-2.51 (m, 1H, H-1), 2.22 (dd, 1H, J = 12.0, 
3.9 Hz, H-9a), 2.15 (dt, 1H, J = 13.7, 8.1 Hz, H-2a), 1.70-1.58 (m, 1H, H-9b), 1.64 (dd, 
3H, J = 2.0, 0.6 Hz, H-15), 1.45-1.38 (m, 1H, H-2b), 1.17 (s, 3H, H-14), 0.99 (t, 9H, J = 
7.9 Hz, CH3-TES), 0.95 (t, 9H, J = 7.9 Hz, CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.70 (q, 6H, 
J = 7.9 Hz, CH2-TES), 0.59 (q, 6H, J = 7.8 Hz, CH2-TES), 0.06 (s, 3H, CH3-TBS), 0.05 (s, 
3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 146.9 (C-4), 139.4 (C-11), 134.1 (C-5), 107.9 (C-7), 105.2 
(C-13), 80.9 (C-3), 76.9 (C-10), 74.1 (C-6), 71.7 (C-12), 71.4 (C-8), 58.7 (C-1), 49.5 (C-9), 
32.1 (C-2), 25.9 (Me3C-TBS), 23.1 (C-14), 18.2 (Me3C-TBS), 11.9 (H-15), 7.1 (CH2-TES), 
6.8 (CH2-TES), 6.7 (CH3-TES), 4.7 (CH3-TES), -4.4 (Me-TBS), -4.8 (Me-TBS) ppm. 
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IR (thin film): 2952, 2860, 1448, 1223, 1110, 1053, 1003 cm
-1
. 
 
HRMS (ESI): m/z calculated for C33H64O5Si3 (M + Na)
+
 647.3959, found 647.3925. 
 
Methyl 2-((2R*,4S*,8S*,8aS*)-2-(tert-butyldimethylsilyloxy)-3,8-dimethyl-8- 
(triethylsilyloxy)-4-(trimethylsilyloxy)-1,2,4,7,8,8a-hexahydroazulen-5-yl)oxirane-2-
carboxylate (216) 
 
 
To a solution of ester 139 (30.0 mg, 0.170 mmol) in dry THF (5 mL) was added TMSOK 
(14.3 mg, 0.370 mmol, 2.2 equiv, 80% technical grade) at room temperature and the 
reaction was stirred for 1 h. Water was added to the reaction mixture, and adjusted tho pH 
2 by the addition of 0.1 M aqueous HCl. The aqueous layer was extracted with ethyl 
acetate (5x) and the combined organic layers were washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 99:1) to give 216 as a colourless oil (14.6 
mg, 48%, dr 1.7:1). 
 
1
H NMR (400 MHz, CDCl3): δ 6.01-5.88 (m, 1H, H-8), 4.90 (d, 1H, J = 1.1 Hz, H-6), 
4.46-4.33 (m, 1H, H-3), 3.73 (s, 3H, COOMe), 3.31-3.11 (m, 3H, H-1 + H-13a + H-9a), 
2.79 (d, 1H, J = 6.5 Hz, H-13b), 2.26-2.02 (m, 2H, H-2a + H-9b), 1.77-1.68 (m, 1H, H-2b), 
1.58 (d, 3H, J = 1.9 Hz, H-15), 1.01 (s, 3H, H-14), 0.95 (t, 9H, J = 7.9 Hz, CH3-TES), 0.88 
(s, 9H, CH3-TBS), 0.58 (q, 6H, J = 8.0 Hz, CH2-TES), 0.10-0.00 (m, 15H, CH3-TBS + 
CH3-TMS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 169.8 (C-12), 137.8 (C-4), 136.8 (C-5), 135.5 (C-7), 131.3 
(C-8), 79.5 (C-3), 76.6 (C-10), 67.3 (C-6), 59.5 (C-11), 57.9 (C-1), 53.3 (C-13), 52.8 
(COOMe), 41.4 (C-9), 34.3 (C-2), 25.8 (Me3C-TBS), 22.0 (C-14), 18.1 (Me3C-TBS), 12.0 
(C-15), 7.2 (CH2-TES), 6.9 (CH3-TES), 0.0 (Me-TMS), -4.4 (Me-TBS), -4.9 (Me-TBS) ppm. 
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IR (thin film): 2954, 2877, 1751, 1249, 1111, 1040, 1010 cm
-1
.  
 
HRMS (ESI): m/z calculated for C31H58O6Si3 (M + Na)
+
 633.3438, found 633.3399. 
 
(4R,6S,6aS,8R,9bS)-8-(tert-Butyldimethylsilyloxy)-4-hydroxy-3,6,9-trimethyl-6-
(triethylsilyloxy)-4,5,6,6a,7,8-hexahydroazuleno[4,5-b]furan-2(9bH)-one (218) 
 
 
To a solution of epoxide 201 (20 mg, 0.033 mmol) in EtOAc (0.5 mL) and γ-terpinene (0.5 
mL) was added calcium carbonate (32 mg, 0.325 mmol, 10 equiv) and 20% Pd(OH)2/C (16 
mg). The reaction mixture was heated to 70 °C and stirred for 2.5 h. The reaction was 
cooled down to rt and the solids filtered off. The filtrate was concentrated in vacuo and the 
residue was purified by flash column chromatography (petroleum ether/diethyl ether, 
50:50) to give 218 as a colourless oil (10 mg, 60%). 
 
1
H NMR (400 MHz, CDCl3): δ 5.48 (s, 1H, H-6), 4.55 (br s, 1H, H-8), 4.41 (d, 1H, J = 8.0 
Hz, H-3), 2.71-2.58 (m, 1H, H-1), 2.16 (dt app, 1H, J = 15.1, 8.6 Hz, H-2a), 2.11-1.98 (m, 
5H, H-9 + H-13), 1.82 (m, 4H, H-15 + H-2b), 1.20 (s, 3H, H-14), 0.95 (t, 9H, J = 7.9 Hz, 
CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.60 (q, 6H, J = 7.9 Hz, CH2-TES), 0.08 (s, 3H, CH3-
TBS), 0.08 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 174.8 (C-12), 162.0 (C-7), 141.2 (C-4), 131.0 (C-5) 128.0 
(C-11), 78.0 (C-3), 78.0 (C-6), 77.6 (C-10), 67.1 (C-8), 55.5 (C-1), 34.3 (C-9), 29.6 (C-2), 
25.8 (Me3C-TBS), 18.1 (Me3C-TBS), 12.6 (C-15), 9.5 (C-13), 7.1 (CH2-TES), 6.8 (CH3-
TES), -4.6 (Me-TBS), -4.9 (Me-TBS) ppm. 
 
IR (thin film): 3453, 2958, 2870, 1763, 1249, 1109, 1048, 1005 cm
-1
.  
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(3R,5S)-3-Hydroxy-5-((S)-2-hydroxyhex-5-en-2-yl)-2-methylcyclopent-1-
enecarbonitrile (221) 
 
 
CeCl3.7H2O (3.90 g, 10.5 mmol, 2.2 equiv) was dried under vaccuum at 60 °C (4h), 80 °C 
(4h), 100 °C (12h), 140 °C (4h), in that order. Dry THF (70 mL) was added and the white 
suspension was sonicated for 1 h. The suspension was then cooled to -78 °C and but-3-
enylmagnesium bromide (13.1 mL, 10.5 mmol, 2.2 equiv, 0.8 M in THF) was added 
dropwise. The resulting solution was stirred for 1 h at -78 °C, after which a solution of 
ketone 84 (786 mg, 4.76 mmol) in dry THF (5 mL) was added dropwise and the reaction 
mixture was left to stir for 1 h. The reaction was quenched with saturated aqueous NH4Cl, 
diluted with brine and the aqueous phase was extracted with ethyl acetate (x3). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petroleum ether/ethyl acetate, 60:40 up to 40:60) to give 221 as a yellow oil (320 mg, 30% 
over 2 steps, dr 2.3:1). 
 
1
H NMR (400 MHz, CDCl3): δ 5.98-5.74 (m, 1H, H-8''), 5.16-4.94 (m, 2H, H-8'), 4.40-
4.28 (m,  1H, H-3), 3.58-3.32 (m, 1H, OH), 2.90-2.79 (m, 1H, H-1), 2.37-2.20 (m, 1H, H-
2a), 2.19-2.11 (m, 1H, H-2b), 2.10 (d, 3H, J = 1.7 Hz, H-15), 1.99 – 1.71 (m, 3H, H-8 + H-
9a), 1.70 – 1.63 (m, 1H, H-9b) 1.46 (s, 3H, H-14) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 164.4 (C-4), 138.0 (C-8'), 117.6 (C-6), 115.3 (C-8''), 
111.1 (C-5), 76.9 (C-10), 73.3 (C-3), 54.2 (C-1), 40.6 (C-9), 34.9 (C-8), 28.5 (C-14), 25.7 
(C-2), 14.6 (C-15) ppm. 
 
IR (thin film): 3398, 2974, 2941, 1639, 1438, 1379, 1161, 1039, 912 cm
-1
. 
 
HRMS (ESI): m/z calculated for C13H19NO2 (M + Na)
+
 244.1308, found 244.1309. 
 
 
169 
 
(3R,5S)-3-(tert-Butyldimethylsilyloxy)-5-((S)-2-hydroxyhex-5-en-2-yl)-2-
methylcyclopent-1-enecarbonitrile (223) 
 
 
To a solution of diol 221 (320 mg, 1.45 mmol) in dry DMF (10 mL) was added imidazole 
(381 mg, 5.60 mmol, 4 equiv) and TBDMSCl (436 mg, 2.80 mmol, 2 equiv). The reaction 
mixture was heated to 40 ºC and stirred overnight. The reaction was quenched with 
saturated aqueous NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). 
The combined organic layers were washed with 1 M aqueous HCl, brine (x4), dried over 
MgSO4, filtered and concentrated in vacuo. The resulting diastereomeric mixture was 
inseparable during column chromatography thus 223 was obtained as a crude colourless oil 
(487 mg) and used directly in the next step. 
 
1
H NMR (400 MHz, CDCl3): δ 5.87-5.64 (m, 1H, H-8'), 5.01-4.93 (m, 1H, H-8''a), 4.91-
4.85 (m, 1H, H-8''b), 4.53-4.37 (m, 1H, H-3), 2.84-2.72 (m, 1H, H-1), 2.28-1.97 (m, 3H, 
H-2 + H-8a), 1.92-1.88 (m, 3H, H-15), 1.62-1.34 (m, 3H, H-8b + H-9), 1.19 (s, 3H, H-14), 
0.80 (s, 9H, CH3-TBS), 0.00 (s, 6H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 163.3 (C-4), 138.7 (C-8'), 117.3 (C-6), 114.9 (C-8''), 
111.3 (C-5), 77.4 (C-10), 73.2 (C-3), 54.4 (C-1), 39.3 (C-9), 35.7 (C-8), 28.2 (C-14), 25.7 
(C-2), 25.7 (Me3C-TBS), 18.0 (Me3C-TBS), 14.6 (C-15), -3.6 (Me-TBS), -4.9 (Me-TBS)  
ppm. 
 
IR (thin film): 3468, 2931, 2858, 1639, 1462, 1438, 1357, 1253, 1099, 1053, 906, 894, 
837, 775 cm
-1
. 
 
HRMS (ESI): m/z calculated for C19H33NO2Si (M + Na)
+
 358.2173, found 358.2163. 
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(3R,5S)-3-(tert-Butyldimethylsilyloxy)-2-methyl-5-((S)-2-(triethylsilyloxy)hex-5-en-2-
yl)cyclopent-1-enecarbonitrile (224) 
 
To a solution of alcohol 223 (487 mg, 1.45 mmol) in dry DMF (20 mL) was added 
imidazole (987 mg, 14.5 mmol, 10 equiv) and TESCl (1.22 mL, 7.25 mmol, 5 equiv). The 
reaction was heated to 80 ºC and stirred for 24 h. The reaction was quenched with saturated 
aqueous NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). The 
combined organic layers were washed with 1 M aqueous HCl, brine (x4), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether/ethyl acetate, 99:1) to give 224 as a colourless oil (554 
mg, 85% over 2 steps, dr 2.3:1).  
 
1
H NMR (400 MHz, CDCl3): δ 5.83-5.68 (m, 1H, H-8'), 4.96 (ddd, 1H, J = 17.1, 3.4, 1.6 
Hz, H-8''a), 4.92-4.82 (m, 1H, H-8''b), 4.54-4.36 (m, 1H, H-3), 2.86-2.72 (m, 1H, H-1), 
2.26-2.15 (m, 1H, H-2a), 2.15-1.95 (m, 2H, H-2b +H-9a) 1.88 (dd, 3H, J = 2.3, 1.1 Hz, H-
15), 1.69-1.40 (m, 3H, H-9b, + H-8), 1.21 (s, 3H, H-14), 0.93-0.84 (m, 9H, CH3-TES), 0.82 
(s, 9H, CH3-TBS), 0.62-0.49 (m, 6H, CH2-TES), 0.01 (s, 3H, CH3-TBS), 0.00 (s, 3H, CH3-
TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 163.8 (C-4), 138.8 (C-8'), 117.2 (C-6), 114.4 (C-8''), 
110.9 (C-5), 77.4 (C-3), 73.2 (C-10), 53.6 (C-1), 39.5 (C-9), 36.0 (C-8), 28.4 (C-14), 25.7 
(Me3C-TBS), 25.6 (C-2),  18.0 (Me3C-TBS), 14.2 (C-15), 7.2 (CH2-TES), 6.9 (CH3-TES), -
4.5 (Me-TBS), -4.9 (Me-TBS)  ppm. 
 
IR (thin film): 2947, 2877, 1643, 1458, 1357, 1249, 1056, 1002, 902 cm
-1
. 
 
HRMS (ESI): m/z calculated for C25H47NO2Si2 (M + Na)
+
 472.3038, found 472.3031. 
 
 
 
 
 
171 
 
(3R,5S)-3-(tert-Butyldimethylsilyloxy)-2-methyl-5-((S)-2-(triethylsilyloxy)hex-5-en-2-
yl)cyclopent-1-enecarbaldehyde (225) 
 
 
To a solution of nitrile 224 (200 mg, 0.445 mmol) in dry hexane (20 mL) at -78 ºC was 
added dropwise a solution of DIBAL-H (0.670 mL, 0.670 mmol, 1.5 equiv, 1 M in 
hexane). The reaction mixture was warmed to 0 
o
C for 20 min then cooled back down to -
78 ºC. Ethyl acetate (1 mL) was added to quench the excess DIBAL-H and the reaction 
mixture was left to stir for 10 min, after which SiO2 (10g) was added and the temperature 
raised to rt and stirring maintained for a further 4 h. The reaction was filtered and 
concentrated in vacuo to give crude aldehyde 225 as a colourless oil (206 mg). The residue 
was determined to be pure enough by NMR to continue without further purification. 
 
1
H NMR (400 MHz, CDCl3): δ 9.92 (s, 1H, H-6), 5.90-5.71 (m, 1H, H-8'), 5.10-4.83 (m, 
2H, H-8''), 4.50-4.43 (m, 1H, H-3), 3.24-3.06 (m, 1H, H-1), 2.33-2.03 (m, 3H, H-2 + H-
9a), 2.04-1.99 (m, 3H, H-15), 1.65-1.37 (m, 3H, H-9b + H-8''), 1.19 (s, 3H, H-14), 0.94-
0.90 (m, 9H, CH3-TES), 0.89 (s, 9H, CH3-TBS), 0.68-0.56 (m, 6H, CH2-TES), 0.10 (s, 3H, 
CH3-TBS), 0.09 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 192.6 (C-6), 157.4 (C-4), 139.3 (C-8'), 137.6 (C-5), 114.0 
(C-8''), 78.6 (C-3), 77.7 (C-10), 53.6 (C-1), 38.8 (C-9), 35.3 (C-8), 28.4 (C-14), 26.5 (C-2), 
25.8 (Me3C-TBS), 18.1 (Me3C-TBS), 13.1 (C-15), 6.8 (CH2-TES), 6.4 (CH3-TES), -4.5 
(Me-TBS), -4.9 (Me-TBS)  ppm. 
 
IR (thin film): 2931, 2877, 1681, 1635, 1458, 1373, 1249, 1149, 1064, 1002 cm
-1
. 
 
HRMS (ESI): m/z calculated for C25H48O3Si2 (M + Na)
+
 475.3034, found 475.3014. 
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(R)-Methyl 4-((3R,5S)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S)-2-
(triethylsilyloxy)hex-5-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (226) 
 
 
CeCl3.7H2O (497 mg, 1.34 mmol, 3 equiv) was dried under vaccuum at 60 °C (4 h), 80 °C 
(4 h), 100 °C (12 h), 140 °C (4 h), in that order. Dry THF (20 mL) was added and the white 
suspension was sonicated for 1 h and then cooled to -78 ºC. To a separate solution of 
HMDS (281 μL, 1.34 mmol, 3 equiv) in dry THF (5 mL) at 0 ºC was added dropwise a 
solution of 
n
BuLi (536 μL, 1.34 mmol, 3 equiv, 2.5 M in hexanes), stirred for 5 min and 
transferred via cannula to the reaction mixture. Methyl propiolate (120 μL, 1.34 mmol, 3 
equiv) was added dropwise and after stirring at -78 ºC for 10 min, crude aldehyde 225 (206 
mg, 0.446 mmol) in dry THF (2 mL) was added dropwise and the reaction mixture was 
stirred at -78 ºC for 1 h. The reaction was quenched with saturated aqueous NH4Cl, diluted 
with brine and the aqueous phase was extracted with ethyl acetate (x3). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (petroleum ether/ethyl 
acetate, 97:3) to give 226 as a colourless oil (141 mg, 59%, dr >20:1), followed by C-10 
epimer 227 as a colourless oil (42 mg, 18%, dr >20:1).  
 
1
H NMR (400 MHz, CDCl3): δ 5.78 (ddt app, 1H, J = 16.9, 10.2, 6.5 Hz, H-8'), 5.25 (d, 
1H, J = 9.2 Hz, H-6), 5.00-4.93 (m, 1H, H-8''a), 4.92-4.84 (m, 1H, H-8''b), 4.74 (d, 1H, J = 
9.3 Hz, OH), 4.39 (dd, 1H, J = 7.3, 4.6 Hz, H-3), 3.73 (s, 3H, COOMe), 2.92 (t app, 1H, J 
= 6.3 Hz, H-1), 2.35-2.13 (m, 2H, H-2a + H-8a), 2.12-1.99 (m, 1H, H-2b), 1.91-1.80 (m, 
1H, H-8b), 1.74 (d, 3H, J = 1.4 Hz, H-15), 1.61 (ddd, 1H, J = 14.3, 12.5, 4.7 Hz, H-9a), 
1.32-1.22 (m, 4H, H-9b + H-14), 0.98 (t, 9H, J = 7.9 Hz, CH3-TES), 0.87 (s, 9H, CH3-
TBS), 0.71 (q, 6H, J = 7.9 Hz, CH2-TES), 0.06 (s, 3H, CH3-TBS), 0.04 (s, 3H, CH3-TBS) 
ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 153.9 (C-12), 142.4 (C-4), 138.9 (C-5), 135.3 (C-8'), 
114.0 (C-8''), 87.8 (C-7), 80.1 (C-11), 78.2 (C-3), 76.1 (C-10), 59.5 (COOMe), 57.4 (C-1), 
52.5 (C-6), 36.7 (C-8), 36.3 (C-9), 28.6 (C-14), 26.4 (C-2), 25.8 (Me3C-TBS), 18.1 (Me3C-
TBS), 12.5 (C-15), 7.0 (CH2-TES), 6.9 (CH3-TES), -4.5 (Me-TBS), -4.8 (Me-TBS) ppm. 
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IR (thin film): 3362, 2954, 2877, 1718, 1434, 1378, 1360, 1243, 1003 cm
-1
. 
 
HRMS (ESI): m/z calculated for C29H52O5Si2 (M + Na)
+
 559.3245, found 559.3235. 
 
[α]25D -6.91 (c 1.0, CHCl3) 
 
(R)-Methyl 4-((3R,5S)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((R)-2-
(triethylsilyloxy)hex-5-en-2-yl)cyclopent-1-enyl)-4-hydroxybut-2-ynoate (227) 
 
 
 
1
H NMR (400 MHz, CDCl3): δ 5.83 (ddt app, 1H, J = 16.7, 10.2, 6.4 Hz, H-8'), 5.39 (d, 
1H, J = 11.1 Hz, H-6), 5.21 (d, 1H, J = 11.1 Hz, OH), 5.13-4.95 (m, 2H, H-8''), 4.44 (dd, 
1H, J = 7.9, 2.7 Hz, H-3), 3.78 (s, 3H, COOMe), 3.17-3.04 (m, 1H, H-1), 2.38-2.19 (m, 
2H, H-2a + H-8a), 2.10 (m, 1H, H-8b), 1.76-1.69 (m, 3H, H-15), 1.69-1.57 (m, 2H, H-2b + 
H-9a), 1.34 (s, 3H, H-14), 1.24 (ddd, 1H, J = 14.1, 4.4, 3.3 Hz, H-9b), 1.02 (t, 9H J = 7.9 
Hz, CH3-TES), 0.91 (s, 9H, CH3-TBS), 0.85 – 0.74 (m, 6H, CH2-TES), 0.10 (s, 3H, CH3-
TBS), 0.08 (s, 3H, CH3-TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 154.0 (C-12), 140.5 (C-4), 138.1 (C-5), 135.9 (C-8'), 
114.6 (C-8''), 88.0 (C-7), 80.4 (C-11), 78.7 (C-3), 75.8 (C-10), 59.5 (COOMe), 52.5 (C-1), 
51.8 (C-6), 40.4 (C-8), 36.0 (C-9), 27.4 (C-14), 25.8 (Me3C-TBS), 25.2 (C-2),  18.1 
(Me3C-TBS), 12.4 (C-15), 7.02 (CH2-TES), 6.6 (CH3-TES), -4.5 (Me-TBS), -4.7 (Me-TBS) 
ppm. 
 
IR (thin film): 3361, 2956, 2878, 1717, 1434, 1247, 1004 cm
-1
. 
 
HRMS (ESI): m/z calculated for C29H52O5Si2 (M + Na)
+
 559.3245, found 559.3231. 
 
[α]25D -4.72 (c 1.0, CHCl3) 
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(R)-Methyl 4-((3R,5S)-3-(tert-butyldimethylsilyloxy)-2-methyl-5-((S)-2- 
(triethylsilyloxy)hex-5-en-2-yl)cyclopent-1-enyl)-4-(trimethylsilyloxy)but-2-ynoate 
(228) 
 
 
To a solution of methyl propiolate (45 μL, 0.507 mmol, 3 equiv) in dry THF (5 mL) at  
-78 ºC was added dropwise a solution of LiHMDS (0.507 mmol, 3 equiv) in dry THF (5 
mL). After stirring at -78 ºC for 10 min, aldehyde 225 (76.5 mg, 0.169 mmol) in dry THF 
(2 mL) was added dropwise to the reaction mixture and stirred at -78 ºC for 1 h. TMSCl 
(210 μL, 1.69 mmol, 10 equiv) was added dropwise and the reaction mixture was allowed 
to warm up to room temperature and stirred for 18 h. The reaction was then quenched with 
saturated aqueous NaHCO3 and the aqueous phase was extracted with ethyl acetate (x3). 
The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petroleum ether/diethyl ether, 99:1) to give 228 as a colourless oil (83 mg,  81%, dr 2.3:1).  
 
1
H NMR (400 MHz, CDCl3): δ 5.92-5.72 (m, 1H, H-8' + H-6), 5.08-4.86 (m, 2H, H-8''), 
4.44-4.32 (m, 1H, H-3), 3.75 (s, 3H, COOMe), 2.88-2.69 (m, 1H, H-1), 2.32-1.99 (m, 3H, 
H-2a + H-8), 1.85 (d, 3H, J = 1.3 Hz, H-15), 1.65-1.39 (m, 2H, H-2b + H-9a), 1.33-1.10 
(m, 4H, H-14 + H-9b), 0.99 (t, 9H, J = 6.8 Hz, CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.74-
0.57 (m, 3H, CH2-TES), 0.18 (s, 9H, CH3-TMS), 0.08 (s, 3H, CH3-TBS), 0.06 (s, 3H, CH3-
TBS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 154.0 (C-12), 143.7 (C-4), 139.3 (C-5), 134.8 (C-8'), 
114.0 (C-8''), 88.8 (C-7), 78.7 (C-11), 78.2 (C-3), 75.7 (C-10), 60.1 (COOMe), 55.2 (C-1), 
52.4 (C-6), 37.0 (C-8), 36.2 (C-9), 28.2 (C-14), 26.1 (C-2), 25.8 (Me3C-TBS),  18.1 
(Me3C-TBS), 12.6 (C-15), 7.3 (CH2-TES), 7.0 (CH3-TES), 0.01 (Me-TMS) -4.5 (Me-TBS), 
-4.8 (Me-TBS) ppm. 
 
IR (thin film): 2953, 2875, 1720, 1433, 1249, 1078, 839 cm
-1
. 
 
HRMS (ESI): m/z calculated for C33H60O5Si3 (M + Na)
+
 631.3646, found 631.3633. 
175 
 
Methyl 2-((2R,4S,9S,9aS,Z)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-3,9-dimethyl-9-
(triethylsilyloxy)-2,4,7,8,9,9a-hexahydro-1H-cyclopenta[8]annulen-5-yl)acrylate (230) 
 
After following the general RCEYM procedure with enyne 228 (20 mg, 0.0328 mmol) the 
crude residue was purified by flash column chromatography (petroleum ether/diethyl ether, 
99:1) to give 230 as a colourless oil (15.4 mg, 77%, dr 5:1).  
 
1
H NMR (400 MHz, CDCl3): δ 5.88 (d, 1H, J = 1.9 Hz, H-13a), 5.69 (t app, 1H, J = 7.1 
Hz, H-8'), 5.47 (s, 1H, H-6), 5.44 (d, 1H, J = 1.9 Hz, H-13b), 4.26 (t app, 1H, J = 6.2 Hz, 
H-3), 3.67 (s, 3H, COOMe), 2.75 (br t app, 1H, J = 7.1 Hz, H-1), 2.53-2.36 (m, 1H, H-2a), 
2.31-2.15 (m, 2H, H-8), 2.06-1.92 (m, 1H, H-2b), 1.79 (s, 3H, H-15), 1.74 – 1.58 (m, 2H, 
H-9), 1.19 (s, 3H, H-14), 0.94 (t, 9H, J = 8.0 Hz, CH3-TES), 0.90 (s, 9H, CH3-TBS), 0.57 
(q, 6H, J = 8.0 Hz, CH2-TES), 0.11-0.03 (m, 15H, CH3-TBS + CH3-TMS) ppm. 
 
13
C NMR (101 MHz, CDCl3): δ 168.2 (C-12), 139.7 (C-4), 139.0 (C-11), 135.9 (C-7), 
129.1 (C-5), 129.0 (C-8'), 124.1 (C-13), 78.4 (C-3), 77.2 (C-10), 70.8 (C-6), 53.8 (C-1), 
51.7 (COOMe), 42.1 (C-9), 34.3 (C-8), 29.7 (C-9), 25.9 (Me3C-TBS), 25.8 (C-14), 24.6 
(C-2), 18.2 (Me3C-TBS), 12.8 (C-15), 7.2 (CH2-TES), 7.0 (CH3-TES), 0.3 (Me-TMS), -4.4 
(Me-TBS), -4.8 (Me-TBS) ppm. 
 
IR (thin film): 2951, 2873, 1734, 1666, 1325,1249, 1099, 887, 837, 773, 742 cm
-1
. 
 
HRMS (ESI): m/z calculated for C33H60O5Si3 (M + Na)
+
 631.3646, found 631.3626. 
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Appendix A 
 
 
 
 
Views showing the structure and atom labelling scheme of 84, above, and hydrogen 
bonding interactions below. Atomic displacement ellipsoids drawn at 50% probability level. 
 
 
Refinement 
Crystal data, data collection and structure refinement details are summarized in Table 1. 
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Computing details 
Data collection: APEX3 Ver. 2016.9-0 (Bruker-AXS, 2016); cell refinement: SAINT 
V8.37A (Bruker-AXS, 2016); data reduction: APEX3 Ver. 2016.9-0 (Bruker-AXS, 2016); 
program(s) used to solve structure: SHELXT 2014/5 (Sheldrick, 2014); program(s) used to 
refine structure: SHELXL (Sheldrick, 2015); molecular graphics: Olex2 (Dolomanov et al., 
2009); software used to prepare material for publication: Olex2 (Dolomanov et al., 2009). 
 
References 
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Cryst. 2009, 42, 339. 
Sheldrick, G. M. Acta Cryst. 2015, C71, 3. 
 
Crystal data 
 C9H11NO2 Dx = 1.267 Mg m
-3
 
Mr = 165.19 Cu K radiation,  = 1.54178 Å 
Orthorhombic, P212121 Cell parameters from 9509 reflections 
a = 6.6747 (12) Å  = 3.2–68.3° 
b = 9.2458 (16) Å  = 0.74 mm-1 
c = 14.037 (2) Å T = 150 K 
V = 866.3 (3)  Å
3
 Block, colourless 
Z = 4 0.26 × 0.24 × 0.16 mm 
F(000) = 352  
 
Data collection 
Bruker D8 VENTURE  
diffractometer 
1564 independent reflections 
Radiation source: microfocus sealed tube, 
INCOATEC Is 3.0 
1563 reflections with I > 2(I) 
Multilayer mirror optics monochromator Rint = 0.036 
Detector resolution: 7.4074 pixels mm
-1
 max = 68.3°, min = 5.7° 
 and  scans h = -88 
Absorption correction: multi-scan  
SADABS2016/2 (Bruker,2016/2) was used for 
absorption correction. wR2(int) was 0.1111 
before and 0.0529 after correction. The Ratio of 
minimum to maximum transmission is 0.6795. 
The /2 correction factor is Not present. 
k = -1111 
Tmin = 0.512, Tmax = 0.753 l = -1616 
19408 measured reflections  
 
Refinement 
 Refinement on F2 Hydrogen site location: inferred from 
neighbouring sites 
Least-squares matrix: full H-atom parameters constrained 
185 
 
R[F
2
 > 2(F2)] = 0.027  w = 1/[2(Fo
2
) + (0.033P)
2
 + 0.1846P]   
where P = (Fo
2
 + 2Fc
2
)/3 
wR(F
2
) = 0.069 (/)max < 0.001 
S = 1.10 max = 0.16 e Å
-3
 
1564 reflections min = -0.12 e Å
-3
 
112 parameters Absolute structure:  Flack x determined using 
633 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Acta Cryst. 
2013, B69, 249). 
0 restraints Absolute structure parameter: -0.01 (4) 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
O1 0.91653 (18) 0.41443 (13) 0.47119 (9) 0.0312 (3) 
H1 0.934434 0.500184 0.489028 0.047* 
O2 0.42929 (18) 0.78354 (12) 0.49417 (8) 0.0275 (3) 
N1 0.2144 (3) 0.5694 (2) 0.68998 (11) 0.0385 (4) 
C1 0.4020 (2) 0.53656 (16) 0.44821 (11) 0.0210 (3) 
H1A 0.281256 0.483954 0.424190 0.025* 
C2 0.5934 (3) 0.48161 (19) 0.39573 (12) 0.0272 (4) 
H2A 0.556026 0.425541 0.338340 0.033* 
H2B 0.677993 0.564259 0.375903 0.033* 
C3 0.7075 (3) 0.38482 (18) 0.46705 (12) 0.0251 (4) 
H3 0.688144 0.281350 0.448451 0.030* 
C4 0.6047 (2) 0.41065 (16) 0.56131 (12) 0.0235 (3) 
C5 0.4437 (2) 0.49434 (16) 0.55024 (11) 0.0210 (3) 
C6 0.3153 (3) 0.53655 (18) 0.62739 (11) 0.0259 (4) 
C10 0.3770 (2) 0.69812 (18) 0.43305 (11) 0.0215 (3) 
C14 0.2905 (3) 0.74386 (19) 0.33954 (12) 0.0295 (4) 
H14A 0.145312 0.728226 0.340072 0.044* 
H14B 0.350993 0.686676 0.288271 0.044* 
H14C 0.318609 0.846651 0.328984 0.044* 
C15 0.6830 (3) 0.3463 (2) 0.65123 (13) 0.0333 (4) 
H15A 0.826510 0.367060 0.656895 0.050* 
H15B 0.662259 0.241378 0.650211 0.050* 
H15C 0.611809 0.388122 0.705706 0.050* 
 
Atomic displacement parameters (Å2) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
O1 0.0208 (6) 0.0266 (6) 0.0464 (7) 0.0028 (5) 0.0020 (5) -0.0048 (5) 
O2 0.0319 (7) 0.0231 (6) 0.0276 (6) 0.0009 (5) -0.0014 (5) -0.0035 (5) 
N1 0.0379 (9) 0.0481 (9) 0.0296 (8) 0.0077 (8) 0.0088 (7) 0.0018 (7) 
C1 0.0190 (7) 0.0211 (7) 0.0228 (7) -0.0007 (6) -0.0006 (6) -0.0030 (6) 
C2 0.0264 (8) 0.0309 (8) 0.0243 (7) 0.0049 (8) 0.0026 (7) -0.0050 (7) 
C3 0.0224 (8) 0.0195 (8) 0.0334 (9) 0.0008 (7) 0.0012 (7) -0.0052 (7) 
C4 0.0241 (8) 0.0174 (7) 0.0291 (8) -0.0025 (7) -0.0017 (7) -0.0012 (6) 
C5 0.0206 (8) 0.0186 (7) 0.0237 (7) -0.0031 (6) 0.0018 (6) -0.0009 (6) 
C6 0.0263 (8) 0.0263 (8) 0.0252 (8) 0.0007 (7) -0.0001 (7) 0.0029 (7) 
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C10 0.0173 (7) 0.0242 (8) 0.0232 (7) 0.0006 (6) 0.0038 (6) -0.0021 (6) 
C14 0.0329 (9) 0.0305 (9) 0.0252 (8) 0.0037 (8) -0.0007 (7) 0.0014 (7) 
C15 0.0363 (10) 0.0289 (9) 0.0346 (9) 0.0042 (8) -0.0048 (9) 0.0035 (7) 
 
Geometric parameters (Å, º) 
O1—H1 0.8400 C3—C4 1.509 (2) 
O1—C3 1.423 (2) C4—C5 1.333 (2) 
O2—C10 1.217 (2) C4—C15 1.490 (2) 
N1—C6 1.148 (2) C5—C6 1.435 (2) 
C1—H1A 1.0000 C10—C14 1.495 (2) 
C1—C2 1.560 (2) C14—H14A 0.9800 
C1—C5 1.510 (2) C14—H14B 0.9800 
C1—C10 1.518 (2) C14—H14C 0.9800 
C2—H2A 0.9900 C15—H15A 0.9800 
C2—H2B 0.9900 C15—H15B 0.9800 
C2—C3 1.544 (2) C15—H15C 0.9800 
C3—H3 1.0000   
    
C3—O1—H1 109.5 C15—C4—C3 121.33 (14) 
C2—C1—H1A 110.0 C4—C5—C1 114.14 (14) 
C5—C1—H1A 110.0 C4—C5—C6 123.45 (15) 
C5—C1—C2 102.29 (13) C6—C5—C1 122.37 (14) 
C5—C1—C10 114.05 (12) N1—C6—C5 179.06 (18) 
C10—C1—H1A 110.0 O2—C10—C1 120.53 (15) 
C10—C1—C2 110.15 (13) O2—C10—C14 123.10 (15) 
C1—C2—H2A 110.4 C14—C10—C1 116.36 (14) 
C1—C2—H2B 110.4 C10—C14—H14A 109.5 
H2A—C2—H2B 108.6 C10—C14—H14B 109.5 
C3—C2—C1 106.65 (13) C10—C14—H14C 109.5 
C3—C2—H2A 110.4 H14A—C14—H14B 109.5 
C3—C2—H2B 110.4 H14A—C14—H14C 109.5 
O1—C3—C2 113.49 (14) H14B—C14—H14C 109.5 
O1—C3—H3 108.8 C4—C15—H15A 109.5 
O1—C3—C4 112.30 (14) C4—C15—H15B 109.5 
C2—C3—H3 108.8 C4—C15—H15C 109.5 
C4—C3—C2 104.63 (13) H15A—C15—H15B 109.5 
C4—C3—H3 108.8 H15A—C15—H15C 109.5 
C5—C4—C3 110.86 (14) H15B—C15—H15C 109.5 
C5—C4—C15 127.82 (16)   
 
Hydrogen-bond geometry (Å, º) 
 D—H···A D—H H···A D···A D—H···A 
O1—H1···O2i 0.84 2.01 2.8358 (17) 166 
C1—H1A···O1ii 1.00 2.60 3.447 (2) 142 
 
Symmetry codes:  (i) x+1/2, -y+3/2, -z+1;  (ii) x-1, y, z. 
Document origin: publCIF  [Westrip, S. P. J. Apply. Cryst. 2010, 43, 920] 
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